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ABSTRACT 
Jacob J. Adler 
 
THE INHIBITION OF MAMMARY EPITHELIAL CELL GROWTH BY THE LONG 
ISOFORM OF ANGIOMOTIN 
 
Mammary ductal epithelial cell growth is controlled by microenvironmental signals in 
serum under both normal physiological settings and during breast cancer progression. 
Importantly, the effects of several of these microenvironmental signals are mediated by the 
activities of the tumor suppressor protein kinases of the Hippo pathway. Canonically, Hippo 
protein kinases inhibit cellular growth through the phosphorylation and inactivation of the 
oncogenic transcriptional co-activator Yes-Associated Protein (YAP). This study defines an 
alternative mechanism whereby Hippo protein kinases induce growth arrest via the 
phosphorylation of the long isoform of Angiomotin (Amot130). Specifically, serum starvation is 
found to activate the Hippo protein kinase, Large Tumor Suppressor (LATS), which 
phosphorylates the adapter protein Amot130 at serine-175. Importantly, wild-type Amot130 
potently inhibits mammary epithelial cell growth, unlike the Amot130 serine-175 to alanine 
mutant, which cannot be phosphorylated at this residue. The growth-arrested phenotype of 
Amot130 is likely a result of its mechanistic response to LATS signaling. Specifically, LATS 
activity promotes the association of Amot130 with the ubiquitin ligase Atrophin-1 Interacting 
Protein 4 (AIP4). As a consequence, the Amot130-AIP4 complex amplifies LATS tumor 
suppressive signaling by stabilizing LATS protein steady state levels via preventing AIP4-
targeted degradation of LATS. Additionally, AIP4 binding to Amot130 leads to the ubiquitination 
and stabilization of Amot130. In turn, the Amot130-AIP4 complex signals the ubiquitination and 
degradation of YAP. This inhibition of YAP activity by Amot130 requires both AIP4 and the 
ability of Amot130 to be phosphorylated by LATS. Together, these findings significantly modify 
  
vii 
 
the current view that the phosphorylation of YAP by Hippo protein kinases is sufficient for YAP 
inhibition and cellular growth arrest. Based upon these results, the inhibition of cellular growth in 
the absence of serum more accurately involves the stabilization of Amot130 and LATS, which 
together inhibit YAP activity and mammary epithelial cell growth. 
 
Clark D. Wells, Ph.D., Chair 
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CHAPTER 1. INTRODUCTION 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Some text in this chapter was originally published in The American Biology Teacher. Adler et al. 
Day as a Pathologist: Utilization of Technology to Guide Students in Exploring Careers in Breast 
Cancer Pathology. The American Biology Teacher. 2013; Vol: 75, 8: 559-565. © the National 
Association of Biology Teachers.  
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1.1. Organization of the Mammary Organ, Mammary Organogenesis, and the Origins of Breast 
Cancer 
  
Human body systems contain many growth control mechanisms that help regulate and 
maintain cellular homeostasis and tissue-specific function (Xu et al., 2009). Many of these 
mechanisms are biochemical or biophysical cues, working through cellular architecture and 
biochemical signals, which modify tissue function via physiological perturbations. The mammary 
organ is an example of such, containing tissue that is highly sensitive to a wide-variety of growth 
control mechanisms (Bissell et al., 2003). Thus, studying normal and cancerous mammary cell 
models is useful to dissect growth control signaling that is likely relevant to the functions of the 
mammary organ.  
The breast, while composing a basic overall structure during fetal and infant growth, 
undergoes remodeling events during puberty, pregnancy, lactation, and menopause that require 
cells to move, change size and to divide or conversely to die (Hassiotou and Geddes, 2013; Russo 
and Russo, 2004). The composition of the mature breast is mainly deposits of adipose tissue, 
glandular tissue, blood vessels, and muscle that are embedded into fibrous connective tissue 
called the stroma (Figure 1-1). The glandular tissue, in turn, is composed of hollow tubes called 
ducts that are formed by luminal cuboidal epithelial cells. These epithelial cells are surrounded by 
a layer of myoepithelial cells, which have properties of smooth muscle cells and are able to 
squeeze the ducts for milk movement during lactation. This glandular tissue develops and grows 
during puberty and upon its maturation is a crucial element in the function of the breast (Neville 
MC, 2002; Russo J, 1992). Such glandular tissue forms a tree-like branching system that arises 
from clusters of 10-100 alveoli comprising lobules (Going and Moffat, 2004; Hartmann, 2007). 
During lactation, milk is produced by lactocytes in the lobules and travels through the lumens of 
the ducts to reach the nipple (Hassiotou and Geddes, 2013).  
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Importantly, key remodeling events in the mammary gland during pregnancy and 
lactation promote healthy physiological changes during the woman’s life cycle (Figure 1-2). 
Termed together as the pregnancy lactation cycle (PLC) (Russo and Russo, 2004), these 
physiological changes are important for the development of a functional milk-secreting organ. 
Within this cycle, growth and remodeling events occur followed by massive cell death and whole 
organ involution. These remodeling events include ductal branching, alveolar morphogenesis, 
secretory differentiation, and post-lactation involution (Hassiotou and Geddes, 2013). The PLC 
requires major changes in the organization and the size of the mammary organ, involving changes 
in the epithelial cells and surrounding stromal tissue. For example, during involution, the final 
step of the PLC, the breast is completely reorganized. Involution begins with massive cell death 
and then clearing of cell debris. A complete redevelopment of the ductal network and surrounding 
tissue follows, which is maintained until the next gestation (Stein et al., 2007). These steps are 
partially regulated by estrogen, progesterone, and prolactin hormones (Pang and Hartmann, 
2007). While hormones play a large role in this process, many details controlling this process are 
ambiguous. The capacity of this organ to undergo large remodeling events throughout adulthood 
may explain why abnormal changes leading to pathogenic conditions like cancer are so prevalent. 
Abnormal changes may occur anywhere and at any time in the breast to initiate cancer at 
that location. Breast cancer is one of the most frequently diagnosed cancers and one of the 
leading causes of cancer deaths in women (Ferlay et al., 2007; Ferlay et al., 2010). These cancers 
are categorized into particular types based on the origin of the tissue from which they arise and by 
their invasive capacity. For instance, ductal tumors arise out of ducts whereas lobular tumors arise 
from lobules. Even though cancer can occur in any cell, it is frequently seen in the epithelial cells 
that line the ducts. The pathological event of cancer begins when these epithelial cells, due to 
environmental or genetic cues, begin to divide and grow inappropriately, undergoing hyperplasia, 
and fail to form normal breast structures (Figure 1-3). This typically is observed by cells growing 
into the lumen of the duct in a process termed intra-ductal hyperplasia, also known as benign 
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proliferative breast disease (Hussein and Hassan, 2006). As benign hyperplastic cells undergo 
deregulated cell growth, they have an increased probability of acquiring cancer-initiating 
mutations that further drive higher rates of cell growth and loss of ductal morphology. When 
these cells remain within the confines of the duct, this is termed ductal carcinoma in situ (DCIS). 
DCIS is not diagnosed as breast cancer, but can be detected by a mammogram. However, if these 
cells break through the ductal layer and invade into the surrounding stroma and adipose tissue, 
they are then recognized as cancer and are termed invasive ductal carcinoma (IDC). These cancer 
cells are frequently able to migrate into the bloodstream and vasculature to be deposited 
elsewhere in the body, creating a highly lethal metastasized breast cancer.  
Many of the factors involved in breast cancer remain elusive and treatments consequently 
often do not result in a cure. Thus, early detection is still the best way to prevent breast cancer 
(Erbas et al., 2006; Key et al., 2001; Wren, 2007). Research into the natural history of breast 
cancer is therefore essential to understand the microenvironmental, genetic, and molecular factors 
that will serve as the targets for better therapeutics (Xu et al., 2009).  
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Figure 1-1 Organization of the Breast. 
The breast is composed of adipose tissue and the stroma, a network of connective tissue, both of 
which surround the secretory ductal tissue. The ductal tissue presents as a tree-like branching 
path, where milk is stored and secreted from in lobules and is transported to the nipple 
(lactiferous sinus). A cross-section of the duct is presented, indicating two layers of epithelial 
cells lining the mammary ducts. A layer of simple cuboidal epithelial cells faces the inner hollow 
lumen. In the lobules, these epithelial cells can differentiate into secretory cells for milk 
production. The second layer is the myoepithelial cells, which surround and help hold the luminal 
epithelial cells in place. Overall, these epithelial cells are very important for the structure and 
function of the mammary organ. Figure adapted from (Adler et al., 2013c). 
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Figure 1-2 Normal Mammary Gland Organogenesis. 
A selected series of mouse mammary tissue whole mounts, illustrating morphological changes at 
selected phases of development. This particular series highlights the embryonic through adult 
mammary gland. It begins with a postnatal, prepuberty gland (2-week old), a rapidly growing 
pubertal mammary gland (5-week old), and a developed adult ductal gland (10-week old). Upon 
gestation, the ductal system undergoes rapid changes in structure and function. These changes 
occur as a cycle, termed the pregnancy lactation cycle (PLC). Initially, remodeling occurs during 
pregnancy (gestation day 18.5). This is followed by lactation, in which the gland is functionally 
differentiated and milk is being produced. Then, during post-lactation the ductal tissue undergoes 
rapid cell death followed by whole organ involution (day 8 post-lactation). This is followed by a 
reorganization of the breast until the next PLC. Scale bars = 1 mm (Prepuberty-Adult); 50 µm 
(PLC). Figure designed by William Ranahan. Figure adapted from (Khokha and Werb, 2011). 
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Figure 1-3 Progression of Invasive Ductal Carcinoma in the Breast. 
Representation of a labeled duct and stromal tissue with different cells indicated (above). A closer 
examination of a selected cross-section of a duct undergoing cancer progression is presented 
(below). Featured are two layers of epithelial cells and changes that occur to the duct through this 
progression. Epithelial cells lining the mammary ducts begin to grow and divide inappropriately 
and begin to fill the duct (hyperplasia). As these cells undergo deregulated growth, they acquire 
mutations that drive further loss of ductal morphology and increased cell growth into the lumen 
of the duct (DCIS). Eventually, these cells could break through into the stroma and are diagnosed 
as invasive ductal carcinoma. Figure adapted from (Sternlicht, 2006) and (Adler et al., 2013c). 
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1.2. Serum Factors and Their Roles in Epithelial Cell Growth 
 
Breast cancer can arise from changes in the epithelial cells that line the ducts. Within the 
breast tissue, these epithelial cells react to changes in their microenvironment, which can modify 
their rates of cell division and growth. These microenvironmental conditions are influenced by 
cell-cell contact with neighboring cells and various juxtacrine, autocrine, or paracrine factors that 
come into contact with the cell (Castor, 1972). In many cases these factors are packaged and 
released from one cell and then distributed through the bloodstream or extracellular fluids to the 
targeted cell. Within blood, serum contains many factors important for cell division and 
proliferation (Rutherford and Ross, 1976). These factors are easily distributed via the bloodstream 
and extracellular fluids, throughout tissues accessing cells where they may act via interactions 
with membrane receptors on the cell surface. In turn, these factors act to initiate changes within 
the cell. Specifically, a subset of factors has been identified to influence cell growth and apoptosis 
in mammary epithelial cells and is demonstrated to impact cancers. 
An example of a secreted polypeptide factor that promotes cell growth is the epidermal 
growth factor (EGF), which can activate a number of intracellular signaling pathways. EGF, upon 
binding to a growth factor receptor, causes that receptor to dimerize with another growth factor 
receptor. These dimerized receptors undergo auto-phosphorylation and activation, which leads to 
a cascade of pro-growth intracellular signaling pathways (Ushiro and Cohen, 1980; Wells, 1999) 
(Figure 1-4). 
EGF-dependent signaling plays a major role in the ductal development of breast (Tonelli 
and Sorof, 1980), and are deregulated in cancer development. Several of the receptors that bind 
the EGF ligand are overexpressed in many types of breast cancers. Further, inhibition of epithelial 
cell proliferation can be achieved via specific drug inhibition of the EGF receptors in human 
DCIS xenograph models (Bundred et al., 2001; Chan et al., 2001; Muthuswamy et al., 1994; 
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Ullrich and Schlessinger, 1990; Wells, 1999). Thus, EGF plays a key role in the induction of 
growth in mammary epithelial cells. 
Mitogenic lipids in the mammary microenvironment also play major roles in promoting 
cellular growth. The family of lysophospholipids, which have similar functions as the polypeptide 
growth factors, are produced in a variety of cell types; however, 90 % are produced from platelets 
(Xie et al., 2002). They are active when bound to protein albumin in human serum at 
concentrations ranging from 0.5-5 µM (Baker et al., 2001; Sano et al., 2002; Yatomi et al., 2000). 
Upon reaching a targeted epithelial cell, they bind highly specific membrane-bound receptors that 
are coupled to G-proteins (commonly known as G-protein coupled receptors, GPCRs). Initiation 
of different GPCRs leads to the activation or inhibition of a variety of biochemical pathways. 
Two bioactive lysophospholipids, lysophosphatidic acid (LPA) and sphingosine 1-phosphate 
(S1P) induce signaling through specific GPCRs to promote cellular proliferation and suppression 
of apoptosis. This, in turn, has implications on cellular differentiation and survival in many cell 
types (Ishii et al., 2004) (Figure 1-4). LPA is important in wound healing, cell growth, actin stress 
fiber formation, and regenerating tissue (Moolenaar, 2000). Importantly, LPA has a role in breast 
development and is upregulated in cancers, being able to induce breast cancer cells to initiate 
cellular growth, migration, and promote metastasis to bone (Du et al., 2010; Yuh, 2011). 
Additionally, LPA levels are elevated in the plasma of ovarian cancer patients (Xu et al., 1995b) 
and correlate with cell proliferation in breast cells (Yuh, 2011). 
S1P acts similar to LPA, but works through its own set of specific GPCRs. Both are able 
to activate many growth and survival pathways like those involving mitogen-activated protein 
kinase and phosphoinositide 3-kinase (Ishii et al., 2004). Recent examination of the Hippo 
signaling pathway, important in the regulation of growth control and organ size, was found to be 
highly inhibited by LPA, S1P, and EGF (Fan et al., 2013; Miller et al., 2012; Yu et al., 2012). 
However, the exact mechanisms whereby the components of serum regulate Hippo signaling are 
still poorly understood. 
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Figure 1-4 Brief Overview of Serum Factors LPA, S1P, and EGF Signaling Pathways. 
Growth signaling in mammary epithelial cells is initiated in response to microenvironmental 
factors found in the serum including the lysophospholipids LPA and S1P, and the protein EGF. 
LPA and S1P bind to specific receptors coupled to G-proteins (GPCR), which upon activation 
induce cell growth and survival pathways. EGF binds to receptor tyrosine kinases (RTK), to 
induce their dimerization and activation of many cell growth and survival pathways. Figure 
adapted from an unpublished figure by Brandon Lane. 
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1.3. Hippo Signaling and Its Role in Epithelial Cell Growth 
 
Over the past decade, the Hippo tumor suppressor pathway has been identified as a 
preeminent signaling network in the control of organ size, stem cells, and cancer (Harvey et al., 
2013; Pan, 2007; Zhao et al., 2011b). Many of the Hippo pathway components were originally 
discovered in Drosophila melanogaster via genetic mosaic screens (Harvey et al., 2003; Jia et al., 
2003; Justice et al., 1995; Pantalacci et al., 2003; Udan et al., 2003; Wu et al., 2003; Xu et al., 
1995a). Recent studies have identified mammalian homologues of the Hippo pathway that can 
functionally rescue their Drosophila mutants in vivo, suggesting functional conservation of the 
Hippo pathway across metazoans (Huang et al., 2005; Lai et al., 2005; Wu et al., 2003). The 
Hippo pathway functions to negatively regulate the transcriptional co-activators Yes-associated 
protein (YAP) and its functional homologue transcriptional co-activator with PDZ-binding motif 
(TAZ) (Kanai et al., 2000; Yagi et al., 1999). Upon entry into the nucleus, YAP and TAZ act as 
potent co-activators of transcriptional programs involved in organ size control, cell proliferation, 
and apoptosis. This is through their ability to co-activate many different transcription factors, 
including the RUNX, p73, and TEA-domain containing (TEAD) (Strano et al., 2001; Vassilev et 
al., 2001; Vitolo et al., 2007) (Figure 1-5). Specifically, the TEAD transcription factors are well 
described in transcribing a subset of the CCN family of matricellular proteins, whose name is 
derived from the first three members, cysteine-rich angiogenic inducer 61 (Cyr61 or CCN1); 
connective tissue growth factor (CTGF or CCN2); nephroblastoma overexpressed (NOV or 
CCN3). CTGF and Cyr61 are transcribed by activated TEAD via YAP and TAZ, which regulate 
pathways involved in cell proliferation and survival, but their effects tend to be cell specific 
(Dupont et al., 2011; Lai et al., 2011; Zhao et al., 2008b). Likely, other CCN family members are 
also targets of YAP and TAZ, but the evidence to date on these members are not as strong. CTGF 
and Cyr61, interact with several extracellular matrix proteins and integrins leading to increased 
survival and cell proliferation (Chen and Lau, 2009; Hoshijima et al., 2006; Lin et al., 2004). In 
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breast cancer, Cyr61 and CTGF are associated with poor prognosis, tumorigenesis, resistance to 
anti-cancer drugs, and metastasis (Hu et al., 2008; Kang et al., 2003; Lai et al., 2011; Xie et al., 
2001). 
Given the high association of the genes that are induced by YAP and TAZ with breast 
cancer, it reasons that YAP and TAZ should promote breast cancer as well. Consistently, YAP 
and TAZ are classified as potent oncogenes (Overholtzer et al., 2006; Zender et al., 2006), whose 
inhibition is considered a prime target for cell growth inhibition and prevention of tumorigenesis 
(Kango-Singh and Singh, 2009; Zhao et al., 2008a). Thus, the understanding of YAP and TAZ 
activity in cancer epithelial cells may yield how cancer potently activates and manipulates cell 
growth signaling. Consistent with their involvement in breast cancer, the general induction of 
YAP is linked to migration and tumorigenesis in normal mammary epithelial cells (Overholtzer et 
al., 2006). Further, recent work on TAZ revealed its requirement for sustaining breast cancer stem 
cell populations (Cordenonsi et al., 2011). 
YAP and TAZ activity are inhibited by formation of cell-cell contacts and serum 
deprivation. These changes in the cellular microenvironment inhibit YAP and TAZ by spawning 
activation of the Hippo signaling pathway (Dong et al., 2007). Canonical Hippo signaling entails 
the activation of two sets of related protein kinases (Figure 1-5). Protein kinases, in general, 
catalyze the transfer of a phosphoryl group from the γ-phosphate of adenosine triphosphate (ATP) 
to the hydroxyl group of a serine, threonine, or tyrosine residue on the substrate protein (Endicott 
et al., 2012). Within the Hippo pathway, the mammalian Ste20-like protein kinases 1 and 2 
(MST1/2) (Avruch et al., 2012), catalyze the phosphorylation and activation of the large tumor 
suppressor protein kinases 1 and 2 (LATS1/2) (Chan et al., 2005). LATS1/2, in turn, catalyze the 
phosphorylation of YAP and TAZ at multiple residues, including residues serine-127 on YAP and 
serine-89 on TAZ (Hao et al., 2008). Upon phosphorylation, these sites bind 14-3-3 proteins, 
which in turn, sequester YAP and TAZ in the cytosol (Kanai et al., 2000; Zhao et al., 2007). This 
is typical of 14-3-3 proteins, which bind phosphorylated serine and threonine residues in 
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hundreds of proteins to alter their function (Bridges and Moorhead, 2005; Jin et al., 2004). It was 
suggested that the phosphorylation of YAP and TAZ also targets them for ubiquitination by the 
ubiquitin ligase SCF-(β)-TRCP that is reported to lead to the degradation of TAZ via the 26S 
Proteasome (Liu et al., 2010; Zhao et al., 2010). However, there is no direct evidence linking 
ubiquitination of YAP by SCF-(β)-TRCP with its degradation. Therefore, the exact mechanism 
for the degradation of YAP in response to Hippo signaling remains unclear. This will be the topic 
of this thesis. 
YAP and TAZ are also inactivated by the prevention of actin stress fiber formation 
(Dupont et al., 2011; Sansores-Garcia et al., 2011). Conversely, the stiffening of the extracellular 
matrix and stress fiber formation activates YAP and TAZ, which in turn, further increase matrix 
stiffening, via increased CCN transcription and integrin signaling (Calvo et al., 2013). This sets 
up a self-reinforcing activation loop to activate growth. While LATS inhibits this process, its 
exact role is unknown (Wada et al., 2011). It is possible that LATS works indirectly to influence 
the activity of YAP, as very recent work indicates that the mechanical forces are the predominant 
determinant of YAP nuclear activity (Aragona et al., 2013). Overall, YAP activity is heavily 
impacted by actin dynamics. 
YAP and TAZ contain several distinct regions that orchestrate their function in cells 
(Figure 1-6). The first region is a C-terminal Post synaptic density protein/Drosophila disc 
large/Zonula occludens-1 protein (PDZ) binding motif that associates with several proteins that 
are integrated in cellular membranes (Kanai et al., 2000). Additionally, YAP binds Zona 
Occluden 2 (ZO-2) via its PDZ binding motif, which can direct YAP into the nucleus (Oka et al., 
2010). N-terminal to the PDZ binding motif is the transactivation domain of YAP and TAZ, 
which is important for the co-activation of the p73 and RUNX transcription factors via YAP and 
TAZ (Yagi et al., 1999). Depending on the splice forms, 1 or 2 WW domains lie roughly in the 
middle of both YAP and TAZ. The WW domains consist of 30-40 amino acids each that are 
 14 
 
named for two conserved tryptophans (WW) (Sudol et al., 1995). These WW domains bind many 
proteins involved in cell growth regulation including the LATS1/2 protein kinases (Hao et al., 
2008; Zhao et al., 2011a). Finally, the N-terminal TEAD binding domain allows YAP and TAZ to 
associate with TEAD transcription factors that promote the transcriptional co-activation of 
TEAD-dependent genes and growth signaling (Li et al., 2010). 
Recent work on Hippo signaling in mammals has focused on the upstream activation of 
Hippo protein kinases. Compared to Drosophila, these events are still largely unknown, due to 
the increased complexity found in mammals involving numerous adapter proteins and redundant 
kinases. 
Recently, serum factors were found to promote growth via inhibition of Hippo protein 
kinases. Specifically, LPA, S1P, and EGF were uncovered as factors in serum that inhibit Hippo 
signaling via loss of LATS1/2 activity (Fan et al., 2013; Yu et al., 2012) or indirectly via the 
dephosphorylation of YAP (Cai and Xu, 2013). Together, these factors all promote YAP nuclear 
activity. However, it is unclear how LATS1/2 is inhibited in response to serum levels. 
Cell-cell contacts are a primary means to inhibit cell growth (Castor, 1972). As it turns 
out, cell-cell contacts activate Hippo signaling to inhibit YAP and TAZ activities through 
multiple proposed mechanisms (Dong et al., 2007; Hao et al., 2008; Lei et al., 2008; Oka et al., 
2008; Zhao et al., 2007). For instance, in Drosophila, protocadherins atypical Fat and Dachsous, 
as well as other complexes, including the Expanded-Merlin-Kibra pathway activate Hippo 
signaling (Matakatsu and Blair, 2004). However, studies in mammals suggest that neither Fat, 
Dachsous, nor the Expanded axis are major contributors to Hippo activation, as many of these 
Drosophila proteins are not even present in the same form in mammals (Bossuyt et al., 2013) 
(Figure 1-7). For example, mammalian protein Expanded lacks a C-terminal region found in its 
counterpart from Drosophila and other arthropods. Thus, in mammals, unique candidates likely 
play major roles in relaying cell-cell contact inhibition through the Hippo pathway. Recently, 
components of cell polarity complexes were demonstrated to activate Hippo signaling in response 
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to cell-cell contacts via formation of cell polarity (Chan et al., 2011; Schlegelmilch et al., 2011; 
Silvis et al., 2011; Wada et al., 2011; Wang et al., 2011; Yi et al., 2011; Zhao et al., 2011a; Zhao 
et al., 2012). Generally, epithelial cells utilize cell polarity protein complexes to maintain 
structure and prevent cell division and growth signaling. These complexes contain proteins that 
surround the contacts between cells and are involved in cell-cell attachment and intracellular 
signaling, linking contact between cells and growth inhibition via control of proteins like YAP 
and TAZ (Genevet and Tapon, 2011; Ota and Sasaki, 2008; Zhao et al., 2007). Closer 
examination of these protein complexes revealed a family of adapter proteins currently being 
investigated as a replacement pathway for Fat and Dachsous in mammals. These are identified as 
a group of tight junction-associated proteins, called Angiomotins (Bossuyt et al., 2013; Wells et 
al., 2006). Importantly, recent studies suggest the Angiomotins are major components of the 
Hippo signaling pathway (Chan et al., 2011; Wang et al., 2011; Zhao et al., 2011a). Therefore, it 
is important to understand the roles of the Angiomotins in the context of Hippo signaling, as these 
proteins could shed light on how the core Hippo signaling components are regulated. 
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Figure 1-5 Overview of Hippo Signaling in Mammals. 
YAP and TAZ proteins enter the nucleus and co-activate transcription factors, such as TEAD that 
promote the transcription of pro-growth and survival genes, including CTGF (above). Hippo 
pathway activation (below) initiates with the activation of MST1/2 protein kinases and 
consequent phosphorylation of LATS1/2 protein kinases. As a consequence, LATS1/2 is 
activated, resulting in phosphorylation of YAP and TAZ at multiple residues. Phosphorylation of 
YAP and TAZ signals inactivation through their binding 14-3-3, which sequesters YAP and TAZ 
in the cytosol, as well as targeting these transcriptional co-activators for ubiquitination, via the 
protein ubiquitin ligase SCF-(β)-TRCP (β-TRCP), and degradation. Prevention of YAP and TAZ 
nuclear activities suppresses cell growth and survival. Interestingly, the serum factors LPA, S1P, 
and EGF can inhibit LATS1/2 phosphorylation of YAP and TAZ, and thus inhibit Hippo 
signaling. Figure adapted from an unpublished figure by Clark Wells. 
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Figure 1-6 The Functional Regions of the Transcriptional Co-activators YAP and TAZ. 
This is a schematic of the domain architecture of mammalian YAP and TAZ. Each protein 
contains a PDZ binding motif on their C-terminus. This motif interacts with different PDZ 
domain containing proteins, like ZO-2. They also contain transactivation domains that elevate the 
activity of transcription factors. Further, WW domains in the center of these proteins allow for 
key functional interactions with proteins that regulate their activity, like LATS1/2 and 
Angiomotin family members (section 1.4). Importantly, both of these proteins are phosphorylated 
at multiple residues by LATS. LATS phosphorylation sites, serine-127 (YAP) and serine-89 
(TAZ), are highlighted in this schematic. Finally, each contains a TEAD binding domain on their 
N-terminus, which directly interacts with the TEAD transcription factors. 
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Figure 1-7 Comparison of Upstream Effectors of Canonical Hippo Signaling in Drosophila 
Versus Mammals. 
While the core Hippo pathway components in mammals and Drosophila melanogaster are 
similar, the upstream regulation is quite different. For example in Drosophila, atypical cadherins 
Fat and Dachsous (Dachs), Echinoid (Ed), and the Expanded (Ex)-Merlin (Mer)-Kibra complex 
play critical roles in regulating Hippo signaling. However, in mammals many alternative 
pathways have evolved to control Hippo signaling. For example, the Angiomotin (Amot) protein 
family links polarity proteins, including Crumbs (Crb), to the regulation of Hippo signaling. 
Figure adapted from (Bossuyt et al., 2013). 
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1.4. The Angiomotins and Their Roles in Epithelial Cell Growth and Hippo Signaling 
 
The Angiomotin family of adapter proteins coordinates the core signaling pathways that 
regulate cell shape and growth control (Aase et al., 2007; Paramasivam et al., 2011; Wells et al., 
2006; Zhao et al., 2011a). These proteins play pivotal roles in cell polarity and growth control by 
binding Hippo signaling and polarity proteins. Three separate genes, paralogs in humans, 
Angiomotin (AMOT), Angiomotin-like 1 (AMOTL1), and Angiomotin-like 2 (AMOTL2) encode 
proteins that can be grouped by sequence homology and analogous domain topology (Bratt et al., 
2002) (Figure 1-8). Each Angiomotin protein contains a C-terminal PDZ binding motif, important 
for anchoring it to polarity proteins composing the Partition defective (Par) and Crumb (Crb) 
polarity protein complexes. These complexes control the organization of the apical cortex of 
epithelial cells, helping to mediate intercellular signaling and associated gene transcription 
(Assémat et al., 2008). Importantly, Angiomotin is present at the tight junctions near cell-cell 
contacts and regulates cell polarity via binding and modifying the localization of the Par and Crb 
polarity protein complexes (Wells et al., 2006). 
N-terminal to the PDZ binding motif, the Angiomotins all contain an Amot coiled-coil 
homology (ACCH) domain, which is important for their ability to associate with lipids in the 
membrane of cells. The ACCH domain drives Angiomotin association with the membrane and 
helps Angiomotin influence changes in cellular polarity (Heller et al., 2010). Further, the ACCH 
domain is required for the Angiomotin family members to homo- and hetero-dimerize (Ernkvist 
et al., 2008; Gagné et al., 2009; Moreau et al., 2005; Patrie, 2005). These dimerization events 
allow for multiple Angiomotins to be in the same complex spatially and temporally; however, the 
functions of the individual pairs of homo- and hetero-dimers remain to be identified. 
N-terminal to the ACCH domain, each Angiomotin contains a set of conserved proline 
and tyrosine-rich (P-Y) motifs. These P-Y motifs bind WW domains of a variety of proteins 
(Sudol et al., 1995). In fact, P-Y motifs in the Angiomotin proteins bind a variety of WW domain 
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containing proteins involved in growth signaling, including YAP and TAZ (Adler et al., 2013a; 
Wang et al., 2012; Wang et al., 2011; Zhao et al., 2011a). 
Two less well characterized regions of the Angiomotins are the residues that mediate 
binding to actin and LATS. These regions are both predicted to lie in the N-terminus of the 
protein in a region containing the P-Y motifs, as previously described (Paramasivam et al., 2011). 
Although the precise locations and mechanisms are vague, the functional relevance is highly 
visible. For example, the ability of the Angiomotins to bind actin allows them to modify the 
architecture of filamentous actin in several cell types (Ernkvist et al., 2006; Gagné et al., 2009). 
Also, the Angiomotin family members activate the protein kinase activity of LATS2, via direct 
binding, leading to increased phosphorylation of YAP by LATS2 (Paramasivam et al., 2011). 
However, exactly how the Angiomotins are able to accomplish actin reorganization and the 
activation of LATS remains unknown. Therefore, this thesis further examined the relationships 
between the Angiomotins and LATS activity and their impact on actin fiber formation, as these 
are likely important aspects of the functions of the Angiomotins. 
Angiomotin was first identified in 2001 as an 80-kDa isoform (Amot80) in endothelial 
cells (Troyanovsky et al., 2001). In mammary epithelial cells, Amot80 induces the loss of 
organization of apical junctions and stimulates cellular proliferation (Ranahan et al., 2011; 
Sugihara-Mizuno et al., 2007; Wells et al., 2006; Yi et al., 2011). This may explain why high 
levels of AMOT transcript strongly correlate with increased breast tumor grade as well as poor 
patient survival (Jiang et al., 2006). Angiomotin, therefore, was considered likely to be an 
oncogene. However in 2005, an alternative longer splice isoform of Angiomotin, the 130-kDa 
isoform of Angiomotin (Amot130) was identified, which was subsequently shown to inhibit 
migration and cell growth (Bratt et al., 2005; Ernkvist et al., 2006; Ernkvist et al., 2008). Thus, 
the AMOT gene encodes a transcript that is spliced to produce a long protein (Amot130) and a 
shorter version (Amot80) that have opposing functions. Mechanisms by which Amot130 could 
present such a different phenotype was largely unanswered (Roudier et al., 2009) until 2011, 
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when Amot130 along with the two other Angiomotin family members, Angiomotin-like 1 
(AmotL1) and Angiomotin-like 2 (AmotL2), were demonstrated to directly bind the 
transcriptional co-activators, YAP and TAZ. YAP and TAZ bind Angiomotins via their WW 
domains that recognize P-Y motifs within the long forms of Angiomotins (Chan et al., 2011; 
Wang et al., 2011; Zhao et al., 2011a). Interestingly, Amot80 lacks these N-terminal P-Y motifs, 
and no evidence exists that it directly binds YAP and TAZ. Importantly, Amot130, AmotL1, or 
AmotL2 prevents YAP nuclear localization and they inhibit cell proliferation in mammary 
epithelial cells (Chan et al., 2011). Various mechanisms for how Angiomotins inhibit YAP 
nuclear activity, both dependent and independent of YAP phosphorylation by LATS1/2 have 
been proposed (Chan et al., 2011; Leung and Zernicka-Goetz, 2013; Zhao et al., 2011a) (Figure 
1-9). Thus, further research into the mechanisms of YAP inhibition by the Angiomotins could 
lead to insight into their roles as tumor suppressor proteins and involvement in Hippo signaling. 
This thesis work found that the Neuronal-precursor-cell-expressed developmentally 
down-regulated protein 4 (Nedd4) family of ubiquitin ligases bind and regulate Angiomotin 
proteins via their P-Y motifs. The interactions identified an important family of proteins whose 
involvement in growth control and Hippo signaling is now being appreciated (Skouloudaki and 
Walz, 2012; Wang et al., 2012). 
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Figure 1-8 A Schematic Diagram of the Angiomotin Family. 
The Angiomotin family of adapter proteins consists of three genes Angiomotin (AMOT), 
Angiomotin-like 1 (AMOTL1), and Angiomotin-like 2 (AMOTL2) transcribing the four proteins 
presented. The gene AMOT has two protein isoforms, the 130-kDa isoform of Angiomotin 
(Amot130) and the 80-kDa isoform of Angiomotin (Amot80). AMOTL1 and AMOTL2, both have 
one protein form each in Angiomotin-like 1 (AmotL1) and Angiomotin-like 2 (AmotL2). These 
proteins share architecture. Each member has a PDZ binding motif that allows for interactions 
with polarity proteins containing PDZ domains. In the heart of all these proteins lies an ACCH 
domain, which is a coil-coiled domain that allows for homo- and hetero-dimerization of the 
Angiomotins and also interactions with membrane lipids. The long forms of the Angiomotins 
contain 2-3 P-Y motifs in their N-termini that allow them to bind proteins containing WW 
domains, such as YAP and TAZ. Finally, less well documented regions in Angiomotin proteins 
promote LATS activation and binding to actin in their N-termini. Relative amino acid residues for 
each domain/motif are provided in parentheses below the protein diagrams. 
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Figure 1-9 The Role of Angiomotin in the Inhibition of YAP and TAZ Nuclear Activity. 
Amot130 inhibits YAP and TAZ nuclear activity by multiple mechanisms. First, Amot130 
localizes YAP/TAZ to cell contacts, which is in part promoted by association with polarity 
proteins of the Crb and Par polarity complexes, possibly via the interaction of Amot130 with 
PALS1-associated tight junction protein (Patj). Secondly, Amot130 can also localize YAP/TAZ 
to filamentous actin and prevent their nuclear localization. Finally, Amot130 can increase the 
amount of phosphorylated YAP/TAZ, via Amot130 interaction with and activation of LATS 
protein kinases. Overall, Amot130 interacts with YAP and TAZ and prevents their translocation 
into the nucleus. This prevents YAP and TAZ from initiating transcription of pro-growth genes. 
The locations and size representations in this diagram are relative and not to scale. Figure 
modified from an unpublished figure by Clark Wells. 
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1.5. The Nedd4 Ubiquitin Ligases and Their Roles in Epithelial Cell Growth 
 
The attachment of ubiquitin moieties to target proteins is an important signal for a variety 
of cellular processes (Glickman and Ciechanover, 2002). Covalent attachment occurs first with 
the activation of a small ubiquitin protein. Activated ubiquitin requires energy from ATP 
hydrolysis to allow the ubiquitin activating enzyme (E1) to form a thiol-ester bond with ubiquitin 
(Pickart, 2001). This ubiquitin is then transferred and covalently attaches to an ubiquitin 
conjugating enzyme (E2). Typically, the E2 will bind to a specific ubiquitin ligase (E3) and 
transfer the ubiquitin directly to the bound targeted substrate. The ubiquitin binds to the substrate 
through an isopeptide bond between the C-terminal glycine residue of ubiquitin and the ε-amino 
group of a lysine residue on the substrate protein (Figure 1-10). However, in the case of some E3 
ligases, like the homologous to the E6-AP carboxyl-terminus (HECT) family, the E2 transfers the 
ubiquitin to a specific cysteine residue within the E3 before linking it to the already bound 
targeted substrate (Glickman and Ciechanover, 2002). 
The Nedd4 family proteins are examples of HECT E3 ubiquitin ligases that utilize 
themselves as an intermediate in the process of covalently attaching an ubiquitin moiety to a 
targeted substrate. Nedd4-like family proteins are encoded in eukaryotes that are grouped by their 
common architecture. Saccharomyces cerevisiae encode a single protein, Rsp5, which regulates 
varied cellular pathways involved in cell growth and cell shape (Rotin et al., 2000). Humans 
encode nine known Nedd4 family ligases that regulate many diverse cellular signaling including 
targeting for degradation many proteins like those involved in transforming growth factor beta 
and EGF signaling pathways (Chen and Matesic, 2007; Ingham et al., 2004). Because of their 
involvement in the degradation of tumor suppressive proteins, many of the Nedd4 ligases are 
labeled as proto-oncogenes. 
Nedd4 proteins rely on three important moieties for their function (Figure 1-11). First, 
they contain in their C-terminus, a catalytic HECT domain (Huibregtse et al., 1993a, b). A 
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cysteine in HECT domains transfers the ubiquitin moiety from an ubiquitin-conjugated E2 to the 
target substrate (Scheffner et al., 1995). This reaction is part of a thiol-ester cascade resulting in 
ubiquitination of a target protein. The reaction can add a single ubiquitin moiety, termed 
monoubiquitination, or it can serially add multiple ubiquitin moieties to form a polymer, termed 
polyubiquitination. Monoubiquitination is recognized by subcellular trafficking machineries for 
substrate internalization via endocytosis and recycling pathways (Hicke and Riezman, 1996; 
Marchese and Benovic, 2001; Roth and Davis, 1996). There are different types of 
polyubiquitination that vary in the lysine residue from which the new ubiquitin forms an 
isopeptide bond. Self-conjugation of ubiquitin occurs commonly at lysine-29, -48, or -63 on 
ubiquitin. Ubiquitination at lysine-48 almost exclusively targets substrates for degradation via the 
26S Proteasome (Thrower et al., 2000). Ubiquitination at lysine-29 and lysine-63 present 
different outcomes for the target based upon signaling context, localization, and specificity of the 
E3 ligase (Bonifacino and Traub, 2003; Hicke, 2001; Soetens et al., 2001). 
Nedd4 proteins also contain a C2 domain in their N-terminus that promotes direct 
interactions with phospholipids and proteins at the cellular membrane. The C2 domain therefore 
promotes interactions with substrates that localize at membranes (Nalefski and Falke, 1996; Plant 
et al., 1997). The C2 domain was originally identified in Ca2+-dependent isoforms of protein 
kinase C (Knopf et al., 1986). Beyond changes in localization, the C2 domain in some Nedd4 
proteins is inhibitory to the catalytic activity of the enzyme. In some cases, this inhibition can be 
released upon Ca2+-dependent binding to the C2 domain (Wang et al., 2010). 
Nedd4 proteins also contain 2-4 WW domains, similar to those seen in YAP and TAZ 
(section 1.3). These WW domains provide the E3 ligase with substrate specificity, by binding 
substrates with P-Y motifs (Chen and Sudol, 1995; Macias et al., 2002). The activity and function 
of Nedd4 proteins are altered or enhanced based upon their interactions with these proteins. For 
example, the Nedd4 ligase, Nedd4-2, is able to bind to and ubiquitinate the epithelial sodium 
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channel protein via its P-Y motif, leading to its degradation and thus reduce sodium transport 
across cell membranes. 
Nedd4 ligases ubiquitinate and thereby regulate proteins in a variety of cellular pathways. 
Generally, Nedd4 ligases are found to function as proto-oncogenes in many different types of 
cancers including breast cancer (Chen et al., 2009; Wang et al., 2007; Yeung et al., 2013). 
However, the Nedd4 ligase Atrophin-1 interacting protein 4 (AIP4), also known as Itch, is one of 
only three Nedd4 ligases that is not known to be altered, overexpressed, or amplified in cancer 
cells (Chen and Matesic, 2007). Therefore, the precise role of AIP4 in growth control is of 
significant interest. There is also evidence that AIP4 increases cell survival by degrading various 
proteins involved in apoptosis (Azakir et al., 2010; Rossi et al., 2005). Initially, AIP4 was 
examined in immune response pathways, as inactivation of AIP4 in mice results in a variety of 
inflammatory conditions due to an altered immune response (Hustad et al., 1995; Perry et al., 
1998). Direct evidence of AIP4 in pro-growth signaling was first identified in studies that showed 
that AIP4 polyubiquitinated and led to the degradation of the protein kinase, LATS1, via the 26S 
Proteasome. Expression of AIP4 increased cellular growth and tumorigencity in mammary 
epithelial cells (Ho et al., 2011; Salah et al., 2011; Yeung et al., 2013). Further analysis of how 
AIP4 influences Hippo signaling and cell proliferation is therefore important to clarify its role in 
growth control regulation in mammary cells, and is examined in this thesis. 
The lack of specificity of HECT domains is compensated by the ability of Nedd4 proteins 
to be directed to specific subcellular regions and substrates by binding to adapter proteins. Thus, 
depending on the adapter protein which interacts with the Nedd4 ligase, Nedd4 proteins can have 
dramatically different substrates and cellular effects. Further, the Nedd4 ligase AIP4 exists 
normally in an inhibited conformation that prevents AIP4 from ubiquitinating its substrates 
(Scialpi et al., 2008). The scaffold protein Spartin contains one P-Y motif that binds AIP4 and 
activates it, allowing for its self-ubiquitination. Self-ubiquitination is therefore a sign of increased 
ligase activity of AIP4. Binding of AIP4 to Spartin also brings AIP4 to lipid droplets allowing 
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AIP4 to ubiquitinate its substrate adipophilin (Hooper et al., 2010). Another adapter protein 
Nedd4 family-interacting protein 2 (NDFIP2) has three P-Y motifs, which bind to AIP4 and 
localize to the membrane, where active AIP4 ubiquitinates endophilin (Mund and Pelham, 2009). 
Both adapter proteins activate AIP4 through relieving its auto-inhibited conformation through the 
WW domain binding the adapter instead of the HECT domain (Figure 1-12). In both cases, the 
adapter protein was also essential for bringing the ligase into a specific region with the targeted 
substrate. Recently, the Angiomotins were also found to bind Nedd4 family proteins (Adler et al., 
2013a; Skouloudaki and Walz, 2012; Wang et al., 2012). Therefore, the relationship between the 
Nedd4 ubiquitin ligases and the Angiomotin adapter proteins is considered of great interest and is 
examined in this thesis. 
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Figure 1-10 Overview of the Process of Ubiquitination of a Target Protein. 
(A) Ubiquitination of a target protein begins with the activation of an ubiquitin moiety and 
subsequent covalent attachment to an ubiquitin activating enzyme (E1), using one molecule of 
ATP. The ubiquitin is then transferred and covalently attached to an ubiquitin conjugating 
enzyme (E2). Typically the E2 then binds to the ubiquitin ligase (E3). The ubiquitin is then 
transferred from the E2 to the targeted substrate via a covalent bond to a lysine residue (Lys). (B) 
Some E3 ubiquitin ligases function differently than presented in A. In this example, as seen with 
HECT domain ubiquitin ligases, the E2 binds to the E3, but instead of a direct transfer of the 
ubiquitin to the targeted substrate, the HECT domain is used as an intermediate via covalent 
attachment of the ubiquitin to a specific cysteine residue prior to its transfer to the targeted lysine 
on the substrate protein. Figure adapted from (Rotin and Kumar, 2009). 
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Figure 1-11 Conserved Domains of the Nedd4 Family of Ubiquitin Ligases in Humans. 
Nedd4 ubiquitin ligases share three characterized domain regions that are important for their 
functions in cells. The HECT domain (blue) is the catalytic core of the protein and contains a 
required cysteine for the transfer of an ubiquitin moiety to the targeted substrate. Secondly, each 
contains 2-4 WW domains (red) that interact with P-Y motifs in other proteins. These WW 
domains help bring specificity to the ligase, via direct interactions with substrates or adapter 
proteins containing P-Y motifs. They also serve to inactivate the HECT domain when not bound 
to adapter proteins. Finally, in the N-terminus, a C2 domain (green) allows for phospholipid and 
protein binding at the cell membrane and brings specificity for substrates localized in these 
regions. Figure adapted from (Ingham et al., 2004). 
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Figure 1-12 Adapter Proteins Increase the Activity of Nedd4 Ubiquitin Ligases. 
Nedd4 ubiquitin ligases have active and inactive conformations. Typically, Nedd4 ligases remain 
in an inactive form until needed. There are many ways to form this inhibited conformation. One 
way pictured (below) is through the WW domains, which can directly interact with the HECT 
domain, preventing it from functioning. The C2 domain can also inhibit the HECT domain in a 
similar manner. However, upon binding of an adapter protein like the one pictured here (N4BP1) 
(above) the conformation of the protein opens up allowing the HECT domain to perform its 
catalytic function of transferring the ubiquitin moiety to the targeted substrate. Therefore, these 
adapter proteins can alter the function of the ligases. Figure adapted from (Rotin and Kumar, 
2009). 
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1.6. Cell Lines and Model Systems Used in This Study 
 
The cell growth control pathways involved in mammary tumorigenesis were analyzed in 
a panel of cell lines. Mammary tumors are influenced by a variety of hormones and growth 
factors that have differing cancerous potentials (de Waard, 1969; Russo J, 1992). Importantly, 
examination of mammary epithelial cell growth regulation requires establishment of cell lines that 
are able to reflect tumor types from which they were derived (Kao et al., 2009; Neve et al., 2006). 
To this end, both tumorigenic and non-tumorigenic mammary epithelial cells were utilized to 
create a more accurate picture of influences on growth control across mammary epithelia. Cancer 
cell lines chosen were representative of a range of tumor types. These are examined below and 
include receptor status examining estrogen receptor (ER), progesterone receptor (PR), and human 
epidermal growth factor receptor 2 (HER2) as diagnostic markers for tumor type. The status of 
these receptors helps differentiate tumor type and may provide clues about specific growth 
signaling pathways in one tumor type versus another (Neve et al., 2006). Further, different cell 
lines had different signaling properties that enabled particular experimental approaches. 
MDA-MB-468 cells were used to represent a basal A, triple negative (ER-, PR-, HER2-) 
metastatic adenocarcinoma tumor type, lacking hormone (ER- and PR-) dependence and HER2 
overexpression (HER2-) (Cailleau et al., 1978). These cells were originally obtained from a 
pleural effusion of a 51-year old African American woman. These cells typically show high 
endogenous protein levels of Angiomotin and moderate levels of AIP4 and YAP. 
MCF7 cells represent a luminal, hormone receptor positive (ER+ and PR+) lacking 
HER2 overexpression (HER2-) IDC tumor type (Soule et al., 1973). These cells were obtained 
from a pleural effusion of a 69-year old Caucasian woman. The MCF7 cells were used especially 
in imaging experiments due to their high adhesiveness and flatness. This cancer cell model has 
very little endogenous Angiomotin and YAP protein levels, but maintains moderate AIP4 protein 
levels. 
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BT-474 cells represent a luminal, hormone receptor positive (ER+, PR+), and HER2 
overexpression (HER2+) IDC tumor type (Lasfargues et al., 1978). These cells were obtained 
from a primary breast tumor of a 60-year old Caucasian woman. This cancer cell line model has 
relatively high protein levels of Amot130 compared to Amot80. 
 MCF10A cells represent non-tumorigenic mammary epithelia. These cells were obtained 
from a reduction mammoplasty of a primary breast of a 36-year old Caucasian woman, which 
spontaneously immortalized (Soule et al., 1990). Interestingly, these cells share the same receptor 
status as MDA-MB-468 cells (ER-, PR-, HER2-) and other basal-like linages (Neve et al., 2006), 
but do not form tumors in nude mice. Therefore, these cells have been classified as a model to 
study normal mammary gland function (Debnath and Brugge, 2005). 
Experiments requiring high levels of endogenous proteins (Angiomotin and AIP4) or for 
co-immunoprecipitation experiments utilized the Human Embryonic Kidney (HEK) 293T cells. 
HEK 293T cells are genetically modified HEK 293 cells that contain the SV40 T-antigen 
(DuBridge et al., 1987). These cells excel at lentivirus production, gene expression, and protein 
production. Parental HEK 293 cells, were derived from embryonic kidney cells transformed with 
fragments of adenovirus type 5 DNA (Graham et al., 1977). 
Because two-dimensional growth of mammalian cells on plastic lacks 
microenvironmental cues and responses (Barcellos-Hoff et al., 1989; Bissell et al., 1982; Xu et 
al., 2009), a three-dimensional system was employed. This utilized a laminin-rich extracellular 
matrix (lrECM), termed MatrigelTM (Petersen et al., 1992). This system allows for formation of 
more physiologically relevant microenvironments (Debnath and Brugge, 2005; Debnath et al., 
2003; Kenny et al., 2007). For example, MCF10A cells, grown in the presence of lrECM, form 
polarized growth arrested structures called acini (Muthuswamy et al., 2001) (Figure 1-13). These 
acini more accurately represent a normal ductal environment according to genetic expression 
profiles (Kenny et al., 2007). Further, examination of cancer cell lines in this environment allows 
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for differentiation between cancer types, which present themselves differently in lrECM, 
depending upon the cancer tumor types from which they were derived (Kenny et al., 2007). 
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Figure 1-13 Growth Conditions of Mammary Epithelial Cells. 
(A) Illustration of mammary epithelial cells grown on two-dimensional plastic dishes or in a 
laminin-rich extracellular matrix (lrECM). Normal mammary epithelial cells plated on plastic 
grow into a monolayer, until contact-mediated inhibition shuts down their growth (left). When 
normal mammary epithelial cells are grown in lrECM (right), cells form a hollow sphere termed 
acini, which display functionally and genetically similar characteristics as mammary ductal 
epithelia in vivo. Acini have dramatically different morphologies and are sensitive to some 
biochemical signaling not seen when cells are grown on plastic. (B) The growth of normal and 
cancerous mammary epithelial cells appears different in lrECM. In normal cells, they undergo a 
quick proliferation phase, followed by a period of apoptosis of luminal cells resulting in luminal 
clearing and polarized acini (top). Cancer cells grown in lrECM display tumor-like properties and 
many times can grow into a tumor-like mass of cells, well after the polarized acini have stopped 
proliferating. Figure adapted from (Xu et al., 2009) and (Vargo-Gogola and Rosen, 2007). 
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1.7. Rationale and Central Focus 
 The overarching goal of this dissertation is to describe the signaling mechanisms that 
relate microenvironmental cues such as serum loss to the control of cell growth. Epithelial cells 
respond to factors in their surrounding microenvironment to modulate their rates of cellular 
division and proliferation (Hussein and Hassan, 2006; Rutherford and Ross, 1976). Some factors 
in serum, including LPA, S1P, and EGF, activate specific receptors that then initiate complex 
signaling that promotes cell proliferation and survival (Ishii et al., 2004; Wells, 1999). Recent 
studies find such signaling includes the Hippo pathway, a major mechanism for controlling cell 
growth, organ size, and tumorigenesis. LPA, S1P, and EGF accomplish this by inducing the 
activity of the transcriptional co-activators YAP and TAZ (Fan et al., 2013; Miller et al., 2012; 
Yu et al., 2012). However, very little is known about how epithelial cells, in the absence of these 
factors keep YAP and TAZ inhibited. In cell culture, epithelial cells are typically grown in 
medium containing 10 % Fetal Bovine Serum (FBS) (v/v), which contains high levels of LPA and 
S1P. Upon depriving cells of FBS, YAP phosphorylation increases and its ability to activate 
transcription is blocked (Miller et al., 2012). How this occurs remains unknown. 
Recent work implicates the Angiomotins in Hippo signaling, by directly binding and 
sequestering YAP out of the nucleus (Chan et al., 2011; Wang et al., 2011; Zhao et al., 2011a). 
Further, Angiomotins activate LATS1/2 protein kinases leading to increased phosphorylation of 
YAP (Paramasivam et al., 2011). However, there are no reported links between serum factors and 
the regulation of Angiomotins. It is hypothesized that serum factors play an important role in 
YAP activity through modulation of the functions of Angiomotins. 
 Further, the Nedd4 ubiquitin ligase, AIP4 binds to and polyubiquitinates LATS1, leading 
to LATS1 degradation (Salah et al., 2011). Recently, AIP4 was demonstrated to bind 
Angiomotins, although the functional outcome of this interaction is unclear (Wang et al., 2012) 
 Based upon the above observations, there is a gap in the understanding about the function 
of factors in the microenvironment that influence the growth of epithelial cells through Hippo 
 36 
 
signaling. While significant advances have been made in our understanding of this pathway, the 
role of the Angiomotins and Nedd4 ligases, like AIP4, in this process remains unknown. 
The central focus of this dissertation is the discovery of a major mechanism for growth 
inhibition in response to serum deprivation. The central focus was tested by examining: 1) The 
phosphorylation of the long isoform of Angiomotin, Amot130, and its effects on growth in 
mammary epithelial cells. 2) The fundamental role of Amot130-AIP4 complex formation and its 
effects in mammary cancer epithelial cells. 3) The effects of both serum deprivation and 
Amot130-AIP4 complex formation on downstream YAP activity in mammary cancer epithelial 
cells. Here, serum deprivation is found to activate the Hippo protein kinase, LATS1, which 
phosphorylates Amot130. Phosphorylation of Amot130 promotes the stability of Amot130 via 
formation of a complex with AIP4. The Amot130-AIP4 complex is further found to promote the 
degradation of YAP. Together, these events help explain how serum deprivation activates Hippo-
dependent pathways to prevent cellular proliferation and growth in mammary epithelial cells. 
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CHAPTER 2. MATERIALS AND METHODS 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Some text in this chapter was originally published in The Journal of Biological Chemistry and the 
Proceedings of the National Academy of Sciences USA. Adler et al. Amot130 Adapts Atrophin-1 
Interacting Protein 4 to Inhibit Yes-Associated Protein Signaling and Cell Growth. Journal of 
Biological Chemistry. 2013; Vol: 288, 25: 15181-15193. © the American Society for 
Biochemistry and Molecular Biology. Adler et al. Serum deprivation inhibits the transcriptional 
co-activator YAP and cell growth via phosphorylation of the 130-kDa isoform of Angiomotin by 
the LATS1/2 protein kinases. Proceedings of the National Academy of Sciences. 2013; Vol: 110, 
43: 17368-17373. © Proceedings of the National Academy of Sciences USA. 
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2.1. Methods of Cell Culture 
 
 Cells in two dimensions were cultured at 37 oC with 5 % CO2 (v/v) and defrosted and 
passaged as follows. Cells were rapidly defrosted from -80 oC in a 37 oC water bath. Then cells 
were collected by centrifugation for 1.5 minutes at 0.4 x g at room temperature. Medium was 
aspirated from the cell pellet, and the cells were resuspended with fresh medium into a 10 cm2 
plate. During the next day and continuing as needed, cells were washed with warm phosphate-
buffered saline (PBS). Cells were coated with a solution of 2.5 g/L trypsin (Sigma) combined 
with 5 mM EDTA (Sigma), rocked back and forth gently, and placed in the 37 oC incubator until 
the cells no longer adhered to the plastic. The released cells were then collected in an equal 
volume of medium, as that used to trypsinize cells. Cells were transferred to a conical vial and 
centrifuged at 0.4 x g for 1.5 minutes at room temperature. The resulting cell pellets were 
resuspended in medium before further dilutions or cell counting, transferred to the appropriate 
size plate, and placed back in the incubator. 
MDA-MB-468, MCF7, and HEK 293T cells were cultured in Dulbecco’s Modified Eagle 
Medium (DMEM) with 10 % FBS (v/v) (10 % serum). BT-474 cells were cultured in Roswell 
Park Memorial Institute (RPMI) medium with 10 % FBS. MCF10A cells were cultured in equal 
parts Hams-F12/DMEM supplemented with 50 µg/mL Bovine Pituitary Extract (Hammond, 
1078-NZ), 0.5 µg/mL hydrocortisone, 5 µg/mL human insulin, 10 ng/mL EGF, and 100 ng/mL 
cholera toxin. MCF10A cells were placed onto laminin-rich extracellular matrix (lrECM) 
(MatrigelTM, 7.5 mg/mL or greater protein, BD Bioscience) in MCF10A medium as described 
above except lacking only EGF. The cultured cells were incubated overnight and then replaced 
after 16 hours with medium supplemented with 5 ng/mL EGF. All cell lines were cultured with 1 
% (v/v) penicillin/streptomycin. MDA-MB-468, MCF7, and BT-474 cell lines were gifts from 
Harikrishna Nakshatri, Linda Malkas, and Brittney Shea-Herbert, respectively. MCF10A and 
HEK 293T cells were purchased from American Type Culture Collection (ATCC). 
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Cells were treated with cycloheximide (CHX) (Sigma, C7698) at 200 µg/mL as 
previously reported (Pervin et al., 2011), and treated with MG-132 (Calbiochem, 474790) at 25 
µM, as indicated. Cells were treated with Opti-MEM (Gibco, ref. # 31985-070) for all serum 
starvation studies, for times indicated. 
 
2.2. Stable Cell Line Generation Using Lentivirus 
 
The following method was used to generate stably expressed proteins or short hairpin 
RNA (shRNA). At the first day, HEK 293T cells were seeded at 4 million cells into a 10 cm2 
dish, before noon. Transient transfection of HEK 293T cells was carried out the next day about 32 
hours after plating. The target DNA construct (protein or shRNA) required the following: 1 mL 
Opti-MEM, 6 µg pCMV-VSVG, 5 µg psRSV-Rev, 10 µg pMDLg-RRE, 20 µg target DNA 
construct, and 25 µL polyethylenimine (PEI) (2 µg/mL). Transient transfections utilizing PEI 
were carried out as described below (section 2.3). The cells at the time of transfection should be 
about 75 % confluent. If less, reduce the PEI to 20 µL. The following morning, about 16 hours 
after transfection, the medium was aspirated and replaced with 7 mL of fresh medium. At that 
same time, target cell lines were plated for infection in cell line specific medium. For example, 
400,000 cells were split into a 6 cm2 dish per condition for the infection of 1-2 target DNA 
constructs. The following day about 24 hours after medium change, viral medium was removed 
from the HEK 293T cells, and then passed through a 0.45 µm filter before 10 µL polybrene (5 
mg/mL) was added per plate of viral medium. This viral medium was stored at 4 oC for up to two 
weeks. If a second round of viral harvesting was desired, 7 mL of fresh medium was added to 
viral producing HEK 293T cells. Finally, harvested viral medium was added to target cell lines 
(which had at least 24 hours to adhere) and allowed to infect for at least 4-6 hours prior to being 
replaced with appropriate cell line specific medium. Target cells were harvested between 24 and 
72 hours as indicated. 
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2.3. Method of Transient Transfection 
 
Transient transfection of cells was accomplished as follows. Cells were plated based on 
assay requirements. Typically, cells were allowed about 24 hours to adhere to the culture dishes, 
reaching about 80 % confluent, prior to transfection. The desired construct(s) or shRNA was 
added to a plastic falcon tube containing 1 mL of Opti-MEM. While vortexing at medium speed, 
a slightly lower volume of 2 µg/mL PEI (Sigma) was added dropwise to the Opti-MEM/DNA 
solution compared to the amount of DNA added (i.e. 4 µL PEI for 5 µg DNA). This mixture was 
allowed to incubate for 5 minutes at room temperature before addition to the cells. Transfection 
mixture was added to the sides of the plate of cells already covered in the appropriate medium 
from the previous cell split. 
 
2.4. Plasmids, Antibodies, and Lysis Buffers 
 
Plasmids: Full length Amot130, AmotL1, AmotL2, Nedd4 ligases, MST2, and YAP2 
were subcloned by PCR from Kazusa and IMAGE complimentary DNAs (cDNAs) into Creator 
based acceptor vectors (Colwill et al., 2006) for mammalian expression with the N-terminal tags 
2X-Myc, 3X-Flag-, monomeric(m) mCitirine- (referred to as YFP), mCerulean- (referred to as 
CFP), and mCherry-. Previously described vectors include Myc-tagged AIP4, Myc-tagged AIP4 
(C830A) (Ingham et al., 2005), HA-tagged Ubiquitin (Guo et al., 2006), and pRL-TK-Renilla 
(Promega, E2241) (Ranahan et al., 2011). Vectors acquired from Addgene: Flag-tagged YAP2 
(19045), Flag-tagged LATS1 (18971), HA-tagged Lys-0 (K0) Ubiquitin (17603) (Lim et al., 
2005), pCMV-VSVG (8454), psRSV-Rev (12253), pMDLg-RRE (12251), and shRNA control 
pLKO.1 (1864). The three P-Y motifs LPTY (P-Y1), PPEY (P-Y2), and PPEY (P-Y3) as well as 
serine-175 in Amot130 were mutated by the Stratagene QuikChangeTM site directed mutagenesis 
to encode LPTF (P-Y1F), PPEF (P-Y2F), PPEF (P-Y3F), and serine-175 mutated to alanine 
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(S175A) as single mutations. The P-Y mutants were subsequently used as templates for the 
double mutations. The lysine-481 in Amot130 was mutated to an arginine (K481R) and was 
ordered as a synthesized gene fragment from Eurofins MWG Operon and cloned into pBluescript 
II SK(+). The cDNA encoding Amot130 (K481R) mutant was sub-cloned by restriction enzymes 
into the vectors described in the Appendix. All mutants cloned are also outlined in the Appendix. 
The cDNA segments encoding the WW domains of AIP4 and YAP2 were amplified by PCR and 
cloned into PGEX-KG for glutathione s-transferase (GST) pull-down analysis. Plasmids used in 
this thesis that were given as gifts and described previously include: His-tagged Ubiquitin wild-
type, (K48R), and (K63R) (Hua Lu) (Lo et al., 2012), 5XGal4-luc and Gal4-TEAD4 (Lawrence 
Quilliam) (Nguyen et al., 2012). Full descriptions of each cloning strategy for each cDNA used 
and all sets of sense and anti-sense oligonucleotide primers are found in the Appendix. 
Antibodies for immunoblot and dilutions: Amot 1:1000, AmotL1 1:5000, HA (12CA5) 
1:1000, Myc (9E10) 1:1000, as described in (Ranahan et al., 2011). Purchased antibodies include: 
Flag (Sigma, F3165) 1:10000, Flag (Sigma, F7425) 1:1000, Myc (Cell Signaling, 2272S) 1:1000, 
YFP/GFP (Invitrogen, A6455) 1:1000, AIP4 (BD Biosciences, 611198) 1:1000, AIP4 (Santa 
Cruz, G-11 sc-28367) 1:200, GAPDH (Millipore, MAB374) 1:5000, LATS1 (Bethyl, A300,-
477A) 1:1000, pS909 LATS1 (Cell Signaling, 9157S) 1:1000, YAP (Abnova, H00010413-MO1) 
1:1000, pS127 YAP (Cell Signaling, 4911S) 1:1000, TAZ (BD Biosciences, 560235) 1:1000, His 
(Abnova, MAB1274) 1:1000, Caveolin1 (BD Biosciences, 610407) 1:1000, snRNP70 (Santa 
Cruz, C-18 sc-9571) 1:1000, and Thiophosphate Ester (Abcam, 92570) 1:5000. Antibodies for 
immunoprecipitation and amount used per reaction: AIP4 (Santa Cruz, G-11 sc-28367) 4 µg, 
YFP/GFP (Invitrogen, A6455) 2 µg, Amot (Heller et al., 2010) 2 µg, or Flag (Sigma, F3165) 2 
µg. 
Lysis buffers: Cells on plastic and lrECM were lysed in radioimmunoprecipitation assay 
(RIPA) buffer (50 mM Tris pH 8.0, 2 mM EDTA, 10 % Triton-100, 150 mM NaCl, 0.1 % SDS) 
containing 1 mM NaVO4, 2 mM β-glycerol phosphate, and protease inhibitor cocktail (Sigma) 
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unless otherwise noted. For immunoprecipitation reactions, cells on plastic were lysed in 
phospholipase C (PLC) lysis buffer (50 mM HEPES pH 7.5, 150 mM NaCl, 10 % Glycerol, 1 % 
Triton X-100, 1.5 mM MgCl2, and 1 mM EGTA) containing protease inhibitor cocktail (Sigma). 
The volume of lysis buffer used was variable between assays. 
 
2.5. Method of Immunoblot and Western Analysis 
 
 Proteins were resolved and analysis of protein completed via a sodium dodecyl sulfate 
polyacrylamide gel electrophoresis (SDS-PAGE) combined with a western blot analysis method 
that follows. First, cells were placed on ice and medium was aspirated off the cells. Cells were 
washed twice with cold PBS. Lysis buffer, described in section 2.4, was added directly to cells on 
plates. For HEK 293T cells, plates were scraped immediately and mixture was transferred to 1.5 
mL tubes. For all other cell lines, cells were left to incubate with the lysis buffer on the plates for 
5 minutes, then were scraped and transferred to 1.5 mL tubes. Cells in lysis buffer were pipetted 
several times to ensure disruption of aggregates, then transferred to ice and incubated for 10 
minutes before a 10 minute centrifugation at 17,949 x g at 4 oC. The supernatant was saved and 
used as clarified lysates. Bicinchoninic acid (BCA) (Bio-Rad) assay was used to determine the 
protein concentrations of clarified lysates. Normalized protein concentrations from lysates were 
boiled in SDS-PAGE sample buffer and loaded onto 6, 8, or 10 % polyacrylamide gels, 
depending upon size of proteins of interest. For example, the Angiomotins are best visualized 
with an 8 % polyacrylamide gel. Gels were run at 80 Volts for 15 minutes, then 140 Volts for 
about 45 minutes. Proteins were then transferred to Protran BA85 nitrocellulose membranes (GE 
Healthcare Life Sciences) via Genie-Blotter (Idea-Scientific) for 1.5 hours at 12 Volts. 
Membranes were briefly washed with ultrapure water. Then, membranes were blocked in a 5 % 
low-fat milk solution for 30 minutes on an orbital shaker at room temperature. Membranes were 
washed 3 X in TBS with 0.075 % (v/v) Tween20 (Sigma) (TBST) for 5 minutes using an orbital 
 43 
 
shaker at room temperature. Then, membranes were transferred to sealed hybridization bags and 
incubated with 4 mL TBST and diluted primary antibody, as described in section 2.4, on a nutator 
for 1 hour at 4 oC. Then, membranes were washed 3 X in TBST for 5 minutes on an orbital shaker 
at room temperature. Membranes were then incubated with goat anti-rabbit Dylight 680 (Thermo-
Scientific) conjugated secondary and/or goat anti-mouse Dylight 800 (Thermo-Scientific) 
conjugated secondary or a donkey anti-goat Dylight 800 (Licor Odyssey) conjugated secondary at 
a 1:20000 dilution in TBST for 30 minutes, on an orbital shaker at room temperature, in the dark. 
Membranes were washed 3 X in TBST for 5 minutes on an orbital shaker at room temperature in 
the dark before being imaged on LiCor Odyssey scanner and quantified with ImageJ (Rasband, 
2011). 
 
2.6. Immunoprecipitation Procedure 
 
 Immunoprecipitation of proteins from cell lysates with a Flag (Sigma, F3165) or 
YFP/GFP (Invitrogen, A6455) antibodies was achieved as follows. Cells were grown on a 10 cm2 
plate and harvested in 1 mL PLC lysis buffer, as described in section 2.4. After the centrifugation 
step described for cell harvesting of protein, as described in section 2.5, 100 µL of lysate from 
tube was removed and saved on ice as lysate. To the remaining volume, 2 µg of the desired 
antibody was added to the 1.5 mL tube containing the immunoprecipitation (IP) reaction. The IP 
reaction was allowed to rock for 1-2 hours on a nutator at 4 oC. IP reactions were then centrifuged 
at 956 x g for 2 minutes at 4 oC. To the tube, 20 µL of diluted protein G sepharose, using a cut 
pipette tip, was added to each IP reaction. The IP reaction rotated on a nutator at 4 oC for 1 hour. 
IP reactions were then centrifuged at 956 x g for 2 minutes at 4 oC. The supernatant was removed 
and discarded. The bead pellet was then washed 3 X with PLC lysis buffer, without protease 
inhibitors for 5 minutes each at 4 oC and then centrifuged at 956 x g for 2 minutes at 4 oC 
following each wash. At end of the last centrifugation, the supernatant was removed, and 60 µL 
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of 2X-concentrated SDS-PAGE sample buffer was added to each tube. At the same time, 20 µL 
of 1X SDS-PAGE sample buffer was added to the lysates that were saved. Both lysates and IP 
reactions were boiled for 5 minutes at 100 oC. The IP reactions were centrifuged at 956 x g for 2 
minutes at room temperature. Then roughly 60 µL of IP reaction mixture was removed and added 
to a new 1.5 mL tube, which was centrifuged again at 956 x g for 2 minutes at room temperature. 
Finally, 15 µL of the IP reactions and lysates were added to an appropriate SDS-PAGE gel and 
analyzed, as described in section 2.5. 
Immunoprecipitation of proteins from cell lysates with Amot (Heller et al., 2010) or AIP4 
(Santa Cruz, G-11 sc-28367) antibodies were achieved as follows. Following protocol outlined 
above, prior to incubation with primary antibody, IP reaction was pre-incubated with 20 µL 
diluted protein A sepharose and allowed to rock on nutator for 30 minutes at 4 oC. Then tubes 
were centrifuged at 956 x g for 2 minutes at 4 oC. The supernatant was saved and transferred to a 
new tube. Remaining steps are the same as outlined above. Exceptions include the utilization 4 µg 
of the AIP4 antibody for the IP and utilizing protein A sepharose instead of protein G sepharose 
for the 1 hour incubation to bind the primary antibodies. 
 
2.7. Glutathione S-Transferase Pull-Down Procedure 
 
 Analyses of GST-fused proteins binding to endogenous proteins from cellular lysates 
were accomplished as follows. HEK 293T cells were grown in a 10 cm2 plate and were lysed, as 
described in section 2.5, with 500 µL PLC lysis buffer. From this clarified lysate, 100 µL was 
saved as a control. In a separate 1.5 mL tube, 20 µL glutathione-sepharose beads were added 
using a cut tip on a pipette. Beads were washed with cold PBS twice and centrifuged at 956 x g 
for 2 minutes at 4 oC. Further, these beads were then incubated with 500 µmol GST-fused protein 
for 30 minutes on nutator at 4 oC. Finally, beads were centrifuged at 956 x g for 2 minutes at 4 oC 
and washed 3 X in cold PBS. The immobilized GST-fused protein on glutathione-sepharose was 
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incubated in its 1.5 mL tube to a final concentration of 2 µg/µL, with the remaining HEK 293T 
cell lysate to a total volume of 500 µL for 2 hours at 4 oC on nutator with constant mixing. 
Immobilized protein complexes were washed 3 X with PLC lysis buffer with centrifugation steps 
of 956 x g for 2 minutes at 4 oC. The bound protein was eluted with 2X-concentrated SDS-PAGE 
loading buffer, and analyzed as described in section 2.5. 
 
2.8. RNA Interference and Short Hairpin RNA Information 
 
 Transient knockdown of proteins utilized 20 nM small interference RNA (siRNA) AIP4 
ON-TARGETplus SMARTpool (L-007196-00-0005, Dharmacon), 20 nM siRNA LATS1 
siGenome SMARTpool (M-003865, Dharmacon), or 20 nM control ON-TARGETplus (#1 D-
001810-01-20, Dharmacon) and the DharmaFECT transfection protocol using the DharmaFECT 
Duo transfection reagent (# T-2010-01, Dharmacon). 
For stable silencing, shRNA plasmid Angiomotin (Sigma, cat. # TRCN0000162009), 
shRNA plasmid AIP4 (Sigma, cat. # TRCN0000002087) (Salah et al., 2011), or shRNA plasmid 
LATS1 (Sigma, cat. # TRCN0000001777) (Nguyen et al., 2012) sequences in pLKO.1 or a 
scramble shRNA control pLKO.1 (1864, Addgene) were transfected into HEK 293T cells with 
packaging vectors (pCMV-VSVG, psRSV-Rev, pMDLg-RRE) by PEI method, as described in 
sections 2.2 and 2.3. All plasmids have been previously described or validated. Cells silenced for 
Angiomotin were harvested 24 hours after infection. All other silencing experiments were 
harvested 48 hours after infection. The shRNA sequences are provided in the Appendix. 
 
2.9. RNA Extraction, cDNA Synthesis, and Quantitative Real Time PCR 
 
 RNA for quantitative real time polymerase chain reaction (qRTPCR) was extracted by 
the following method. Stably infected cells were plated onto 6 cm2 plate. When ready for harvest, 
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media was aspirated and cells were washed with 1 mL cold PBS. Then 1 mL Tri-Reagent LS 
(Sigma) was added directly to cells. This mixture was transferred to a 1.5 mL tube and incubated 
at room temperature for 5 minutes. Then 200 µL of chloroform was added, followed by inverting 
the tube to mix for 15 seconds. This mixture was allowed to incubate at room temperature for 5 
minutes. Tube was centrifuged at 4 oC for 10 minutes at 17,949 x g. Importantly, all remaining 
steps were performed on ice, unless otherwise noted. The upper aqueous phase containing RNA 
was transferred to new 1.5 mL tube. The other two layers, interphase (DNA, white) and organic 
phase (proteins, lipids, pink), were discarded. To the upper aqueous phase, 500 µL cold 
isopropanol was added to precipitate the RNA. The tube was inverted to mix for 15 seconds and 
allowed to incubate on ice for 5 minutes. The sample was centrifuged at 4 oC for 10 minutes at 
17,949 x g. Supernatant was removed completely from tube and discarded, being careful not to 
lose the pellet. The RNA pellet was washed with 1 mL cold 70 % ethanol. The sample was 
centrifuged at 10,621 x g at 4 oC for 5 minutes, and then ethanol was removed completely and 
discarded. The RNA pellet dried for 7 minutes with tube open before resuspension in 20-50 µL 
diethylpyrocarbonate (DEPC)-treated water. Finally, the NanoDrop spectrophotometer 
(Nanodrop Technologies) was used to determine RNA concentration. 
 Utilizing the RNA generated above, generation of cDNA was accomplished as follows. 
First, 2-5 µg RNA were added to 2 µL Oligo dT (Invitrogen) and 4 µL dNTP Mix (10 mM) 
(Invitrogen). The total volume was raised to 24 µL with DEPC-treated water in a 1.5 mL tube. 
Mixture was incubated for 5 minutes at 65 oC. Mixture was quickly placed on ice followed by 
rapid centrifugation. Then 9.5 µL DEPC-treated water, 0.5 µL RNase Out (Invitrogen), 4 µL 10X 
reverse transcriptase buffer MulV (New England Biolabs), and 2 µL of an in-house reverse 
transcriptase (RT) was added to a tube. Tube was gently mixed with a pipette tip then incubated 
at 50 oC for 45 minutes. This followed with incubation at 85 oC of the tube for 5 minutes to 
inactivate the RT. The sample was placed on ice and followed with a quick centrifugation. The 
sample was then incubated with 0.4 µL RNAse Cocktail (Ambion, cat. #AM2286) for 30 minutes 
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at 37 oC. Samples were then placed on ice, followed with a quick centrifugation, and then stored 
at 4 oC for up to one week until ready for real time PCR. Longer term storage was at -20 oC. 
 The cDNA made from above steps was then used for qRTPCR as follows. Realplex2 
epGradient mastercycler (Eppendorf) with 2X SensiMix SYBR No-ROX Mastermix (BioLine) 
was utilized per manufacturer’s instructions for all qRTPCR reactions. cDNA was diluted to 400 
ng/mL in DEPC-treated water. Each reaction was 20 µL, and contained 3 µL DEPC-treated 
water, 1 µL sense primer (2.5 µM), 1 µL anti-sense primer (2.5 µM), 10 µL 2X SYBR 
Mastermix, and 5 µL cDNA template. Oligonucleotides primers used for qRTPCR are described 
in the Appendix. All values were normalized to GAPDH, which was run alongside the genes of 
interest. 
 
2.10. Three-Dimensional Growth Assay Procedure 
 
 Three-dimensional growth assays for MCF10A and MDA-MB-468 cells was completed 
by the following method to be used for stereomicroscopic imaging and immunoblot. Four hours 
prior to seeding, 1 mL aliquots of lrECM were placed on ice. Once depolymerization of lrECM 
was complete, cells were trypsinized, as described in section 2.1. Then 200 µL of lrECM was 
spread per 35 mm2 dish. Dishes were transferred to the tissue culture incubator and allowed to 
incubate for 10 minutes. Each 35 mm2 dish received 300,000 MCF10A cells or 200,000 MDA-
MB-468 cells. MCF10A cells were resuspended in MCF10A medium, as described in section 2.1, 
lacking only EGF, overnight then replaced after 16 hours with medium supplemented with 5 
ng/mL EGF. MDA-MB-468 cells were resuspended in DMEM with 10 % FBS (v/v). MCF10A 
medium was replaced every four days as needed. Stereoscope images were taken at times 
indicated. MDA-MB-468 cell stereoscopic images taken at 10X magnification in lrECM were 
analyzed for total pixel intensity per field of view because of the complex structures they formed 
in lrECM. MCF10A acini stereoscopic images taken at 4X magnification in lrECM were 
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analyzed for cross-sectional area/acini because of the fairly uniform spheres they formed in 
lrECM. MCF10A acini were also imaged with 10X magnification for high resolution images.  
 Proteins were extracted from MCF10A acini grown on 35 mm2 dishes at time of imaging 
for immunoblot with the following protocol. Plates were placed on ice and medium was aspirated, 
and acini were washed with 500 µL cold PBS. Then acini were lysed by addition of 100 µL RIPA 
with inhibitors, as described in section 2.4. Acini were scraped into slurry and transferred to a 1.5 
mL tube. Solution was passed 3 X through a 27-gauge needle into a 10 mL syringe, then 
transferred to ice for 10 minutes. Tubes were centrifuged at 4 oC for 15 minutes at 20,817 x g. 
Supernatant was removed and transferred to new tube. Subsequent steps are described in section 
2.6. 
 
2.11. TEAD Reporter Assay 
 
 Cells were transiently transfected 24 hours after passaging, as described in section 2.3, 
with 0.02 µg TK-Renilla as a transfection control, 0.05 µg 5XGal4-luc, and 0.4 µg Gal4-TEAD4, 
in addition to the indicated plasmid vectors (0.63 µg Flag-tagged YAP2 along with 0.63 µg YFP-
tagged Amot130 or YFP-tagged Control Vector). Luciferase was allowed to accumulate for 16 
hours before cell lysis in passive lysis buffer per manufacturer’s instructions (Promega). Samples 
were processed per manufacturer’s instructions for Dual-Luciferase Reporter Assay System 
(Promega, TM040). A dual luminometer (BioSystems) was used to analyze all samples. Data is 
presented as average ratios of Firefly luciferase counts over control Renilla luciferase counts. 
 
2.12. Cell Accumulation Assay 
 
Cellular accumulation was assayed after plating 10,000 MDA-MB-468 cells in 12-well 
plates in 10 % serum (v/v) or in Opti-MEM (Gibco, ref. # 31985-070), for serum starved 
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conditions. Cells were trypsinized at the indicated times, as described in section 2.1. Cells were 
counted with a hemocytometer. Data represents the mean of three experiments. 
 
2.13. Cell Proliferation Assay 
 
 Measurement of cellular proliferation was carried out per manufacturer’s instructions for 
the CellTiter96® Non-Radioactive Cell Proliferation Assay (Promega, G4000). Measurements 
were made three days after plating 5,000 MDA-MB-468 cells stably expressing indicated proteins 
into 100 µL total volume of 10 % serum (v/v) in a 96-well chamber. Data represents the mean of 
four experiments. 
 
2.14. Method of Nuclear Fractionation 
 
In order to isolate the nuclear fraction of cells for immunoblot analysis, the method that 
follows was used. MDA-MB-468 cells were harvested 24 hours after plating 5 million cells onto 
a 10 cm2 dish. Cells were removed from the incubator and the medium was aspirated. Cells were 
washed 2 X with cold PBS. Cells were lysed using 500 µL Nuclear Fractionation Buffer (10 mM 
HEPES (pH 7.9), 1.5 mM MgCl2, 10 mM KCl, and 0.05 % IGEPAL 
(octylphenoxypolyethoxyethanol), supplemented with inhibitors, as described in section 2.4. 
Cells were immediately scraped into a 1.5 mL tube and incubated on ice for 10 minutes. Cells 
were centrifuged at 956 x g for 10 minutes at 4 oC. Then the supernatant was removed and saved 
as the cytosolic fraction. Pellet was gently washed 3 X in 1 mL Nuclear Fractionation Buffer, and 
each wash followed with centrifugation at 956 x g for 1 minute at 4 oC. Pellet was then 
resuspended in 80 µL RIPA lysis buffer with inhibitors, as in section 2.4, and passaged 40 times 
with a P-200 pipette. Mixture was incubated on ice for 10 minutes before centrifugation at 20,817 
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x g for 10 minutes at 4 oC. The supernatant was saved and labeled as the nuclear fraction. The 
protein concentrations of both the cytosolic and nuclear fractions were determined with BCA 
assay, and then analyzed with SDS-PAGE and western blot, as described in section 2.5. 
 
2.15. Method of Membrane Fractionation 
 
Membranes were isolated with less than 1 mL PLC buffer as described in section 2.4, but 
lacking detergent. Cells were lysed in a 1 mL glass dounce with 20 strokes of the pestle, and 
added to a 1.5 mL tube and then centrifuge at 1,000 x g for 3 minutes at 4 oC. The supernatant 
was added to a TLA 120.2 rotor (Beckman, SN 0641484) and spun at 175,000 x g for 30 minutes 
at 4 oC. The supernatant was saved as the cytosolic fraction. Then the pellet was washed in PLC 
detergent-free buffer and spun again at 175,000 x g for 10 minutes at 4 oC. Then the pellet was 
resuspended in 80 µL PLC detergent-free buffer with a 20-gauge needle. The mixture was spun at 
20,000 x g for 10 minutes at 4 oC and supernatant was saved as the membrane fraction. These 
fractions were analyzed for protein concentrations of both the cytosolic and membrane fractions. 
Immunoprecipitation reactions were carried out, as described in section 2.6, with detergent-free 
PLC lysis buffer. 
 
2.16. In Vitro SPOTS Phosphorylation Assay Procedure 
 
15-residue peptides were synthesized using the standard SPOT method onto β-alanine 
derivatized cellulose membranes via a MultiPep synthesizer (Intavis AG, Cologne, Germany) and 
subjected to a kinase phosphorylation assay in the presence of 25 mM MOPS pH 7.2, 25 mM 
MgCl2, 5 mM EGTA, 2 mM EDTA, 0.2 mg/mL BSA, 1 mM DTT, 12.5 mM β-glycerol 
phosphate, 50 µM cold ATP, 12 µCi/mL [γ-32P] ATP, and 0.8 µg/mL (7 nM) of GST-LATS2 
(SignalChem, L02-11G). The peptide blots were blocked with 0.5 % BSA in PBS pH 7.4 as well 
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as 1 mM ATP in PBS for 30 minutes each followed by PBS washes. The reactions were 
incubated for overnight at room temperature, terminated with three washes (100 mM sodium 
phosphate pH 7.0, 1 M NaCl, 10 mM EDTA) and dried; the extent of radioactive phosphate 
incorporation was quantified using a Fujifilm phosphoimager and expressed as photostimulated 
luminescence density (PSL/mm2). 15-residue peptides used for assay: Amot130 Ser-175: 
QGHVRSLSERLMQMS, Amot130 control (S175A): QGHVRSLAERLMQMS, AmotL1 Ser-
262: QGHVRSLSERIMQLS, AmotL1 control (S262A): QGHVRSLAERIMQLS, AmotL2 Ser-
159: HGHVRSLSERLLQLS, AmotL2 control (S159A): HGHVRSLAERLLQLS, and YAP Ser-
127: PQHVRAHSSPASLQL. 
 
2.17. In Vitro Kinase Assay Procedure 
 
The immunoprecipitated Flag-tagged Amot130, Amot130 (S175A) or control vector was 
incubated with 1.5 µM serine/threonine protein phosphatase 1 (PP1)α (His-tag purified) for 4 
hours at 4 oC in the presence of 50 mM HEPES pH 7.4, 100 mM NaCl, 1 mM MnCl2, 0.01 % 
Brij-35, 2.5 mM DTT, 2X-concentrated Calbiochem Protease Inhibitor Cocktail Set V. The 
samples were then washed 3 X with 25 mM MOPS pH 7.2, 25 mM MgCl2, 5 mM EGTA, 2 mM 
EDTA, 0.2 mg/mL BSA and then subjected to a kinase assay in the presence of 25 mM MOPS 
pH 7.2, 25 mM MgCl2, 5 mM EGTA, 2 mM EDTA, 0.2 mg/mL BSA, 1 mM DTT, 12.5 mM β-
glycerol phosphate, 2X-concentrated Calbiochem Protease Inhibitor Cocktail Set V, 2X-
concentrated Calbiochem Phosphatase Inhibitor Cocktail Set I, and 50 µM ATP-γ-S tetralithium 
salt (Tocris Bioscience, 4080). The substrates were incubated with either purified GST-LATS2 
kinase (0.8 µg/mL) (SignalChem, L02-11G) or immunoprecipitated Flag-tagged LATS1 kinase 
(activated via co-expression with MST2 in HEK 293T cells), as described in section 2.6, 
overnight at 4 oC, terminated with the addition of 50 mM EDTA. The samples were then 
alkylated via the addition of 2.5 mM p-nitrobenzyl mesylate/5 % DMSO (v/v) (Abcam, 
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ab128910), incubated for 1 hour at room temperature, and analyzed by SDS-PAGE and western 
blot, as described in section 2.5. 
 
2.18. Immunofluorescence and Stereomicroscopy 
 
Confocal images were acquired using structured light via an Apotome on a Zeiss Axio 
ObserverZ1 and processed and analyzed with Zeiss Zen. Stereo images were acquired using a 
Nikon SMZ1500 microscope. Immunofluorescence was performed as previously described 
(Heller et al., 2010) with the YAP (Abnova, H00010413-MO1) antibody at a 1:500 dilution. 
Secondary antibodies included Alexa 546 (Invitrogen) at a dilution of 1:500. Endogenous actin 
was imaged with Phalloidin-594 Conjugate (Santa Cruz, sc-363795). Nuclei were stained with 
Hoechst. All labels including primary and secondary antibodies were diluted in blocking buffer 
solution of (PBS/5 % BSA/1 % Saponin). The three fluorescent signals (green, red and blue) were 
excited with the Zeiss epifluorescent YFP, DsRed, and DAPI filter sets. 
Three-dimensional acini images were obtained from 5,000 MCF10A cells plated onto 
lrECM, as described in section 2.10, but onto collagen coated filters. After 14 days, the slides 
were methanol fixed at the indicated times, as previously described (Ranahan et al., 2011). 
 
2.19. Statistical Analysis 
 
Immunoblot (pixel intensities), real time, cell proliferation, cell accumulation, total cross-
sectional area/acini, and pixel integrated intensity/field data are presented as the means ± standard 
deviation (S. D.). P-values showing differences were calculated by an unpaired two-tailed t-test 
and for showing no differences by a one-tailed t-test. 
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CHAPTER 3. THE LONG ISOFORM OF ANGIOMOTIN IS PHOSPHORYLATED BY 
THE LATS1 AND LATS2 PROTEIN KINASES AND INHIBITS GROWTH IN 
MAMMARY EPITHELIAL CELLS 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Some text in this chapter was originally published in Proceedings of the National Academy of 
Sciences USA. Adler et al. Serum deprivation inhibits the transcriptional co-activator YAP and 
cell growth via phosphorylation of the 130-kDa isoform of Angiomotin by the LATS1/2 protein 
kinases. Proceedings of the National Academy of Sciences. 2013; Vol: 110, 43: 17368-17373. © 
Proceedings of the National Academy of Sciences USA. 
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3.1. Introduction 
 
 Cells deprived of serum have inhibited proliferation (Pardee, 1974). Many pathways have 
been implicated in this inhibition of growth via serum starvation, including those that inhibit cell 
division and control cell cycle checkpoints (Khammanit et al., 2008; Welsh et al., 2001). 
Recently, components of the Hippo signaling pathway were found to be regulated by serum 
factors including LPA, S1P, and EGF (Fan et al., 2013; Miller et al., 2012; Yu et al., 2012). For 
instance, these serum factors negatively regulate LATS to promote pro-growth signaling in 
epithelial cells. However, it was unclear how, under steady state conditions, LATS activity was 
inhibited. 
The LATS protein, as its name implies, is a potent tumor suppressor protein. It is a 
serine/threonine protein kinase shown originally to phosphorylate multiple substrates involved in 
cell proliferation and survival pathways in Drosophila (Xu et al., 1995a). There are two 
mammalian homologs (LATS1 and LATS2) (Tao et al., 1999; Yabuta et al., 2000) that play 
critical roles in phosphorylation of substrates involved in cytokinesis, actin polymerization, and 
cell-cycle checkpoints (Chiyoda et al., 2012; Li et al., 2003; Visser-Grieve et al., 2011; Yang et 
al., 2004). Mice with inactivated LATS1 develop soft-tissue sarcomas and other tumors, 
highlighting its tumor suppressive functions (St John, 1999). Reasonably, new substrates of 
LATS will likely regulate cell division and growth control to transmit LATS tumor suppressive 
functions in cells. 
In this thesis, serum starvation is shown to activate the LATS1 protein kinase. Further, 
active LATS1 and LATS2 protein kinases are found to directly phosphorylate the Ser-175 residue 
in the N-terminus of the long isoform of Angiomotin (Amot130). While Amot130 is known to be 
inhibitory to YAP via its ability to promote LATS activity, little is known about a direct 
mechanism for how Amot130 may relay Hippo signaling for growth inhibition (Paramasivam et 
al., 2011; Zhao et al., 2011a). Here, phosphorylation of Amot130 at Ser-175 is shown to be 
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critical for Amot130 to inhibit cellular growth in mammary epithelial cells. This indicates a novel 
kinase-substrate pairing between LATS and Amot130 that likely is part of an inhibitory 
mechanism leading to cellular growth arrest. 
 
3.2. Results 
 
3.2.1. Serum Deprivation and LATS1 Protein Impact the Protein Levels of Amot130 
 The serum factors EGF, S1P, and LPA activate YAP through GPCR and receptor 
tyrosine kinase (RTK) initiated signaling. Here, the converse process, of starving cells of serum is 
shown to induce Hippo signaling and YAP inhibition in breast cancer and non-transformed model 
cell lines. This delineates a mechanism for how cells lacking these factors actively inhibit their 
growth. Initially, the effects of serum starvation over time in MDA-MB-468 breast cancer cells 
were measured on the Hippo pathway proteins LATS1, YAP, and TAZ. The phosphorylation of 
LATS1 at Ser-909, a surrogate measure of activity, increased by 24 hours, while the levels of 
YAP and TAZ declined (Figure 3-1), as previously reported (Miller et al., 2012). Additionally, 
the relative levels of two Angiomotins (Amot130 and AmotL1) were examined during this 
timecourse. Interestingly, the levels of Amot130 increased between 24-30 hours, unlike levels of 
AmotL1, which were unchanged. Thus, serum starvation specifically increases Amot130 steady 
state protein levels. This increase in steady state protein levels in response to serum starvation 
was found to be significant in all lines tested including MDA-MB-468, HEK 293T, and BT-474 
cells (Figure 3-2A-C), which all show relatively high basal protein levels of Amot130. In a study 
by William Ranahan, the dramatic reduction in Amot130 steady state protein levels upon 
reintroduction of medium with 10 % serum highlights that there is a tight regulation of Amot130 
protein stability (Adler et al., 2013b). Importantly, this is the first demonstration that an 
Angiomotin is influenced by factors in serum. 
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The temporal concordance between LATS1 activation and increased steady state protein 
levels of Amot130 at 24 hours suggests that LATS1 activity may contribute to the stability of 
Amot130. Consistently, Amot130 protein (Figure 3-3A) was reduced in HEK 293T cells silenced 
for LATS1 by siRNA expression compared with control cells. Further, LATS1 stable silencing 
with shRNA demonstrated a significant reduction in Amot130 protein steady state levels in HEK 
293T cells (Figure 3-3B), but not AMOT mRNA levels (Figure 3-3C). Overall, serum starvation 
leads to an increase in Amot130 steady state protein levels in cells. Further, this increase in 
Amot130 steady state protein levels appears to correlate with LATS1 activity. Understanding the 
possible connections between Amot130 and LATS1 will be examined in the next section.  
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Figure 3-1 Correlation of Amot130 Protein and Hippo Signaling Components Under Serum 
Starvation Conditions. 
The levels of endogenous proteins at the indicated times after initiation of serum starvation were 
measured by immunoblot from lysates of MDA-MB-468 cells. Pixel intensities of endogenous 
proteins normalized to GAPDH and the ratios of phosphorylated LATS1 at Ser-909 (pS909) to 
total LATS1 are provided. Figure adapted from (Adler et al., 2013b). 
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Figure 3-2 Serum Starvation Conditions Increase Amot130 Steady State Protein Levels. 
(A-B) Graphs (left) of the mean ratios of endogenous Amot130 over GAPDH from PLC lysates 
of (A) MDA-MB-468 or (B) HEK 293T cells grown in DMEM with 10 % serum or serum 
starved for 24 or 16 hours, respectively, for 4 or 6 separate experiments. Immunoblots used to 
calculate ratios are presented (right). (C) BT-474 cells were treated and harvested as in B and the 
ratios of endogenous Amot130 over GAPDH are presented below top panel for two separate 
experiments. Error bars represent ± S. D. p-values: ** < 0.005. Figure adapted from (Adler et al., 
2013b). 
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Figure 3-3 Loss of LATS1 Protein Decreases Amot130 Steady State Protein Levels. 
(A) Immunoblot analysis of the levels of endogenous Amot130, LATS1, and GAPDH in lysates 
from HEK 293T cells expressing LATS1 or control siRNA. (B) A graph of the mean ratio of 
endogenous Amot130 over GAPDH from three experiments (n = 3) detected by immunoblot from 
lysates prepared from HEK 293T cells stably expressing control or LATS1 shRNA. Immunoblots 
used to calculate Amot130 ratios are presented, with ratios of LATS1 normalized to GAPDH 
below middle panel (right). (C) Real time quantitative PCR measurements of AMOT mRNA from 
three separate experiments with each performed in technical triplicate (n = 3) from paired cells 
cultured identically and at the same time as in B. Error bars represent ± S. D. p-values: ** < 
0.005; n.d. no statistical difference. Figure adapted from (Adler et al., 2013b). 
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3.2.2. Amot130 is Phosphorylated by LATS1 and LATS2 at Serine Residue 175 
 
Because of the observed correlated changes in the levels of steady state Amot130 protein 
in response to LATS1 activity, connections between the Angiomotins and LATS1/2 protein 
kinases were examined. In doing so, a consensus LATS phosphorylation motif (HVRSLS) in 
Amot130 (Ser-175), AmotL1 (Ser-262), and AmotL2 (Ser-159) (Figure 3-4A) was predicted via 
protein sequence analysis. LATS2 catalyzed phosphorylation of these motifs was measured using 
an array of 15-residue peptides encompassing each motif, control peptides with an alanine at the 
predicted site of phosphorylation, and the Ser-127 motif in YAP, as a positive control (Figure 3-
4B). Peptides were synthesized as individual immobilized spots on a membrane. A purified 
fragment of active LATS2 phosphorylated the Amot130 motif similarly to the YAP motif, which 
were both significantly higher than the Amot130 control peptide. AmotL1 motif peptides were 
also phosphorylated to significantly higher levels than the control peptide. The AmotL2 motif and 
control peptides were phosphorylated to a similarly low level. It is possible that the serine outside 
of the LATS consensus site in the control peptides may explain their basal levels of 
phosphorylation. Further, it is unclear why AmotL2, containing a very similar motif as Amot130 
and AmotL1 would not show increased phosphorylation over the control peptide. Closer 
examination of the Angiomotin peptides reveal the sequences surrounding these motifs are more 
similar between Amot130 and AmotL1 compared with AmotL2. Alternatively, this peptide may 
have synthesized poorly. 
To confirm a kinase-substrate connection between LATS and Amot130, the 
phosphorylation of Flag-tagged wild-type Amot130 and the mutant Amot130 with an alanine 
substituted for serine-175 (S175A) by purified LATS2 and immunoprecipitated Flag-tagged 
LATS1 was measured in an in vitro kinase assay. The purified LATS2 was constitutively active, 
while Flag-tagged LATS1 was activated in HEK 293T cells by co-transfection with MST2. 
Immunoprecipitated Amot130 samples were pre-incubated with the protein phosphatase PP1α 
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and then assayed for phosphorylation via incorporation of ATP-γ-S by either LATS1 or LATS2, 
as previously described (Allen et al., 2007). Wild-type Amot130 was phosphorylated 10-fold 
more than Amot130 (S175A) by LATS2 and over 2-fold more by activated LATS1 (Figure 3-
4C). Together, this directly demonstrates that Amot130 is phosphorylated by LATS1 and LATS2 
at Ser-175. 
The 14-3-3 family of proteins binds specifically to phosphorylated serine residues 
(Muslin et al., 1996), including phosphorylated Ser-127 in YAP (Zhao et al., 2007). Based upon 
the similarity between the consensus motifs of Ser-127 in YAP and Ser-175 in Amot130 (Figure 
3-4A), the ability of LATS1 to induce 14-3-3 binding to Amot130 was defined. The co-
immunoprecipitation of YFP-tagged Amot130 with Flag-tagged 14-3-3γ was found to be induced 
in cells expressing MST2 and LATS1, but not from HEK 293T cells expressing either protein 
kinase in isolation or control vector (Figure 3-5A). Importantly, the LATS1 protein kinase in low 
confluent HEK 293T cells was relatively inactive, unless it was co-expressed with its upstream 
protein kinase, MST2 (Figure 3-5B). Together, this demonstrates that active LATS1 protein 
kinase induces Amot130 to bind 14-3-3γ. Because 14-3-3γ failed to bind Amot130 (S175A) 
under these conditions of high LATS1 activity (Figure 3-5C), the binding of 14-3-3γ to Ser-175 
in Amot130 indicates Amot130 phosphorylation in vivo. These results raise many questions about 
the possible role of 14-3-3 in Amot130 function. While no evidence exists about a connection 
between 14-3-3 binding and Amot130 function, many studies show that 14-3-3 inhibits cell 
signaling by blocking interactions with effector proteins and promoting cytosolic sequestration 
(Bridges and Moorhead, 2005). Studies exploring the impact of 14-3-3 interacting with Amot130 
in response to LATS phosphorylation at this residue will potentially explain how this promotes 
Amot130 to transduce LATS1/2 signaling. 
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Figure 3-4 LATS1 and LATS2 Phosphorylate Amot130 at Serine-175. 
(A) Schematic of the predicted LATS phosphorylation motifs in Amot130, AmotL1, and 
AmotL2. (B) Graph of the means incorporation of 32P-phosphate from three independent 
experiments (n = 3) into the indicated immobilized 15-residue peptides by purified active LATS2. 
Values represent photostimulated luminescence density (PSL/mm2). Spots are re-arranged from 
their orientation on original membrane for matching clarity. A = Amot. (C) Immunoblot detecting 
the ATP-γ-S incorporated into immunoprecipitated Flag-tagged wild-type Amot130 or Amot130 
(S175A) by purified LATS2 or immunoprecipitated Flag-tagged LATS1, using an antibody 
against thiophosphate esters (Thiophos. ester) (top panel) and the ratio of phosphorylated 
Amot130 to total Amot130 (below), Flag-tagged Amot130 with antibodies against Amot or Flag 
(middle panel) or LATS1 (bottom panel). Parts B-C were in collaboration with Derrick Johnson. 
Error bars represent ± S. D. p-values: *** < 0.005; n.d. no statistical difference. Figure adapted 
from (Adler et al., 2013b). 
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Figure 3-5 LATS1 Phosphorylation of Amot130 at Serine-175 Promotes Binding of the 14-3-
3γ Protein. 
(A) Immunoblot of the levels of YFP-tagged wild-type Amot130 in an anti-Flag (14-3-3γ) 
immunoprecipitation and the indicated proteins in lysates from HEK 293T cells transfected as 
indicated. (B) Immunoblot of phosphorylation of Flag-tagged LATS1 at Ser-909 (pS909) as well 
as YFP-tagged MST2, total Flag-tagged LATS1, endogenous YAP and GAPDH from lysates of 
HEK 293T cells transfected as indicated. (C) Immunoblot of the levels of YFP-tagged wild-type 
Amot130 or Amot130 (S175A) in anti-Flag (14-3-3γ) immunoprecipitations and the indicated 
proteins in lysates from HEK 293T cells transfected as indicated. Figure adapted from (Adler et 
al., 2013b). 
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3.2.3. The Mutant Amot130 (S175A) Lacks the Ability of Wild-type Amot130 to Inhibit 
the Growth of Breast Cancer Cells and Mammary Acini 
Hippo signaling has long been associated with a tumor suppressive role in mediating 
growth inhibition in response to cell-cell contacts. Therefore, the impact on the ability of 
Amot130 to be phosphorylated by LATS on cellular growth in breast cancer cells was examined. 
To measure the effects of expression of wild-type Amot130 and Amot130 (S175A) on contact 
inhibition, the rate of growth of MDA-MB-468 cells, in tissue culture, in serum free medium or 
medium containing 10 % serum that stably expressed either protein or a control vector over 4 
days was measured by cell counting (Figure 3-6A-C). Cells were stably infected with proteins as 
indicated (Figure 3-6A) and then 10,000 of these cells were plated into 12-well dishes and 
allowed to grow. Cells were trypsinized and counted each day. Cells expressing wild-type 
Amot130 grew at significantly slower rates in the presence or absence of serum, while cells 
expressing Amot130 (S175A) grew similarly to cells expressing a control vector. Growth of cells 
was also analyzed using a Promega CellTiter 96® Non-Radioactive Cell Proliferation Assay 
(Figure 3-6D). The results demonstrated that the wild-type Amot130 had lower rates of 
proliferation than either the Amot130 (S175A) or control vector. Further, stable expressing cells 
containing wild-type Amot130, Amot130 (S175A), or a control vector were placed onto laminin-
rich extracellular matrix (lrECM) for analysis of their growth as three-dimensional colonies. 
Cancer cells on lrECM grew as colonies. Cells expressing wild-type Amot130 formed colonies 
that were about three-fold smaller after four days versus colonies formed by cells expressing 
Amot130 (S175A) or control vector (Figure 3-6E-G). Thus, in a cancer cell line with defective 
growth control, the ability of Amot130 to be phosphorylated at Ser-175 was essential for it to 
induce cell growth arrest. 
The growth and differentiation of the non-transformed MCF10A cells into hollow acini in 
lrECM is highly sensitive to Hippo signaling. Because of the kinase-substrate connection between 
LATS and Amot130, the effects of expression of wild-type Amot130 and Amot130 (S175A) on 
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the ability of Hippo-sensitive cells to form acini were therefore compared. After one day of 
growth, the sizes of cell clusters were nearly identical between all conditions (Adler et al., 
2013b). However, MCF10A cells expressing wild-type Amot130 formed significantly smaller 
clusters that stopped growing by day 4 (Figure 3-7A-D). Conversely, cells expressing Amot130 
(S175A) displayed a loss of growth inhibition, where colonies were significantly larger at days 4 
and 8 versus those expressing a control vector (Figure 3-7A-D). Furthermore, unlike control cells, 
which formed hollow acini by day 14, cells expressing Amot130 (S175A) formed solid tumor-
like structures (Figure 3-7E). These structures failed to clear their lumen, and resembled cancer-
like colonies in lrECM, as presented in chapter 1. Taken together, phosphorylation of Ser-175 is 
pivotal for Amot130 to inhibit cellular growth in mammary epithelial cancer cells and to inhibit 
acini development. 
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Figure 3-6 Ability of Amot130 to be Phosphorylated at Serine-175 is Essential for Amot130 
to Inhibit the Growth of Cancer Cells. 
(A) The protein levels of YFP-tagged Amot130 and GAPDH in MDA-MB-468 cells transfected 
with YFP-tagged wild-type Amot130, Amot130 (S175A), or control vector. (B-C) Cells from A, 
stably expressing (♦) YFP-tagged control vector, (■) YFP-tagged Amot130, or (▲) YFP-tagged 
Amot130 (S175A) were grown in (B) serum starved or (C) 10 % serum medium. In both B and C, 
cells were grown for the indicated days and counted. Average cell counts were derived from three 
separate experiments (n = 3). (D) Cells from A, were analyzed with a cell proliferation assay for 
four independent experiments (n = 4) with average absorbance values obtained at 490 nm per 
assay instructions. (E-G) MDA-MB-468 cells stably expressing YFP-tagged Amot130, Amot130 
(S175A), or control vector, as in A, were seeded onto lrECM and imaged after one and four days. 
(E) Representative brightfield stereo images and (F-G) plots of the mean pixel integrated intensity 
values/field from four experiments (n = 4) at (F) day 1 and (G) day 4 are presented. Error bars 
represent ± S. D. p-values: *** < 0.001; ** < 0.05; n.d. no statistical difference. Unlabeled scale 
bars represent 50 µm. Figure adapted from (Adler et al., 2013b). 
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Figure 3-7 Ability of Amot130 to be Phosphorylated at Serine-175 is Essential for Amot130 
to Regulate the Growth of Mammary Acini. 
(A-E) MCF10A cells stably expressing YFP-tagged wild-type Amot130, Amot130 (S175A), or 
control vector were seeded onto lrECM and grown for 14 days. (A) Brightfield representative 
stereo images of colonies at day 4 and (B) plots of the mean cross-sectional area/acini (µm2) from 
three experiments each with 61 acini (n = 183) at day 4 are graphed. Below plot is an immunoblot 
measuring YFP-tagged Amot130 or Amot130 (S175A) and GAPDH from cells extracted from 
lrECM at day 4. (C-D) Brightfield representative stereo images of colonies and plots from three 
experiments each with 60 acini (n = 180) at day 8 as in A and B. (E) Confocal fluorescence 
images of representative acini stained with Hoechst for nuclei at day 14 of growth. Figure in 
collaboration with William Ranahan. Error bars represent ± S. D. p-values: *** < 1 X 10-40. 
Unlabeled scale bars represent 50 µm. Figure adapted from (Adler et al., 2013b). 
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3.3. Discussion 
 
3.3.1. A Novel Substrate for LATS1/2 in Hippo Signaling 
Several lines of evidence point to LATS1/2 protein kinases as major controllers of cell 
growth. LATS1/2 protein kinases lead to the phosphorylation of many substrates, including those 
involved in cell growth control, both inside and outside the Hippo pathway. Understanding the 
important roles of LATS1/2 protein kinases in inhibiting cellular growth is therefore tied to 
understanding their substrates. Importantly, this study identifies a novel substrate of LATS1/2 
protein kinases in Amot130. 
Within the Hippo pathway, serum starvation promotes YAP protein phosphorylation at 
Ser-127 and decreases YAP steady state levels (Miller et al., 2012). This is thought to be largely 
due to increased LATS1/2 activity. Here, we show a correlation between prolonged serum 
starvation and LATS1 phosphorylation at Ser-909, an indicator of its activity. These events 
temporally correlated with the decreased steady state levels of YAP and TAZ. Decreases in YAP 
and TAZ protein steady state levels could be due in part to the reported role of LATS1/2 
mediated degradation of YAP and TAZ via recruitment of SCF-(β)-TRCP, as previously 
predicted (Zhao et al., 2010). However, this study indicates that Amot130 is also an important 
determinate of the output of Hippo signaling. The temporal correlation of an increase in Amot130 
steady state protein levels with LATS1 activity and YAP/TAZ reduction indicates a possible 
connection between Amot130 and the Hippo proteins kinases LATS1/2. Further, the reported role 
of Angiomotins binding to and activating the LATS2 protein kinase further connects Amot130 
with LATS (Paramasivam et al., 2011). Here, Amot130 is shown to be phosphorylated by 
LATS1/2 at Ser-175. Because LATS1/2 protein kinases are inhibitory to YAP function and pro-
growth signaling, it was important to examine how this phosphorylation site on Amot130 would 
impact growth in mammary epithelial cells. Importantly, the mutation of the serine-175 to an 
alanine (S175A) prevented the growth inhibition seen by wild-type Amot130. This difference in 
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growth control potentially indicates the LATS1/2 protein kinases are playing a major role in the 
inhibitory actions of Amot130. The possible mechanisms of action are examined in the next 
couple of chapters. 
 
3.3.2. Proposed Mechanism of Amot130 Inhibition of Mammary Epithelial Cell Growth 
in Response to LATS1/2 Activity 
Upon prolonged serum deprivation, MDA-MB-468 breast cancer cells show an activation 
of the tumor suppressor protein LATS1 (Figure 3-8). Active LATS1/2 protein kinases were able 
to directly phosphorylate Amot130. This phosphorylation at Ser-175 appears to play an important 
role in the ability of Amot130 to inhibit cellular growth in cancer cells and to differentiate 
mammary acini, as mutation of this serine to alanine (S175A), prevented its ability to alter 
growth. Interestingly, the mutant Amot130 (S175A) actually significantly increased the area of 
MCF10A acini, which are reported to have active Hippo signaling (Debnath et al., 2003; Kenny 
et al., 2007; Zhao, 2012). Thus, Amot130 could present itself as a transmitter of upstream Hippo 
signaling via LATS phosphorylation. Exactly how this proposed regulation of growth occurs 
downstream of Amot130 phosphorylation by LATS will be examined in the next two chapters. 
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Figure 3-8 Working Model for Serum Starvation Inhibition of Cell Growth. 
Amot130 presents itself as a major contributor to the anti-growth phenotype in mammary 
epithelial cells. Here, LATS1 is activated in breast cancer cells upon serum starvation. Active 
LATS1 phosphorylates Amot130 in vitro and in vivo. This phosphorylation site (Ser-175) is 
critical for growth inhibition, as mutation of this serine to alanine prevents the ability of Amot130 
to inhibit cellular growth in cancer cells. Further, this growth inhibition by Amot130 in normal 
mammary epithelia, that are Hippo sensitive, has a reverse effect when the phosphorylation site is 
mutated. Thus, it appears that this phosphorylation event is essential for the ability of Amot130 to 
transduce Hippo signaling to inhibit cellular growth. However, major questions exist about how 
Amot130 is able to transduce Hippo signaling. Further, the correlation of increased Amot130 
steady state protein levels with serum starvation and LATS activity remains to be examined. 
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CHAPTER 4. SERUM DEPRIVATION AND LATS1 PROTEIN KINASE ACTIVITY 
LEAD TO INCREASED STEADY STATE PROTEIN LEVELS OF THE LONG 
ISOFORM OF ANGIOMOTIN VIA THE NEDD4 UBIQUITIN LIGASE AIP4 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Some text in this chapter was originally published in The Journal of Biological Chemistry and the 
Proceedings of the National Academy of Sciences USA. Adler et al. Amot130 Adapts Atrophin-1 
Interacting Protein 4 to Inhibit Yes-Associated Protein Signaling and Cell Growth. Journal of 
Biological Chemistry. 2013; Vol: 288, 25: 15181-15193. © the American Society for 
Biochemistry and Molecular Biology. Adler et al. Serum deprivation inhibits the transcriptional 
co-activator YAP and cell growth via phosphorylation of the 130-kDa isoform of Angiomotin by 
the LATS1/2 protein kinases. Proceedings of the National Academy of Sciences. 2013; Vol: 110, 
43: 17368-17373. © Proceedings of the National Academy of Sciences USA. 
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4.1. Introduction 
 
Atrophin-1 Interacting Protein 4 (AIP4), also known as Itch, is a member of the Nedd4 
ubiquitin ligases. The effects of ubiquitination on a targeted protein can vary, in some cases it 
signals for cellular relocalization or degradation. AIP4 binds different substrates and adapter 
proteins via its WW domains to confer specificity for its catalytic HECT domain. The 
identification of novel substrates of AIP4 likely will lead to new regulators of growth signaling, 
as have many of the Nedd4 ligases. Recently, mass spectrometry screens identified Nedd4 
ubiquitin ligases interacting with the adapter Angiomotin proteins (Ingham et al., 2005; Wang et 
al., 2011). Additionally, several of the Nedd4 ubiquitin ligases were able to directly interact with 
Angiomotins (Wang et al., 2012); however, the functional consequences of these interactions are 
unknown. Further, while evidence exists for other Nedd4 family members in the degradation of 
Angiomotins, less is known about the regulation via AIP4. 
Here, Amot130 is discovered to be a substrate for AIP4. The interaction is mediated 
through direct interactions between the WW domains of AIP4 and two specific P-Y motifs of 
Amot130. The interaction leads to the ubiquitination of Amot130 at Lys-481 and potentially other 
unidentified sites. Ablation of this ubiquitination site, or silencing of AIP4, leads to decreased 
protein stability of Amot130, likely via a relocalization of Amot130 off of cell-cell contacts. 
Importantly, serum starvation and active LATS1 expression increased the interaction of Amot130 
with AIP4. Further, active LATS1 promoted the ubiquitination of Amot130 by AIP4. Because 
Amot130 phosphorylation at Ser-175 is critical for the stability of Amot130, AIP4 activity is 
identified as a primary mechanism to increase Amot130 steady state protein levels in response to 
serum starvation and phosphorylation of Amot130 by LATS. 
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4.2. Results 
 
4.2.1. Amot130 Directly Binds AIP4 
Consistent with other reports that Angiomotins bind Nedd4 ubiquitin ligases (Wang et al., 
2012), Amot130 co-precipitated with many Nedd4 family members in HEK 293T cells (Figure 4-
1). Interestingly, the different Nedd4 ligases had diverse abilities to interact with Amot130. In 
many cases, the relative binding varied depending on the cellular environment (i.e. cellular 
confluence). However, the consistent high level of AIP4 binding versus six other members, over 
many experiments, indicates that AIP4 is a preferred binding partner of Amot130. This was 
confirmed with endogenous Amot130 co-immunoprecipitation with AIP4 from lysates of HEK 
293T cells (Figure 4-2A). The enhanced levels of Amot130 immunoprecipitated with AIP4 in 
cells treated with MG-132, a drug preventing protein degradation via the proteasome, suggests 
that the Amot130-AIP4 complex is somehow regulated by the proteasome. 
Because AIP4 has four WW domains and Amot130 encodes three P-Y motifs, the 
relative abilities of the WW domains of AIP4 to bind Amot130 were determined (Figure 4-2B). 
Initially, immunoprecipitation of fragments of AIP4 indicate that only the absence of functional 
WW domains reduces binding to endogenous Amot130 (Adler et al., 2013a). Further, pull-downs 
using the purified GST-tagged WW domains of AIP4 and of YAP, a known binding partner of 
the P-Y motifs of Amot130 (Zhao et al., 2011a), indicate that the WW1 and WW2 domains of 
AIP4 precipitate endogenous Amot130 from HEK 293T lysates predominantly versus the WW3 
or WW4 domains (Figure 4-2C). This matches the reported specificity of another Nedd4 family 
member, Nedd4-2, with AmotL1 (Skouloudaki and Walz, 2012). Thus, AIP4 may utilize a 
combination of multiple WW domains to mediate a stronger interaction with Amot130, like other 
Angiomotin family members. 
While three P-Y motifs within Amot130 are reported to mediate their binding to Nedd4-1 
(Wang et al., 2012), their relative importance for binding to AIP4 is undetermined. Consistent 
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with AIP4 binding to the P-Y motifs in Amot130, Amot80 was unable to co-immunoprecipitate 
AIP4 (Figure 4-2D). Further, both the P-Y2 (P-Y2F) and P-Y3 (P-Y3F) mutants of Amot130, 
which contained a phenylalanine residue in the place of the conserved tyrosine residue, showed 
substantially reduced immunoprecipitation with AIP4 (Figure 4-2E). However, unlike Nedd4-1 
(Wang et al., 2012), but like Nedd4-2 (Skouloudaki and Walz, 2012), AIP4 showed no reduction 
in binding to the P-Y1 (P-Y1F) mutant of Amot130. Taken together, the WW1 and WW2 
domains of AIP4 most likely bind the P-Y2 and P-Y3 motifs of Amot130 (Figure 4-2F). Similar 
to other proteins containing multiple WW domains and P-Y motifs, it is likely that two WW 
domains of AIP4 bind to two P-Y motifs of Amot130 for a higher affinity interaction within the 
cell. 
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Figure 4-1 Nedd4 Family of Ubiquitin Ligases Differentially Bind Amot130. 
The relative levels of YFP-tagged Amot130 that co-immunoprecipitate with seven different Flag-
tagged Nedd4 family members were detected by immunoblot from lysates and 
immunoprecipitations with an anti-Flag antibody prepared from HEK 293T cells. The relative 
molecular weights (M.W.) of the Flag-tagged Nedd4 family members (in kDa) based upon a 
protein marker are indicated to left of middle panel. Figure adapted from (Adler et al., 2013a). 
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Figure 4-2 WW Domains of AIP4 Directly Bind Amot130 Specific P-Y Motifs.  
(A) The relative endogenous levels of Amot130, Amot80, and AIP4 in an immunoprecipitation 
with an anti-AIP4 antibody from lysates of HEK 293T cells pre-incubated with (+) 25 µM MG-
132 or (-) vehicle DMSO for 2 hours were measured by immunoblot. (B) A schematic 
representation of Amot130 and AIP4 protein architecture including the P-Y1, 2, and 3 motifs in 
Amot130. Amot80 is represented to indicate the lack of the N-terminal P-Y motifs in this protein. 
(C) An immunoblot showing the relative levels of endogenous Amot130 and Amot80 precipitated 
from HEK 293T cells by purified GST-tagged WW domains of YAP and AIP4. Below top panel 
are the ratios of pixel intensities of bound Amot130 over GST-tagged input. (D) The relative 
levels of Myc-tagged AIP4 that co-immunoprecipitate with YFP-tagged Amot80 or Amot130 
from HEK 293T cells were detected by immunoblot. (E) An immunoblot showing the relative 
levels of Myc-tagged AIP4 that co-immunoprecipitate with Flag-tagged wild-type Amot130 or 
the (P-Y1F) (Y109F), (P-Y2F) (Y242F), or (P-Y3F) (Y287F) mutants of Amot130. Part E 
performed by Brigitte Heller. Figure adapted from (Adler et al., 2013a). 
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4.2.2. Serum Starvation and LATS1 Activity Enhances the Association of AIP4 with 
Amot130 
Due to low serum levels and LATS1 activity enhancing Amot130 protein levels (section 
3.2.1), it was hypothesized that serum starvation and LATS1 activity could promote the 
Amot130-AIP4 complex formation. To examine this possibility, HEK 293T cells were infected 
with lentiviral shRNA targeting LATS1 or an unrelated control shRNA. Infected cells were 
placed in 10 % serum or serum starved conditions for 24 hours prior to harvest. While Myc-
tagged AIP4 co-immunoprecipitated with Amot130 to a greater extent from lysates prepared from 
serum starved cells versus cells grown in 10 % serum (Figure 4-3A), this association was 
undetectable in cells partially silenced for LATS1 regardless of serum conditions. Thus, the 
formation of the Amot130-AIP4 complex is increased upon serum starvation and is dependent on 
LATS1 protein levels within these cells. 
To further examine if LATS phosphorylation of Amot130 plays a role in the Amot130-
AIP4 complex formation, the mutant Amot130 with an alanine substituted for the serine-175 
(S175A) was used to examine its ability to bind AIP4. The co-precipitation of AIP4 with wild-
type Amot130 but not Amot130 (S175A) was enhanced from lysates from cells expressing both 
MST2 and LATS1 (Figure 4-3B). The phosphorylation by active LATS1 on Amot130 thus 
appears to be important for AIP4 binding. The induction of the Amot130-AIP4 complex is likely 
via direct binding, as LATS1 did not induced AIP4 to bind the domain interaction mutant 
Amot130 (P-Y1,2,3F) that encodes phenylalanine at tyrosine residues in all three P-Y motifs 
(Figure 4-3C). Together, the Amot130-AIP4 complex association is enhanced by serum 
starvation. Further, this association requires active LATS1 and might yield an important function 
of LATS and serum levels on Amot130. The outcome of this Amot130-AIP4 complex on 
Amot130 protein will be addressed in the next section. 
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Figure 4-3 Amot130 Binding to AIP4 is Enhanced by Serum Starvation and Requires 
LATS1 Activity. 
(A) An immunoblot of YFP-tagged Amot130 in immunoprecipitates of Myc-tagged AIP4 as well 
as the total levels of indicated proteins in lysates from HEK 293T cells that were co-infected with 
the indicated combinations of shRNA and tagged proteins and then grown with or without 10 % 
serum for 24 hours. Pixel intensities of LATS1 over GAPDH (below panel 4) are indicated. (B) 
Immunoblot of YFP-tagged wild-type Amot130 or Amot130 (S175A) in lysates and 
immunoprecipitations of Myc-tagged AIP4 (anti-Myc) prepared from HEK 293T cells expressing 
the indicated combinations of proteins. (C) Immunoblot analysis of the levels of Flag-tagged 
Amot130 or mutant Amot130 (P-Y1,2,3F), where tyrosines of all three P-Y motifs are mutated to 
phenylalanines, that co-immunoprecipitate with Myc-tagged AIP4 from lysates of HEK 293T 
cells, grown to high confluence, expressing Flag-tagged LATS1 or control vector and other 
indicated proteins. Figure adapted from (Adler et al., 2013b). 
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4.2.3. Amot130 is Ubiquitinated by AIP4 
Because AIP4 is a strong binding partner of Amot130, it was investigated as a substrate 
for the AIP4 ubiquitin ligase. For this purpose, HA-tagged Lys-0 Ubiquitin, where all 7 lysines 
are mutated to arginines to prevent ubiquitin chain extension, was used to monitor the capacity of 
Amot130 to be ubiquitinated. HA-tagged Lys-0 Ubiquitin was co-transfected with combinations 
of Myc-tagged AIP4 and YFP-tagged Amot130 into HEK 293T cells. Ubiquitinated proteins 
were immunoprecipitated with an anti-HA antibody (Figure 4-4A). Immunoblot analysis showed 
an enhanced ubiquitination of Amot130, when it was co-expressed with AIP4. That Amot130 is a 
physiologic substrate of AIP4 was further supported by the over three-fold increase in 
ubiquitination of endogenous immunoprecipitated Amot130 from lysates prepared from HEK 
293T cells co-expressing HA-tagged Ubiquitin and Myc-tagged AIP4 versus the catalytically 
inactive AIP4 mutant, where the catalytic cysteine-830 is substituted for an alanine (C830A), or 
control vector (Figure 4-4B). Because Amot130 migrated with a single gel shifted band that was 
similar in intensity and position when it incorporated wild-type ubiquitin, mutant (K48R) 
ubiquitin, or mutant (K63R) ubiquitin, Amot130 does not seem to be commonly 
polyubiquitinated by AIP4 (Figure 4-4C). If it were polyubiquitinated by either of these chain 
extensions (Lys-63 or Lys-48), the mutation of these lysines should prevent such events. Further, 
the presence of an analogous Amot130 gel shifted band in cells grown to high density (Adler et 
al., 2013a) compared to the lack of in cells grown to low density (Ranahan et al., 2011), further 
suggests that Amot130 is often similarly ubiquitinated as cell-cell contacts are formed. 
Based upon LATS1 activity increasing Amot130-AIP4 complex formation, the impact of 
LATS1 activity on Amot130 ubiquitination by AIP4 was examined in cells grown to high 
confluence, where LATS1 expression promoted the AIP4-dependent ubiquitination of Amot130 
and interestingly, itself (Figure 4-5). This self-ubiquitination of AIP4 is similar to that seen for 
ligases that are activated by adapter proteins. The activity of Nedd4 family ligases is often 
enhanced by binding to adapter proteins containing P-Y motifs (Hooper et al., 2010; Mund and 
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Pelham, 2009). The impact of Amot130 expression on AIP4 activity was therefore examined, and 
revealed an increase in self-ubiquitination of AIP4 in the presence of Amot130 and LATS1 
(Figure 4-5). This self-ubiquitination of AIP4 consistently resulted in a slower migrating gel 
shifted form of Myc-tagged AIP4, but not the catalytically inactive mutant AIP4 (C830A) (Figure 
4-6A). This gel shifted upper band had more incorporated HA-tagged Ubiquitin than the lower 
band. Because the self-ubiquitinated form of AIP4 is reported to indicate active ligase, Amot130 
is likely promoting the ligase activity of AIP4. Therefore, whether this AIP4 activation results in 
changes in its ubiquitination of total cellular proteins was also measured. Co-expression of Flag-
tagged Amot130 with Myc-tagged AIP4, but not catalytically inactive mutant AIP4 (C830A) 
resulted in a synergistic increase in the levels of ubiquitin incorporation into cellular proteins 
extracted with PLC lysis buffer from HEK 293T cells (Figure 4-6B). Because this effect occurs in 
the absence of proteasome inhibitors, these substrates are likely stable following ubiquitination. 
The absence of this effect in cells expressing Amot130 (P-Y2,3F) double mutant (Adler et al., 
2013a), further indicates that the direct association of Amot130 with AIP4 induces the activation 
of its ligase domain. Together, Amot130 is able to activate AIP4 ligase activity and this leads to 
the direct ubiquitination of Amot130. The ubiquitination of Amot130 is increased in response to 
LATS1 activity. The location of this ubiquitination on Amot130 and the impact of this 
ubiquitination will be addressed in the next sections. 
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Figure 4-4 AIP4 Ubiquitinates Amot130. 
(A) The relative levels of ubiquitinated Amot130 and AIP4 following immunoprecipitation of 
HA-tagged Lys-0 Ubiquitin (HA-K0 Ub) in HEK 293T cells co-expressing YFP-tagged 
Amot130, Myc-tagged AIP4, or control vectors were detected by immunoblot. (B) Endogenous 
Angiomotin (Amot) was immunoprecipitated from HEK 293T cells expressing HA-tagged 
Ubiquitin (HA-Ub) and Myc-tagged AIP4 or the catalytically inactive AIP4 (C830A). The levels 
of total and ubiquitinated Amot130 were detected by immunoblot. The ratios of pixel intensities 
of ubiquitinated Amot130 over total Amot130 are indicated. (C) Flag-tagged Amot130 was 
immunoprecipitated from HEK 293T cells co-expressing with and without Myc-tagged AIP4, 
His-tagged wild-type (WT) Ubiquitin, mutant (K48R) Ubiquitin, or mutant (K63R) Ubiquitin. 
The ratios of pixel intensities of ubiquitinated Flag-tagged Amot130 over total Flag-tagged 
Amot130 are indicated below top panel. Figure adapted from (Adler et al., 2013a). 
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Figure 4-5 LATS1 Activity Enhances AIP4 Ubiquitination of Amot130. 
Immunoblot of ubiquitinated Amot130 and AIP4 in immunoprecipitates of HA-tagged Lys-0 
Ubiquitin (HA-K0 Ub) along with the indicated proteins in lysates from HEK 293T cells, grown 
to high confluence, expressing the indicated combinations of proteins. Figure adapted from 
(Adler et al., 2013b). 
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Figure 4-6 Amot130 Binding to AIP4 Activates the AIP4 Ligase. 
(A) The relative incorporation of HA-tagged Ubiquitin (HA-Ub) into immunoprecipitated Myc-
tagged AIP4 or mutant AIP4 (C830A) in HEK 293T cells following co-expression with Flag-
tagged Amot130 was detected by immunoblot. Part A performed by Brigitte Heller. (B) HEK 
293T cells expressing HA-Ub and Myc-tagged AIP4 or mutant AIP4 (C830A) as well as YFP-
tagged Amot130 or control vector were lysed in PLC lysis buffer and soluble HA-Ub modified 
proteins were detected by immunoblot. Molecular mass standards (M.W.) (in kDa) are indicated 
for the bottom panel. Figure adapted from (Adler et al., 2013a). 
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4.2.4. Amot130 is Ubiquitinated at Lysine Residue 481 
In an unbiased screen carried out by the laboratory of Mark Goebl to compare 
ubiquitination sites in all proteins in primary keratinocytes grown in differentiating (with 
calcium) conditions, a single Angiomotin peptide (VSEAYENLVKSSSKR) with a mass 
signature for ubiquitination at residue Lys-481 was identified; a site highly predicted to be 
ubiquitinated by the UbPred program (Adler et al., 2013a). The requirement of this lysine residue 
in Amot130 for its ubiquitination by AIP4 was then defined. For this purpose, HEK 293T cells 
were co-transfected with HA-tagged Ubiquitin, Myc-tagged AIP4 as well as YFP-tagged wild-
type Amot130 or mutants of Amot130 (P-Y2,3F), (K481R), or (P-Y2,3F & K481R). The 
Amot130 (P-Y2,3F) mutant has a phenylalanine substituted for tyrosine at the second and third P-
Y motifs. The Amot130 (K481R) mutant has an arginine substituted for Lys-481. Immunoblot of 
anti-YFP immunoprecipitates revealed that ubiquitination of Amot130 (P-Y2,3F) and (K481R) 
mutants was moderately reduced, while ubiquitination of the Amot130 (P-Y2,3F & K481R) 
mutant was undetectable (Figure 4-7A). This indicates that Lys-481 is a primary site for 
ubiquitination; however, other sites are likely ubiquitinated by AIP4, as the mutant that lacked 
binding to AIP4 showed less ubiquitination than the Amot130 (K481R) mutant. Consistent with 
Lys-481 being a primary site of ubiquitination, HA-tagged Ubiquitin was detected in gel shifted 
bands of Amot130 and AmotL1, but not AmotL2, which encodes an arginine at residue 364; the 
site that aligns with Lys-481/Lys-488 in Amot130/AmotL1 (Figure 4-7B). Together, Amot130 is 
strongly ubiquitinated at Lys-481 by AIP4. The effects of this Amot130 ubiquitination by AIP4 
will be addressed in the next section. 
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Figure 4-7 Amot130 is Ubiquitinated at Lysine-481 by AIP4. 
(A) Ubiquitination of YFP-tagged Amot130 and Amot130 mutants (P-Y2,3F) (Y242F and 
Y287F), (K481R), and (P-Y2,3F & K481R) following co-expression with Flag-tagged AIP4 and 
HA-tagged Ubiquitin (HA-Ub) was examined following immunoprecipitation with an anti-YFP 
antibody and detected by immunoblot. The ratios of ubiquitinated over total YFP-tagged 
Amot130 pixel intensities are provided below top panel. (B) Flag-tagged Amot130, AmotL1, or 
AmotL2 were co-expressed with HA-Ub and with Myc-tagged AIP4 or control vector. 
Immunoblot of Myc-tagged AIP4 in lysates or immunoprecipitated Flag-tagged total (anti-Flag) 
or ubiquitinated (anti-HA) Angiomotin family members were detected by immunoblot. An 
alignment of the protein sequence encompassing Lys-481 in Amot130 with AmotL1 and AmotL2 
is shown below the panels. Part B was performed by Brigitte Heller. Figure adapted from (Adler 
et al., 2013a). 
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4.2.5. Amot130 Protein Levels are Stabilized by AIP4 
The consequences of ubiquitination of Amot130 on its protein stability were investigated. 
Overexpression of Myc-tagged AIP4 in HEK 293T cells caused the average steady state levels of 
endogenous Amot130 protein to be elevated over three-fold compared to cells expressing a 
control vector (Figure 4-8A). The AIP4-induced increase of Amot130 protein spurred an analysis 
of the effects of AIP4 expression on Amot130 protein stability. To this end, protein synthesis was 
blocked in MDA-MB-468 cells by treatment with cycloheximide, as previously described (Pervin 
et al., 2011), for the indicated times before being lysed. The relative levels of Amot130, AIP4, 
and GAPDH were then detected by immunoblot analysis. The average half-life derived from 
three independent experiments of endogenous Amot130 was about 4 hours in cells silenced for 
AIP4 compared to approximately 25 hours in control cells (Figure 4-8B). However, in an 
apparent contradiction, it was observed, similar to a previous report (Wang et al., 2012), that the 
steady state protein levels of Amot130 were increased in cells silenced for AIP4, previous to 
treatment with cycloheximide. Conversely, BT-474, HEK 293T, and MCF7 cells showed 
decreased steady state protein levels of Amot130 following silencing of AIP4 (Figure 4-8C-E). 
Given these conflicting effects, the impact of silencing AIP4 on AMOT mRNA transcript levels 
was measured by real time quantitative PCR. This revealed that AMOT transcript levels were 
about three-fold higher in MDA-MB-468 cells silenced for AIP4 versus control cells (Figure 4-
8F). Thus, while AIP4 silencing directly reduces Amot130 protein stability, it can increase AMOT 
mRNA levels. The differing balances between these two effects in different cell types may 
therefore explain the overall impact of silencing AIP4 on Amot130 steady state levels. 
Because silencing and overexpression of AIP4 has pleiotropic effects, the direct impact 
of ubiquitination of Amot130 on Amot130 stability was investigated. For this purpose, the 
stability of the Amot130 (K481R) mutant, which has substantially reduced ubiquitination by 
AIP4, was compared to that of wild-type Amot130. Consistent with ubiquitination having a 
significant stabilizing effect on Amot130, the half-life of wild-type YFP-tagged Amot130 was 
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about 30 hours in cycloheximide treated HEK 293T cells; whereas, YFP-tagged Amot130 
(K481R) was about 8 hours (Figure 4-9A). Because LATS1 activity and the ability for Amot130 
to be phosphorylated increases the association of Amot130 and AIP4 and thereby increases 
Amot130 ubiquitination (sections 4.2.2 and 4.2.3), the mutant of Amot130 (S175A), which has 
reduced phosphorylation by LATS, was also examined for changes in stability. Following the 
inhibition of translation with cycloheximide treatment, the rate of decay of Amot130 (S175A) 
protein was over two-fold higher than that of wild-type Amot130 in MDA-MB-468 cells (Figure 
4-9B). Thus, Amot130 (S175A) likely is less stable, at least in part, due to its inability to bind and 
likely be ubiquitinated by AIP4. Further, comparison of the stability of the Amot130 (S175A) and 
Amot130 (K481R) mutants following cycloheximide treatment in MCF7 cells revealed similar 
significantly higher rates of decay versus wild-type Amot130 (over two-fold higher) (Figure 4-
9C). Together, this leads to a possible connection between the LATS phosphorylation site (Ser-
175) on Amot130 and the ubiquitination event on Lys-481 by AIP4 and consequent effects on 
protein stability. 
Similar localization of Amot130 (K481R) and Amot130 (S175A) to actin also suggests 
that Amot130 phosphorylation by LATS regulates Amot130 ubiquitination. One possibility for 
the observed reduced stability of Amot130 (K481R) and Amot130 (S175A) is that they have 
altered subcellular distribution, possibly localizing them to a less stable location in the cell. 
Consistently, in over 60 % of live MCF7 cells, YFP-tagged wild-type Amot130 localized at 
intercellular contacts and at intracellular compartments that are likely endosomes (Heller et al., 
2010) (Figure 4-10A). In agreement with this, Amot130-AIP4 complexes were found mainly in 
membrane fractions (Figure 4-10B). Interestingly, Amot130 (K481R) localized at cell-cell 
contacts in a significantly lower fraction of cells (around 20 %) and instead was mainly observed 
along actin fibers that were not on cell-cell contacts (Figure 4-10A, C-D). Because of the reduced 
stability connection between the Amot130 (K481R) and Amot130 (S175A) mutants, the 
localization of Amot130 (S175A) was also examined in the same experiment. This revealed an 
 88 
 
even stronger phenotype of that seen with the Amot130 (K481R) (Figure 4-10E). The Amot130 
(S175A) is seen tightly bundled with filamentous actin stress fibers and is rarely seen at junctions 
or at cortical actin. Together, similar localizations along with the decrease in stability of both 
mutants, reveal that the phosphorylation site and the ubiquitination site are likely connected in a 
common mechanism for regulating Amot130 stability. 
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Figure 4-8 Amot130 Stability is Increased by AIP4. 
(A) The levels of endogenous Amot130 were detected by immunoblot analysis from HEK 293T 
cells expressing Myc-tagged AIP4. The mean ratios of pixel intensities of endogenous Amot130 
over GAPDH from three replicates were graphed (left). (B) The levels of endogenous Amot130 
were detected by immunoblot from lysates derived from MDA-MB-468 cells expressing AIP4 or 
control shRNA and treated with vehicle (DMSO) or 200 µg/mL of cycloheximide (CHX) for 
indicated times. The ratios of pixel intensities of endogenous Amot130 over GAPDH for both 
conditions were graphed with linear regression analysis. The mean half-lives were calculated 
from the three numbered independent experiments and graphed (left). (C) The levels of 
endogenous Amot130 were detected by immunoblot analysis of lysates from BT-474 cells 
transfected with AIP4 or control siRNA. (D) The levels of endogenous Amot130 were detected 
by immunoblot from lysates of HEK 293T cells infected with AIP4 or control shRNA. (E) The 
levels of YFP-tagged Amot130 were detected by immunoblot analysis of lysates from MCF7 
cells transfected as in C. (F) The mRNA transcript levels of AMOT from MDA-MB-468 cells 
expressing AIP4 or control shRNA were measured from three independent experiments by real 
time quantitative PCR. Error bars represent ± S. D. p-values: *** < 0.0005; ** < 0.005. Figure 
adapted from (Adler et al., 2013a). 
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Figure 4-9 Two Amot130 Mutants, (K481R) and (S175A), Have Similarly Reduced Protein 
Stability. 
(A) The levels of YFP-tagged wild-type (WT) Amot130 or Amot130 (K481R) were detected by 
immunoblot analysis of lysates prepared from HEK 293T cells treated with vehicle (DMSO) or 
200 µg/mL of cycloheximide (CHX) for the indicated times. The ratio of pixel intensities of YFP-
tagged WT Amot130 or Amot130 (K481R) over GAPDH were graphed with linear regression 
plots. The mean half-lives were calculated from the three numbered independent experiments and 
graphed (left). (B) A graph (left) of the mean regression slopes from three numbered independent 
experiments of immunoblots of the levels of YFP-tagged WT Amot130 or Amot130 (S175A) in 
lysates of MDA-MB-468 cells treated as in A. (C) A graph (left) of the mean regression slopes 
from three numbered independent experiments of immunoblots of lysates prepared from MCF7 
cells of the levels of YFP-tagged WT Amot130, Amot130 (S175A), or Amot130 (K481R) as 
described in B. Error bars represent ± S. D. p-values: * < 0.05. Figure adapted from (Adler et al., 
2013a) and (Adler et al., 2013b). 
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Figure 4-10 Two Amot130 Mutants, (K481R) and (S175A), Have Similarly Altered 
Subcellular Localization. 
(A) The percent of live MCF7 cells that show wild-type (WT) Amot130 or (K481R) localization 
at intercellular contacts or at intracellular structures. (B) Immunoblot analysis of Myc-tagged 
AIP4 in lysates or immunoprecipitated Flag-tagged Amot130 (anti-Flag) after membrane 
fractionation of HEK 293T cells expressing indicated proteins. Fractionation indicated via 
immunoblot of lysates with Caveolin1 and GAPDH. (C-E) Confocal images of fixed MCF7 cells 
of (C) YFP-tagged wild-type Amot130, (D) YFP-tagged Amot130 (K481R), or (E) YFP-tagged 
Amot130 (S175A) (all three green) and Phalloidin-594 for actin (red). Nuclei were stained with 
Hoechst (blue). Parts C-E were in collaboration with Lauren Bringman. Error bars represent ± S. 
D. p-values: * < 0.05. Figure adapted from (Adler et al., 2013a) and (Adler et al., 2013b). 
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4.3. Discussion 
 
4.3.1. Stabilization of Amot130 by AIP4 
Here, levels of Amot130 protein are seen to increase under conditions of high LATS 
activity (chapter 3). Increased Amot130 protein, in turn, is found to likely result from the induced 
binding of AIP4 to Amot130, leading to Amot130 ubiquitination and stabilization. The 
ubiquitination of Amot130 by AIP4 is thought to mainly be unchained, an event frequently 
associated with changes in cellular trafficking (Rotin et al., 2000). Thus, monoubiquitination of 
Amot130 is consistent with its observed changes in localization to the cell membrane, whereas, 
Amot130 (K481R) and Amot130 (S175A) both dominantly localize at enlarged actin stress 
fibers. The change in localization, in turn, through an unknown mechanism reduces Amot130 
stability. Another possible mechanism for increased stability of Amot130 upon AIP4 binding 
could be the prevention of other Nedd4 ligases binding to Amot130, which are reported to lead to 
Amot130 polyubiquitination and degradation. An example of this is Nedd4-1, which reduces the 
stability of Amot130 via binding these same P-Y motifs of Amot130 (Wang et al., 2012). 
Here, AIP4 is proposed to have a high-affinity interaction with Amot130 through binding 
both the P-Y2 and P-Y3 motifs through the first and second WW domains of AIP4. The 
interaction of Amot130 and AIP4 was demonstrated through a series of pull-downs and 
immunoprecipitation reactions (Adler et al., 2013a). A significant consequence of Amot130 
binding to AIP4 is the induction of AIP4 ligase activity and self-ubiquitination of the ligase. 
Here, Amot130, like other adapters is able to initiate the self-ubiquitination of AIP4 via binding 
of its P-Y motifs, presumably relieving the inhibitory conformation of AIP4 (Hooper et al., 2010; 
Mund and Pelham, 2009). Interestingly, AmotL2, lacking the third functional P-Y motif, was 
unable to initiate the doublet-formation of AIP4 and thus appears unable to promote active AIP4. 
This indicates the importance of functional P-Y motifs for interactions with the ligase. 
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The Amot130-AIP4 complex further defines the substrate availability of AIP4 by 
providing Amot130 as a substrate. The result of the Amot130-AIP4 interaction and ubiquitination 
is the increased stability of Amot130. The stabilization of Amot130 by AIP4 is proposed to be a 
result of ubiquitinated Amot130 being targeted to intercellular contacts. While the finding that 
Amot130 is stabilized by AIP4 differs from a previous study (Wang et al., 2012), the findings 
here are supported by multiple approaches. First, the effects of silencing AIP4 both reduce 
Amot130 protein stability and also increases AMOT mRNA transcript levels. The cell type 
specific effects of silencing AIP4 on Amot130 steady state protein levels are therefore likely due 
to a dominance of either effect. Further, while silencing AIP4 is a fairly non-specific approach, 
the reduced stability of the Amot130 (K481R) and Amot130 (S175A) is a more direct indicator 
that the phosphorylation and ubiquitination generally enhances Amot130 stability. Further, 
Amot130 is reported to be more stable in cells at high confluence (Bratt et al., 2005), where it is 
found here that Amot130 is more likely to be ubiquitinated. For instance, an ubiquitinated peptide 
of Angiomotin was identified in differentiated keratinocytes in 4 out of 5 mass spectrometry 
experiments, but was never detected in undifferentiated keratinocytes (Adler et al., 2013a). 
Further, a gel shifted band of Amot130, which is associated with its ubiquitination, is strongly 
seen across mammary epithelial cells grown to high density (Adler et al., 2013a), but not in cells 
at low density (Ranahan et al., 2011). This change in stability is also consistent with the finding 
that wild-type Amot130, but not the ubiquitination-reduced mutant (K481R) nor the LATS 
phosphorylation site deficient mutant (S175A), localized to a much greater extant to intercellular 
contacts. 
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4.3.2. Amot130 Phosphorylation by LATS1 Increases the Stability of Amot130 by 
Promoting AIP4 Binding and Ubiquitination of Amot130 
Importantly, this is the first report of any protein enzymatically increasing Amot130 
steady state protein levels. Further, the interaction between Amot130 and AIP4 is increased by 
the ability of Amot130 to be phosphorylated at Ser-175 by LATS1. Thus, a downstream effect of 
Amot130 phosphorylation is demonstrated to increase the steady state protein levels of Amot130 
(Figure 4-11). This outcome is not surprising in the context of physiological effects of serum 
starvation to inhibit cellular growth. The mammary epithelial cells, upon serum starvation, signal 
to shut down their pro-growth pathways, which should include YAP and TAZ nuclear activities. 
LATS is a potent inhibitor of cell growth, and by stabilizing Amot130, enhances the ability LATS 
to be a tumor suppressor. In order to understand how these proteins (LATS and Amot130) 
influence cell growth, an examination of their reported roles as potent inhibitors of YAP and TAZ 
is warranted, and will be examined in the next chapter. 
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Figure 4-11 Working Model for Serum Starvation Inhibition of Cell Growth. 
Amot130 is a major contributor to the anti-growth phenotype in mammary epithelial cells. 
LATS1 is activated in breast cancer cells upon serum starvation. Active LATS1 phosphorylation 
of Amot130 promotes Amot130 binding to and ubiquitination by AIP4. The ubiquitination occurs 
in part at Lys-481 of Amot130. This ubiquitination, in turn, increases the stability of Amot130. 
How the Amot130-AIP4 complex modulates growth arrest will be examined in the next chapter. 
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CHAPTER 5. THE LONG ISOFORM OF ANGIOMOTIN AND AIP4 COOPERATIVELY 
INHIBIT THE TRANSCRIPTION OF YAP-DEPENDENT GENES 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Some text in this chapter was originally published in The Journal of Biological Chemistry and the 
Proceedings of the National Academy of Sciences USA. Adler et al. Amot130 Adapts Atrophin-1 
Interacting Protein 4 to Inhibit Yes-Associated Protein Signaling and Cell Growth. Journal of 
Biological Chemistry. 2013; Vol: 288, 25: 15181-15193. © the American Society for 
Biochemistry and Molecular Biology. Adler et al. Serum deprivation inhibits the transcriptional 
co-activator YAP and cell growth via phosphorylation of the 130-kDa isoform of Angiomotin by 
the LATS1/2 protein kinases. Proceedings of the National Academy of Sciences. 2013; Vol: 110, 
43: 17368-17373. © Proceedings of the National Academy of Sciences USA. 
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5.1. Introduction 
 
Hippo signaling mainly functions to inhibit YAP and TAZ, co-activators of the 
transcription of genes involved in growth and survival. YAP and TAZ are functional homologues 
that promote cell growth and survival by activating transcription factors that in turn drive the 
expression of genes like, connective tissue growth factor (CTGF). Typically, inhibition of the 
nuclear localization of YAP and TAZ results in cellular growth arrest. This is generally 
accomplished through their phosphorylation by LATS1/2 protein kinases. Recently, the 
Angiomotin family of proteins was also demonstrated by several groups to inhibit YAP and TAZ 
nuclear activities (Chan et al., 2011; Wang et al., 2011; Zhao et al., 2011a). However, the primary 
mechanisms of how Angiomotins inhibit YAP and TAZ are uncertain. 
Here, a novel complex is identified containing YAP and the ubiquitin ligase AIP4, 
through their binding to Amot130. This complex leads to the ubiquitination and decreased steady 
state protein levels of YAP. This, in turn, inhibits the nuclear functions of YAP, as seen by 
decreased endogenous CTGF transcript levels. Importantly, the formation of this complex is 
induced by the phosphorylation of Amot130 by LATS1 upon serum starvation. 
Amot130 binding to AIP4 may also affect YAP signaling, by preventing AIP4 interaction 
with LATS1. Typically, LATS1 is targeted for degradation by AIP4, but Amot130 is able to 
dominantly bind AIP4, preventing LATS1 degradation. Together, the Amot130-AIP4 complex 
likely inhibits YAP signaling, via multiple approaches, in response to serum starvation and LATS 
activity. 
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5.2. Results 
 
5.2.1. Amot130 Repurposes AIP4 from LATS1 Degradation to the Ubiquitination of 
YAP 
Due to the individual important functions of AIP4 and Amot130 in Hippo signaling, the 
impact of the Amot130-AIP4 complex (described in section 4.2.1) on Hippo signaling was 
examined. Because AIP4 binds to P-Y motifs in both Amot130 and LATS1 via the WW domains 
of AIP4, their competition for binding to AIP4 was explored. Myc-tagged AIP4 was 
immunoprecipitated from HEK 293T cells that also expressed a control vector and Flag-tagged 
LATS1 or YFP-tagged Amot130 and Flag-tagged LATS1. Immunoblot analysis revealed that 
YFP-tagged Amot130 expression resulted in dramatically less LATS1 being precipitated by AIP4 
and concomitant binding to Amot130 (Figure 5-1A). Consistent with AIP4 mediating the 
degradation of LATS1 (Salah et al., 2011), the steady state protein levels of endogenous LATS1 
were reduced upon expression of AIP4 (Figure 5-1B). However, expression of Amot130 
increased the levels of endogenous LATS1 protein even when AIP4 was co-expressed. Amot130 
is therefore proposed to uncouple AIP4 from binding and inducing the degradation of LATS1. 
This is important, because LATS1 phosphorylation of YAP and TAZ prevents their nuclear 
activities. Therefore, Amot130 by preventing LATS1 degradation likely promotes LATS1 
activity. 
Amot130 also robustly binds YAP2 (containing two WW domains) but not with YAP1 
(containing one WW domain) (Oka et al., 2012). Therefore, only YAP2 was examined for all 
overexpressed YAP studies and is commonly referred to as YAP, for simplicity.  
It was investigated whether AIP4 is part of a complex with YAP and Amot130. In 
examination of this, Myc-tagged AIP4 and YFP-tagged Amot130 strongly co-precipitated with 
Flag-tagged YAP, whereas only trace levels of Myc-tagged AIP4 (along with endogenous 
Amot130) bound Flag-tagged YAP in the absence of YFP-tagged Amot130, when expressed in 
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HEK 293T cells (Figure 5-2A). Thus, YAP and AIP4 are likely scaffolded by Amot130 into a 
single protein complex. This indicates that YAP and AIP4 are brought together by the adapter 
protein Amot130. 
Because AIP4 and YAP potentially bind to overlapping P-Y motifs in Amot130, the 
mechanisms of interaction of YAP with Amot130 were further examined. The mutation of 
Amot130 P-Y motifs (P-Y1F or P-Y2F), both showed almost no detectable association with 
exogenous YAP in HEK 293T cells (Figure 5-2B), this along with additional binding experiments 
revealed that there is a likely preference of the WW1 of YAP for P-Y1 motif of Amot130 and the 
WW2 of YAP for P-Y2 motif of Amot130 (Adler et al., 2013a). The P-Y3 motif of Amot130 was 
not examined, as this was previously reported not to bind to YAP (Skouloudaki and Walz, 2012). 
Together, this data points to a possible competition for the P-Y2 motif of Amot130 between YAP 
and AIP4, as both need this P-Y2 motif to bind Amot130 (section 4.2.1) (Figure 5-2B). 
Simplistically, this should inhibit AIP4 and YAP from simultaneously being in a complex with 
Amot130. However, because the Angiomotins homo- and hetero-dimerize (Ernkvist et al., 2008; 
Gagné et al., 2009), this may result in AIP4 and YAP both binding separate Amot130 proteins, 
yet remain in a single complex (Figure 5-2C). 
Based upon the evidence that Amot130 brings YAP and AIP4 into a common complex, 
the effects of Amot130 on the ubiquitination of YAP by AIP4 were measured. Ubiquitinated 
Flag-tagged YAP was immunoprecipitated from HEK 293T cells expressing HA-tagged Lys-0 
Ubiquitin with an anti-HA antibody. While ubiquitinated YAP was undetectable in samples not 
expressing Amot130 or AIP4, the expression of either Amot130 or AIP4 alone modestly 
increased the levels of ubiquitinated YAP. However, co-expression of AIP4 and Amot130 
resulted in a strong synergistic increase in the levels of ubiquitinated YAP, indicating the 
importance of Amot130 in adapting YAP as a substrate for AIP4 (Figure 5-3A). This effect 
requires catalytically active AIP4, as co-expression of Amot130 and the catalytically inactive 
mutant of AIP4 (C830A) did not induce the ubiquitination of YAP (Figure 5-3B). 
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The differential effects of incorporation of HA-tagged wild-type Ubiquitin versus Lys-0 
Ubiquitin induced by Amot130 and AIP4 into YAP were compared in HEK 293T cells (Figure 5-
3C). Lys-0 Ubiquitin has all seven lysines mutated to arginines and thus is incapable of ubiquitin 
chain extension. Expression of Amot130 with AIP4 resulted in a gel shifted weak smear of wild-
type ubiquitinated YAP, which is consistent with polyubiquitination and therefore potential 
targeting for degradation. Whereas, Lys-0-ubiquitinated YAP, induced by expression of Amot130 
and AIP4 migrated as a faster/smaller and much stronger single band. The absence of this lower 
band with wild-type Ubiquitin supports that AIP4-catalyzed ubiquitination of YAP could be 
coupled to polyubiquitination. This may also indicate that the ubiquitination of YAP by AIP4 
leads to rapid degradation, as preventing AIP4-mediated chain extension of ubiquitin moieties 
enhances the levels of ubiquitinated protein. 
The role of LATS in promoting Amot130-AIP4 complex-mediated ubiquitination of YAP 
was examined. The ubiquitination of Flag-tagged YAP was increased in HEK 293T cells under 
serum starvation conditions versus control cells in a manner promoted by expression of AIP4 
(Figure 5-4A). Thus, AIP4 ubiquitinates YAP in response to serum starvation. Further, the 
ubiquitination of YAP was dependent on LATS phosphorylation of Amot130. While YAP was 
able to bind the Amot130 (S175A) mutant as effectively as wild-type Amot130 under active 
LATS1 conditions (Figure 5-4B), Amot130 (S175A) was unable to increase the ubiquitination of 
YAP following serum starvation (Figure 5-4C). Therefore, a role exists for Amot130 to promote 
YAP ubiquitination in response to serum starvation and likely LATS activity. Together, the 
Amot130-AIP4 complex promotes the ubiquitination of YAP in a manner that is dependent on the 
ability of Amot130 to be phosphorylated by LATS. 
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Figure 5-1 Amot130 Prevents AIP4-Mediated LATS1 Degradation. 
(A) The levels of Myc-tagged AIP4, Flag-tagged LATS1, and YFP-tagged Amot130 were 
detected by immunoblot from lysates and immunoprecipitations (anti-Myc) prepared from HEK 
293T cells expressing these proteins in the indicate combinations. (B) The levels of endogenous 
LATS1 were measured by immunoblot in MDA-MB-468 cells expressing mCherry-tagged AIP4 
and YFP-tagged Amot130 alone or in combination. The ratios of pixel intensities of LATS1 over 
GAPDH are presented below top panel. Figure adapted from (Adler et al., 2013b). 
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Figure 5-2 YAP is in a Complex with AIP4 and Amot130. 
(A) The levels of Myc-tagged AIP4, YFP-tagged Amot130, and Flag-tagged YAP were detected 
by immunoblot from lysates and immunoprecipitations (anti-Flag) prepared from HEK 293T cells 
expressing these three proteins in the indicated combinations. (B) The levels of Flag-tagged YAP 
and Myc-tagged wild-type Amot130, Amot130 (P-Y1F) (Y109F), Amot130 (P-Y2F) (Y242F) 
mutants, or control vector were detected by immunoblot from lysates and immunoprecipitations 
(anti-Myc) prepared from HEK 293T cells expressing these proteins in the indicated 
combinations. Part B performed by Brigitte Heller. (C) Model of the binding relationships of the 
YAP-Amot130-AIP4 complex. A (?) denotes unknown sites of binding. Figure adapted from 
(Adler et al., 2013a). 
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Figure 5-3 YAP is Ubiquitinated by the Amot130-AIP4 Complex. 
(A) The levels  of ubiquitinated Flag-tagged YAP were detected by immunoblot following 
immunoprecipitation (anti-HA) from HEK 293T cells expressing HA-tagged Lys-0 Ubiquitin 
(HA-K0 Ub) in combination with YFP-tagged Amot130 or control vector as well as Myc-tagged 
AIP4 and Flag-tagged YAP. (B) The relative incorporation of HA-K0 Ub into 
immunoprecipitated Flag-tagged YAP in HEK 293T cells co-expressing YFP-tagged Amot130, 
Myc-tagged AIP4, mutant AIP4 (C830A), or control vectors was detected by immunoblot. (C) 
The levels of total and ubiquitinated Flag-tagged YAP were detected by immunoblot following 
immunoprecipitation from HEK 293T cells expressing HA-tagged wild-type (WT) or K0 
Ubiquitin in combination with YFP-tagged Amot130 or control vector as well as Myc-tagged 
AIP4 and Flag-tagged YAP. Figure adapted from (Adler et al., 2013a). 
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Figure 5-4 Serum Starvation and Ability of Amot130 to be Phosphorylated at Serine-175 
Enhances YAP Ubiquitination by the Amot130-AIP4 Complex. 
(A) Immunoblot with an anti-HA antibody was used to detect ubiquitinated Flag-tagged YAP and 
YFP-tagged Amot130 in immunoprecipitations with an anti-Flag antibody from HEK 293T cells 
expressing HA-Lys-0 Ubiquitin (HA-K0 Ub) and the indicated combinations of proteins. Before 
lysis, cells were cultured in DMEM with 10 % serum or serum starved for 24 hours. (B) 
Immunoblot of LATS1 and Amot130 in lysates or immunoprecipitated Flag-tagged YAP (anti-
Flag) from HEK 293T cells transiently expressing proteins in indicated combinations. (C) 
Ubiquitinated proteins were immunoprecipitated with an anti-HA antibody from HEK 293T cells 
expressing the indicated combinations of recombinant proteins. Individual proteins were then 
detected by immunoblot as indicated. Figure adapted from (Adler et al., 2013b). 
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5.2.2. The Ability of Amot130 to be Phosphorylated at Serine Residue 175 Allows for 
Amot130 to Reduce the Stability of YAP 
Taking into account that the Amot130-AIP4 complex ubiquitinates YAP, the ability of 
the complex to influence the stability of YAP was examined. Initially, the effects of Amot130 
expression on the endogenous stability of YAP protein in the presence or absence of AIP4 were 
defined. For this, MDA-MB-468 cells stably expressing YFP-tagged Amot130 or control vector 
in combination with shRNA control or shRNA targeting AIP4 were lysed at the indicated times 
following treatments with cycloheximide (Figure 5-5A). Unlike control cells, which showed no 
reduction of endogenous YAP by 8 hours, cells expressing YFP-tagged Amot130 showed a 40 % 
loss of YAP (Figure 5-5A, top left). Further, as previously reported (Salah et al., 2011), silencing 
of AIP4 reduced the levels of YAP by over 80 % over this time, likely via stabilized LATS1. 
Consistent with Amot130 uncoupling YAP from regulation by LATS (Hao et al., 2008; Zhao et 
al., 2010), the expression of Amot130 partially reversed the effects of silencing AIP4 (Figure 5-
5A, top right). However, the reported destabilization of LATS1 by AIP4 likely explains the 
inability to see a reversal of the inhibition of YAP by Amot130 expression upon the silencing of 
AIP4. This event is also complicated by the potential for Amot130 to regulate other Nedd4 family 
members (Wang et al., 2012). However, because co-expression of Amot130 and AIP4 results in a 
synergistic reduction in the steady state protein levels of YAP, there appears to be some role for 
AIP4 in directing Amot130-mediated reduction of YAP protein levels (Figure 5-5B). Thus, the 
inhibition of YAP is complicated by multiple roles of AIP4. 
Based upon the differences in wild-type Amot130 versus Amot130 (S175A) to induce 
YAP ubiquitination (section 5.1), their effects on YAP stability were defined. This analysis was 
carried out in MCF7 cells due to their high AIP4 levels (Adler et al., 2013a), which sensitizes 
them to effects of phosphorylation of Amot130. Expression of wild-type Amot130 reduced the 
half-life of CFP-tagged YAP to 8.9 hours, following incubation with cycloheximide. However, 
cells expressing Amot130 (S175A) showed no detectable reduction of YAP stability over this 
 106 
 
period (Figure 5-5C). Thus, the ability of Amot130 to be phosphorylated at Ser-175 appears to be 
important for Amot130 to promote the degradation of YAP. 
Actin stress fibers are highly implicated in the activation of YAP and TAZ (Wada et al., 
2011). Further, the mutants Amot130 (K481R) and Amot130 (S175A) localize to actin stress 
fibers; unlike wild-type Amot130 (section 4.2.5). Therefore, the redistribution of YAP to actin 
stress fibers by Amot130 (S175A) (Figure 5-6A-B) is consistent with Amot130 (S175A) having 
robust YAP binding (section 5.2.1), but not playing a role in suppressing YAP signaling. Overall, 
phosphorylation of Amot130 is likely central to the ability of Amot130 to redirect YAP away 
from actin stress fibers to trigger the destruction of YAP, likely via coupling YAP to an 
Amot130-AIP4 complex. 
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Figure 5-5 Amot130 Expression Induces YAP Degradation. 
(A) The levels of YFP-tagged Amot130 as well as endogenous AIP4, YAP, and GAPDH were 
detected in lysates from MDA-MB-468 cells stably expressing control or AIP4 shRNA in 
combination with YFP-tagged Amot130 or control vector and treated for the indicated times with 
vehicle (DMSO) or 200 µg/mL cycloheximide (CHX). The ratio of pixel intensities with linear 
regression analysis was plotted from the immunoblots, where the YAP/GAPDH levels in cells 
expressing (■) YFP-Control or (●) YFP-Amot130 are depicted (left graph) and the YAP/GAPDH 
levels in cells expressing (●) shControl, (■) shAIP4, or (▲) YFP-tagged Amot130 and shAIP4 
are shown (right graph). (B) The levels of endogenous YAP were detected by immunoblot 
analysis of lysates from HEK 293T cells expressing combinations of YFP-tagged Amot130 and 
Myc-tagged AIP4. The ratios of pixel intensities of endogenous YAP over GAPDH bands are 
below the top panel. (C) The levels of YFP-tagged Amot130, YFP-tagged Amot130 (S175A), 
CFP-tagged YAP, and endogenous GAPDH were detected by immunoblot of lysates from MCF7 
cells stably expressing these proteins following treatment for the indicated times, as described in 
A. Below, a graph of the ratios of CFP-tagged YAP over GAPDH and the resulting half-lives in 
cells expressing (■) YFP-tagged Amot130 (S175A) or (♦) YFP-tagged wild-type Amot130. 
Figure adapted from (Adler et al., 2013a) and (Adler et al., 2013b). 
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Figure 5-6 Wild-type Amot130 and Mutant Amot130 (S175A) Promote Different 
Subcellular Distributions of YAP. 
(A-B) Confocal images of fixed MCF7 cells examining endogenous YAP using an anti-YAP 
antibody (red) and expressing (A) YFP-tagged wild-type (WT) Amot130 or (B) YFP-tagged 
Amot130 (S175A) (both in green). Nuclei are stained with Hoechst (blue). Figure in collaboration 
with Lauren Bringman. Figure adapted from (Adler et al., 2013b). 
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5.2.3. The Amot130-AIP4 Complex Mediates the Inhibition of YAP by LATS 
Given the complex effects of AIP4 and Amot130 on YAP stability, functional analysis 
was undertaken to determine the role of AIP4 in mediating Amot130 induced inhibition of YAP-
dependent transcription. The transcription of CTGF and Cyr61 are regulated by TEAD 
transcription factors that, in turn, are under the control of YAP (Lai et al., 2011; Zhao et al., 
2008b). The endogenous levels of CTGF and Cyr61 transcripts were examined in MDA-MB-468 
cancer cells, which have an average basal YAP levels and relatively high Angiomotin (Adler et 
al., 2013a). These cells were grown to conditions conducive to low Hippo signaling (10 % serum 
or low confluence) or high Hippo signaling (serum starved or high confluence). Representative 
brightfield images were taken of cells at both high and low confluence, so that a reference of what 
constitutes high and low confluence is established (Figure 5-7A). Initially, the effects of AIP4 
silencing in combination with Amot130 expression on both the endogenous CTGF and Cyr61 
mRNA levels was measured by real time PCR under conditions of serum starvation and low 
confluence, where Hippo signaling should be active (Figure 5-7B). Analysis revealed that cells 
stably expressing Amot130 had more than an 85 % reduction in CTGF transcript, while CTGF 
mRNA levels in AIP4 stably silenced cells were reduced by roughly 50 %. The inhibition of 
CTGF mRNA levels in AIP4 silenced cells is likely via gain of LATS activity (Salah et al., 
2011). However, CTGF mRNA levels were reduced by less than 45 % in cells simultaneously 
silenced for AIP4 expression and expressing YFP-tagged Amot130. Similar effects were seen 
with Cyr61 transcript levels. Thus, AIP4 appears to be at least partially required for Amot130 to 
suppress the transcript levels of CTGF and Cyr61. 
Next, the role of Amot130 on LATS reported inhibition of YAP activity was examined. 
These cells were grown in 10 % serum to low confluence, where Hippo signaling should be low. 
Here, following infection of these cells with shRNA targeting Angiomotin for 24 hours, there is 
an isoform selective silencing of Amot130 but not Amot80. Cells expressing CFP-tagged LATS1 
and a control shRNA showed a significant reduction in CTGF levels, as expected with active 
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LATS1 (Figure 5-8A); whereas, there was no significant loss of CTGF transcription in LATS1 
expressing cells with silenced Amot130 levels. Interestingly, silencing of Amot130 without 
LATS1 expression resulted in a significant increase in CTGF levels. Thus, Amot130 is required 
to transmit the inhibition of YAP by LATS1 in these cells. 
The roles of phosphorylation of Amot130 on YAP phosphorylation and YAP-dependent 
transcription were then investigated. MDA-MB-468 cells were grown in 10 % serum, to high 
confluence, therefore placing them in presumably active Hippo signaling. Exogenous expression 
of wild-type Amot130 showed increased levels of phosphorylation of Ser-127 on YAP versus 
control cells, as previously reported (Figure 5-8B) (Zhao et al., 2011a). Conversely, Amot130 
(S175A) expression reduced phosphorylation of YAP at Ser-127 versus control cells. To 
determine if the change in phosphorylation of YAP translated into reduced levels of YAP-
regulated transcripts, CTGF mRNA levels were measured in similarly stably expressing cells 
under presumably low Hippo signaling (10 % serum and low confluence) or high Hippo signaling 
(10 % serum and high confluence) (Figure 5-8C). The expression of wild-type Amot130, but not 
Amot130 (S175A) significantly reduced the levels of CTGF transcript in cells with low Hippo 
signaling. Alternatively, cells with high levels of intercellular contacts showed modestly reduced 
CTGF levels upon wild-type Amot130 expression from presumably already low basal levels of 
YAP activity. However, Amot130 (S175A) expression increased CTGF levels significantly above 
those of control cells. This is consistent with it exerting a dominant negative effect in cells with 
active Hippo signaling. Together, these studies indicate an important role of Amot130 inhibition 
of YAP-dependent transcription. These include an important requirement for AIP4 and the ability 
of LATS to phosphorylate Amot130 at Ser-175 to drive the inhibition of YAP. 
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Figure 5-7 Amot130 Inhibits YAP-Dependent Transcription Cooperatively with AIP4. 
(A) Stereoscopic brightfield images of representative fields of MDA-MB-468 cells grown to low 
and high confluence before harvest at 10 X magnification are presented to illustrate the density of 
cells termed low and high confluence in the real time PCR experiments. (B) MDA-MB-468 cells 
stably expressing YFP-tagged Amot130 or control vector in combination with control or AIP4 
shRNA. Cells were grown under serum starvation conditions 24 hours prior to harvest. The 
mRNA transcript levels from cells of CTGF (upper plot) and Cyr61 (lower plot) are presented for 
conditions indicated. Data represents three experimental replicates (n = 3). Below, immunoblots 
from paired cells validating AIP4 silencing and Amot130 expression are presented. Error bars 
represent ± S. D. p-values: *** < 0.00001; ** < 0.01. Figure adapted from (Adler et al., 2013a) 
and (Adler et al., 2013b). 
 112 
 
 
Figure 5-8 Amot130 Mediates the Inhibition of YAP-Dependent Transcription by LATS. 
(A) Real time quantitative PCR measurements of the levels of CTGF mRNA in MDA-MB-468 
cells co-infected for 24 hours with lentivirus encoding combinations of Angiomotin shRNA 
(shAmot), CFP-tagged LATS1, or the indicated controls. Below, immunoblots from paired cells 
validating Amot130 selective silencing and CFP-tagged LATS1 expression with pixel intensity 
values of Amot130 and Amot80 levels normalized to GAPDH. Data represents three biological 
replicates (n = 3). (B) Immunoblot of phosphorylated YAP at Ser-127 (pS127), total YAP, and 
GAPDH from MDA-MB-468 cells expressing YFP-tagged wild-type Amot130, Amot130 
(S175A), or control vector grown to high confluence prior to harvest. The ratios of pixel 
intensities of pS127 YAP to total YAP are presented below second panel. (C) Real time 
quantitative PCR measurements of CTGF mRNA levels in MDA-MB-468 cells described in B 
and harvested at low (left) or high confluence (right). Data represents three biological replicates 
(n = 3). Error bars represent ± S. D. p-values: * < 0.05; n.d. no statistical difference. Figure 
adapted from (Adler et al., 2013b). 
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5.3. Discussion 
 
5.3.1. The YAP-Amot130-AIP4 Complex Formation and Its Inhibition of YAP Activity 
The inhibition of YAP-dependent transcription by the Hippo kinases is a key element in 
growth control. The Amot130-AIP4 complex is an alternative mechanism to relay Hippo 
signaling to inhibit YAP activity. Importantly, YAP is a novel target for the ubiquitin ligase 
AIP4, when both proteins are bound to Amot130. The YAP-Amot130-AIP4 complex is promoted 
by LATS-dependent Amot130 phosphorylation at Ser-175, that both increases Amot130 stability 
and drives the Amot130-AIP4 complex ubiquitination and degradation of YAP. Further, 
phosphorylation of Amot130 and AIP4 binding is required for them to inhibit YAP activity. 
Together, this comprises a novel mechanism for Hippo signaling to inhibit YAP nuclear activity. 
YAP binding to Amot130 utilizes two P-Y motifs for a high affinity interaction, as does 
AIP4. The complex containing both AIP4 and YAP is proposed to involve Amot130 homo-
dimerization. In effect, the dimerization of the Angiomotins provides double the number of 
available P-Y motifs in a single complex, allowing both proteins to bind the second P-Y motif to 
achieve a high affinity association. Importantly, an interaction between AIP4 and YAP was not 
seen without Amot130 expression, which indicates the importance of the Amot130 adapter 
protein for providing the docking sites for the ubiquitin ligase and the substrate into a common 
complex. Further, the complex formation and YAP ubiquitination is highly dependent on the 
ability of Amot130 to be phosphorylated at Ser-175. 
 
5.3.2. The Essential Role of Amot130 in Reinforcing YAP Inhibition 
The formation of an Amot130-AIP4 complex also prevents AIP4 from binding and 
targeting LATS1 for degradation. Amot130 likely competes for binding to AIP4, with LATS1, 
and thereby prevent LATS1 degradation via the 26S Proteasome (Salah et al., 2011). LATS1 
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remains free to phosphorylate and inhibit YAP activity. Likely, this is one of the multifactorial 
effects of Amot130 in promoting the degradation of YAP. 
Overall, Amot130 is proposed to both activate and transmit Hippo signaling to strongly 
induce the inhibition of YAP activity and cell growth (Figure 5-9). The inhibition of YAP in 
response to Amot130 is likely self-reinforcing, whereby Amot130 directly activates LATS1/2 
(Paramasivam et al., 2011) that, in turn, promotes Amot130 stabilization by driving Amot130 
association with AIP4. Together, these events likely drive the rapid accumulation of active 
LATS1/2 and Amot130 to directly inhibit YAP nuclear activity. The inhibition of YAP is 
predicted to occur by both targeting YAP for phosphorylation by LATS1/2 and ubiquitination by 
SCF-(β)-TRCP (Zhao et al., 2010), as well as by AIP4-induced ubiquitination and degradation. 
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Figure 5-9 Proposed Cyclic Model for Amot130 and LATS1 Inhibition of YAP-Dependent 
Transcription. 
Under conditions of low Amot130 protein levels (above), LATS is degraded by AIP4 and YAP is 
ultimately in the nucleus, where it can activate pro-growth transcription events. However, upon 
increasing Amot130 protein levels (below), it creates a self-reinforcing cycle of LATS and 
Amot130 stability, which ultimately leads to inhibition of YAP. First, LATS, upon activation, 
phosphorylates Amot130, which leads to AIP4 binding and stabilization of Amot130. This 
complex inhibits YAP via its ubiquitination and targeting for degradation by AIP4. Second, stable 
Amot130 is able to inhibit YAP via sequestration mechanisms. Third, Amot130 is able to 
increase the phosphorylation of YAP and inhibition, likely via preferential binding of AIP4 away 
from LATS, creating a stable pool of both LATS and Amot130 to inhibit growth. Upon external 
pro-growth signals, this loop breaks down and YAP can enter the nucleus again. 
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5.3.3. Phosphorylation of Serine Residue 127 on YAP is not Sufficient for YAP 
Inhibition via Serum Starvation 
Recent published evidence indicates that factors can work outside of the phosphorylation 
status of YAP at Ser-127 to inhibit YAP. Importantly, the phosphorylation at Ser-127 is not 
sufficient to exclude YAP from the nucleus (Wada et al., 2011). This same study indicates that 
there is major uncertainty about the location of LATS in the pathway of YAP inhibition. Further, 
where growth was inhibited, under serum starvation conditions, the phosphorylation of YAP at 
Ser-127 was differentially regulated in a panel of adenocarcinoma cell lines (Levin et al., 2009). 
In some cases, serum starvation increased YAP phosphorylation at Ser-127, while in other cell 
lines it decreased. Together, these two studies give evidence to an alternative model of LATS 
inhibiting YAP via the phosphorylation of Amot130 and not directly on YAP. The ability of 
LATS to phosphorylate both YAP and Amot130 provides an alternative explanation for inhibition 
of YAP regulation that supports Amot130 and LATS as dual-inhibitors of YAP. Overall, 
Amot130 likely inhibits YAP through a combination of mechanisms that likely include both 
direct activation of LATS (Paramasivam et al., 2011) and independent effects via AIP4 (Figure 5-
10). 
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Figure 5-10 An Alternative Mechanism for Serum Starvation Inhibition of Cellular 
Growth. 
The ability of Amot130 to homo-dimerize allows for multiple binding partners to exist in a 
complex together. This homo-dimerization may allow for both YAP and AIP4 to form a complex, 
which leads to the ubiquitination and degradation of YAP. The end result of the Amot130-AIP4 
complex is reduced CTGF transcript levels, which likely explains how Amot130 is able to inhibit 
cellular growth. Additionally, the phosphorylation of Amot130 by LATS1 is required for YAP 
ubiquitination by AIP4 in response to serum starvation. Further, the inhibition of CTGF 
transcription by Amot130 requires the ability of Amot130 to be phosphorylated at Ser-175. 
Together, these data suggest an alternative mechanism for growth inhibition in mammary 
epithelial cells that is independent of the canonical phosphorylation of YAP, through the YAP-
Amot130-AIP4 complex. 
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CHAPTER 6. CONCLUDING REMARKS ON THE ROLE OF THE LONG ISOFORM 
OF ANGIOMOTIN IN GROWTH SIGNALING IN MAMMARY EPITHELIAL CELLS 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Some text in this chapter was originally published in The Journal of Biological Chemistry and the 
Proceedings of the National Academy of Sciences USA. Adler et al. Amot130 Adapts Atrophin-1 
Interacting Protein 4 to Inhibit Yes-Associated Protein Signaling and Cell Growth. Journal of 
Biological Chemistry. 2013; Vol: 288, 25: 15181-15193. © the American Society for 
Biochemistry and Molecular Biology. Adler et al. Serum deprivation inhibits the transcriptional 
co-activator YAP and cell growth via phosphorylation of the 130-kDa isoform of Angiomotin by 
the LATS1/2 protein kinases. Proceedings of the National Academy of Sciences. 2013; Vol: 110, 
43: 17368-17373. © Proceedings of the National Academy of Sciences USA. 
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6.1. Introduction 
 
A novel mechanism for the inhibition of YAP activity by Amot130 and the Nedd4 ligase 
AIP4 is presented in this study. Deeper understanding of how microenvironmental factors 
regulate the Hippo pathway is of great importance. Unfortunately, understanding the roles of 
specific Angiomotins and Nedd4 ligases is complicated by the multiple overlapping, redundant, 
and non-overlapping roles of these proteins. Further, the regulation of their expression in normal 
and pathologic contexts is largely unknown. This thesis suggests possible routes by which 
Angiomotins and Nedd4 ligases may transduce microenvironmental cues as part of the Hippo 
signaling pathway. 
 
6.2. Influencing Angiomotins and Their Impact on Signaling 
 
6.2.1. The Role of Serum Factors in Angiomotin Signaling 
While the role of specific serum factors in the microenvironment of the cell was not 
discussed in this thesis, the deprivation of these and other unknown factors is clearly an important 
signal for cells to cease cell division and growth. Evidence is presented here that illustrates how 
serum deprivation at least in part increases the protein steady state levels of Amot130 to induce 
growth arrest. The response to serum deprivation was found to be specific to Amot130 and not 
AmotL1. This information further led to the investigation of how Amot130 in response to serum 
deprivation is at the heart of a novel mechanism by which Hippo signaling inhibits YAP and 
cellular growth. Interestingly and surprisingly, throughout this investigation of Amot130, the 
short isoform of Angiomotin (Amot80) also had a robust increase in its protein steady state levels 
in response to serum deprivation (Figure 6-1A). However, this increase in protein steady state 
levels was not as consistent as those seen with Amot130 (Figure 6-1B). The explanation for this 
increase is not clear because Amot80 lacks the N-terminal P-Y motifs, thus cannot directly bind, 
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be ubiquitinated, or stabilized by AIP4. Additionally, the predicted LATS binding site also is 
lacking in Amot80. Based upon the absence of important binding relationships, the increase in 
steady state protein levels of Amot80 in response to serum deprivation is likely indirect. A 
possible explanation lies in the ability of Amot80 to hetero-dimerize with other Angiomotins, 
which have these functional N-terminal regions. Depending upon what Angiomotin Amot80 
dimerizes with (AmotL1, Amot130, or AmotL2) could greatly impact if Amot80 is influenced by 
serum deprivation. For example, AmotL1 steady state protein levels are not influenced by serum 
deprivation, thus if Amot80 dimerizes with AmotL1, it is likewise hypothesized to not be 
influenced. However, if Amot130 dimerizes with Amot80, it would allow Amot80 to be in the 
same complex with AIP4, which increases the ubiquitination and stability of Amot130, and thus 
also possibly bound Amot80. Regardless, Amot80 increases sometimes in response to serum 
deprivation. Further analysis of the Amot80 response to serum deprivation and its relationship 
with cell growth remains to be investigated. Perhaps serum deprivation is generally trying to 
achieve a balance of the Angiomotins to inhibit cellular growth. The action of increasing steady 
state protein levels of Angimotin versus AmotL1 is likely a signal for other growth and survival 
related pathways, with unknown outcomes. Overall, specific Angiomotins are influenced by 
serum deprivation and this action is likely a key mediator of their abilities to influence growth 
control. 
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Figure 6-1 Serum Starvation Increases Amot80 Steady State Protein Levels. 
(A) Amot80 and GAPDH steady state protein levels were analyzed via immunoblot of lysates 
from MDA-MB-468 cells subjected to serum starvation for times indicated. The normalized pixel 
intensities of Amot80 over GAPDH for each condition are indicated. (B) Immunoblot of 
Amot130, Amot80, and GAPDH protein steady state levels as analyzed in A in MDA-MB-468 
cells after 24 hour serum starvation or with 10 % serum. 
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6.2.2. The Similarities and Differences Between the Angiomotins 
Upon initial structural examination of the long Angiomotins, they appear very similar. 
All contain a PDZ-binding motif, P-Y motifs, and an ACCH domain, among other features. This 
could lead to the assumption that all of the Angiomotins are functionally redundant. Further, this 
is enforced by the overlapping role of the long Angiomotins to inhibit YAP and TAZ. While 
redundant roles have been demonstrated, this thesis provides important differences between these 
family members. Further, these differences are likely important for understanding their general 
roles as adapter proteins and their non-overlapping roles. 
Amot130 and likely AmotL1 are phosphorylated by LATS2. However, AmotL2 does not 
appear to be able to be phosphorylated, based upon the peptide in vitro kinase assays. The 
inability of AmotL2 to be phosphorylated by LATS2 may help explain why AmotL2 also failed 
to be ubiquitinated by AIP4, unlike both AmotL1 and Amot130. The amino acids that surround 
the LATS consensus motif of AmotL2 are more diverse when compared to AmotL1 and 
Amot130. Thus, it is not surprising that AmotL2 would have the greatest difference in 
phosphorylation compared to the other Angiomotins. Further establishing the uniqueness of 
AmotL2, it contains an arginine residue in the site that aligns with the lysine ubiquitination sites 
of Amot130/AmotL1. In support of the inability of AmotL2 to be ubiquitinated by AIP4, AmotL2 
lacks a third conserved P-Y motif seen in both Amot130 and AmotL1. This motif is required for 
Amot130 to bind to AIP4. The inability to have this third functional P-Y motif, may in part 
explain the inability of AmotL2 to be ubiquitinated by AIP4. Together, AmotL2 lacks key 
functional residues seen in AmotL1 and Amot130, which prevent the ability of AmotL2 to be 
phosphorylated at its predicted LATS consensus motif and lacks ubiquitination by AIP4. Given 
the evidence above, it is likely that AmotL2 would also not respond to serum deprivation nor be 
able to transmit Hippo signaling through this particular growth-arrest mechanism. 
Based upon the similarities presented thus far between Amot130 and AmotL1, it is 
tempting to conclude that both are functionally the same. However, the increase in Amot130 
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steady state protein levels upon serum deprivation was not seen for AmotL1. Interestingly, both 
seem capable of being phosphorylated by the LATS2 protein kinase. Thus, the specificity of 
Amot130 in response to serum deprivation remains to be answered. This could possibly be 
answered by observations that AmotL1 seems to preferentially bind another Nedd4 ubiquitin 
ligase, Nedd4-1, better than AIP4. Nedd4-1 leads to the ubiquitination and degradation of both 
AmotL1 and Amot130 (Wang et al., 2012), whereas AIP4 increases the steady state protein levels 
of Amot130 (Adler et al., 2013a). Thus, if AmotL1 preferentially binds Nedd4-1, it will not be 
able to also bind AIP4, and thus prevents an AIP4-dependent increase in steady state protein 
levels of AmotL1. Together, AmotL1 steady state protein levels are not influenced in response to 
serum deprivation and LATS phosphorylation likely because these events do not lead to binding 
of AIP4, which is shown here to be critical for stabilizing Amot130 protein. Future studies 
examining the specificity of Nedd4 ligases for binding with specific Angiomotins may clarify 
their functioning in cells. 
Taken together, AmotL2 and AmotL1 are not regulated the same as Amot130 in 
epithelial cells. Clearly, these Angiomotins are not completely functionally redundant and future 
studies will help differentiate the family members in the context of epithelial cell signaling. 
 
6.2.3. The Role of Angiomotin in Mammary Tissue 
In normal breast development, especially during the pregnancy lactation cycle, major 
changes in tissue architecture in the breast occur via the regulation of cell growth, migration, and 
cell death pathways. These are especially apparent during the process of involution. During this 
time, changes in the cellular microenvironment modify cellular polarity and lead to signaling that 
promotes physiological changes in the architecture of the breast. In mouse models, mRNA 
profiles identified prolonged AMOT signatures at day 3 of involution (Stein et al., 2009). This 
upregulation of AMOT was correlated with the highest level of metastasis and cell movement. 
This physiological correlation best associates with the reported functions of Amot80 and not 
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Amot130 (Bratt et al., 2005). However, based upon the functions of Amot130 presented in this 
study it is likely that Amot130 also plays a role in tissue remodeling. A major function of 
Amot130 presented here is its ability to inhibit growth signaling pathways in mammary epithelial 
cells. Thus, Amot130 is predicted to be involved in cellular differentiation. Evidence of Amot130 
inducing cellular differentiation is seen upon expression of Amot130 in MCF10A acini, which 
appears to force the acini into early differentiation, yielding a structure likely incapable of 
physiological function. Further, Amot130 is associated with control of differentiation of the inner 
cell mass cells in pre-implantation mouse embryos (Leung and Zernicka-Goetz, 2013). Together, 
it is hypothesized that Amot130 likely has an opposing role to Amot80 in tissue architecture. 
However, the exact roles of Amot130 versus Amot80 in tissue remodeling are currently 
unknown. A balance between the pro-growth and migratory functions of Amot80 and the 
differentiation and growth-arrest functions of Amot130 likely underlies a critical mechanism for 
tissue remodeling in the breast. Future understanding of the roles of all the Angiomotins in 
normal tissue remodeling processes, including involution, where Angiomotin appears to play an 
important role, will shed light into the key physiological functions of these proteins. 
 
6.2.4. The Involvement of the Angiomotins in Viral Signaling 
The roles of specific Nedd4 ligases and Angiomotins in transducing changes from the 
microenvironment of mammary epithelial cells to Hippo signaling and growth control was an 
important aspect of this study. Specifically, the role of factors in serum was examined; however, 
other potential microenvironmental effectors are likely impacting Hippo signaling and this 
specific mechanistic pathway. These factors include viruses, which have underappreciated roles 
in Hippo signaling. 
The microenvironment of the breast can contain viruses, which may potentially impact 
the growth and survival of cells. Viruses account for about 12 % of all cancers (Moore and 
Chang, 2010) and act on numerous signaling pathways within epithelial cells, regulating 
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processes of cell division, cell polarity, and Hippo signaling (Banks et al., 2012). For example, 
the Par and Crb polarity proteins complexes, which associate with Angiomotin, are hijacked by 
viruses to promote replication of infected cells (Banks et al., 2012). Fortunately, there are 
inhibitory pathways to prevent viral production. One such pathway utilizes AmotL1 to interact 
with and inhibit the activity of a protein involved with virus production (Pei et al., 2010). 
Interestingly, this same process has been thought to involve disassembly of the actin cytoskeleton 
(Lamb et al., 1976; Pei et al., 2010) and recruitment of Nedd4 ubiquitin ligases (Martin-Serrano 
et al., 2005; Rauch and Martin-Serrano, 2011). Additionally, Nedd4 proteins can promote actin 
assembly in yeast cells (Stawiecka-Mirota et al., 2008). Further, this thesis reinforces connections 
between the Angiomotins, Nedd4 ligases, and actin rearrangements and their impact on cell 
growth. Together, it is hypothesized that a mechanism of Nedd4 recruitment and actin remodeling 
in virus production could be through the Angiomotins in processes similar to that presented 
herein. For example, Amot130 is able to remodel actin through its ability to be phosphorylated by 
LATS. Further, the Nedd4 ligase AIP4 is recruited to bind to Amot130, which changes its cellular 
localization and availability for substrates. Therefore, inhibition of viral signaling could occur 
through sets of Angiomotins and their unique abilities to anchor Nedd4 ligases and rearrange 
actin. However, the precise role of these proteins in viral budding and virus production is unclear. 
Regardless, the links between the Angiomotins with the microenvironment and Hippo signaling 
yields room for future studies to identify how the Angiomotins are utilized in viral signaling for 
growth regulation. 
 
6.2.5. Promoting AMOT Transcription via Microenvironmental Elements in Mammary 
Tissue 
The paracrine microenvironment of mammary tissue contains growth regulatory elements 
including various cytokines and chemokines secreted by inflammatory cells, many of which are 
associated with breast cancer development, particularly in inflammatory breast cancers (Hussein 
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and Hassan, 2006; Lieblein et al., 2008; O'Shea and Murray, 2008). Specifically, the cytokine 
interleueken-6 (IL-6), promotes the accumulation of the signal transducer and activator of 
transcription (STAT) 3 and nuclear factor-κB (NFκB) transcription factors (Yang et al., 2007). 
IL-6 activates transcription, which promotes the oncogenic transformation of mammary epithelial 
cells (Hodge et al., 2005; Mohankumar et al., 2008). Interestingly, these physiological effects are 
similar to those seen upon exogenous Amot80 expression in mammary epithelial cells (Ranahan 
et al., 2011). Further, expression array studies implicate IL-6 and STAT3 in the induction of 
AMOT transcription (Yang et al., 2007). Sequence analysis of the 5’-upstream region of the 
AMOT gene indicates several potential STAT and NFκB binding sites (Figure 6-2). Thus, AMOT 
transcription is hypothesized to be under control of these transcription factors, and thus under 
control of cytokines, such as IL-6. Future studies examining the response to microenvironmental 
factors, will likely give clues to the control of growth via the microenvironment of the breast 
tissue. Based upon the opposing roles of Amot80 versus Amot130, these factors that control the 
transcription of AMOT are likely isoform specific. Thus, understanding the isoform specific 
regulation of their transcription could unlock clues to understanding the balance of growth control 
via gene expression in mammary epithelial cells. This would point at an interesting role for the 
microenvironment in the control of cell growth. 
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Figure 6-2 Possible Transcription Factor Binding Sites for Promoting AMOT Transcription. 
Prediction programs designed to identify transcription factor binding sites in DNA sequences 
were utilized for the sequences upstream of AMOT and between its first two exons. These 
programs utilize the set of binding sites available from TRANSFAC® to predict future unknown 
binding sites. Two prediction programs revealed several potential STAT and NFκB binding sites 
in these regions. The diagonal double lines indicate that this is a selection of a much longer DNA 
sequence. 
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6.2.6. Regulation of the Angiomotins into the Nucleus 
Understanding how the microenvironment influences the nuclear functions of YAP was a 
major goal of this study. One important aspect of YAP function not examined in this study was 
how YAP does or does not enter the nucleus. However, this study and some unpublished work 
present a possible role of Angiomotin in YAP nuclear import. Previous work with Zona Occludin 
2 (ZO-2) implicates it as a known positive regulator of YAP activity, via shuttling YAP into the 
nucleus (Oka et al., 2010). No other protein is reported to have this unique shuttling ability. 
However, recent work with Amot80 shows the ability of it to activate cellular growth and have 
similar properties to overexpression of YAP in mammary epithelial cells (Ranahan et al., 2011; 
Yi et al., 2011). The precise mechanism by which Amot80 is able to promote cellular growth has 
not been reported. However, in unpublished work by William Ranahan, YAP presents itself in a 
complex with Amot80, via hetero-dimerization with Amot130. Amot80 is then able to 
dominantly redistribute Amot130, along with its associated YAP, away from cell contacts and 
actin and into compartments surrounding the nucleus. Finally, Amot80 was able to increase the 
nuclear activity of YAP. However, the mechanism for this Angiomotin activation of YAP is 
unknown. A proposed direct import of YAP via Amot130 is hypothesized based upon several 
observations. First, Amot130 contains a canonical nuclear localization sequence from residues 
585-605, and is proposed to allow Amot130 to directly shuttle bound YAP into the nucleus. Thus, 
the overall hypothesis is that when YAP-Amot130 complex is dimerized with Amot80, the 
complex is brought into the vicinity of the nucleus, by the dominate redistribution via Amot80. 
Once surrounding the nucleus, the nuclear import via Amot130 nuclear localization sequence can 
occur, likely shuttling both YAP and Amot80 into the nucleus. This hypothesis helps explain data 
where Amot130, under conditions of low cell confluence, significantly promotes TEAD 
transcription across mammary epithelial cells (Figure 6-3A). At first, this seems counter to 
Amot130 as a tumor suppressor protein, which is at the crux of this study. However, there 
appears to be a dual function of Amot130, which prior to this study has not been appreciated. The 
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promotion of nuclear YAP is likely a result of the dominate redistribution of Amot130 to 
surrounding the nucleus by Amot80. Thus, in cells with low Amot80, this phenotype goes largely 
unnoticed. In fact, most cells examined in this thesis were at high cell confluence and had lower 
levels of Amot80 compared to Amot130. Thus, Amot130 was largely inhibiting cell growth by 
keeping YAP out of the nucleus by various mechanisms. However, it is possible that under low 
cell confluence conditions, Amot80 levels are increased, and thus phenotypically could outweigh 
the growth suppressive properties of Amot130, which is classically witnessed upon Amot80 
overexpression (Ranahan et al., 2011). Secondly, in support of Amot130 promoting growth via its 
nuclear import, the Angiomotins have been differentially seen in nucleus. For instance, in cells 
grown to low confluence, cell fractionation experiments revealed Amot80 and Amot130, but not 
AmotL1, are primarily seen in a nuclear fraction (Figure 6-3B). Amot130 appears to be almost 
exclusively seen in a nuclear fraction, whereas Amot80 appears almost equally in both fractions. 
These findings encourage Amot130 having functions in the nuclei of cells. 
In order for Amot130 to have polarizing roles in control of YAP, it likely requires an 
upstream signal as a switch. This thesis focused on the role of Hippo signaling in the functions of 
the Angiomotins. It is believed that the functions of serum factors and LATS phosphorylation of 
Amot130 are likely switches influencing Amot130 control of YAP nuclear activity. In 
investigation of this, the mutant of Amot130, which cannot be phosphorylated by LATS at Ser-
175 (S175A), was used to determine a possible switch in Amot130 control of YAP. Interestingly, 
Amot130 (S175A) presents a similar phenotype as witnessed with Amot80 expression in 
MCF10A acini (Ranahan et al., 2011), unlike wild-type Amot130 which was growth suppressive. 
Further, stable expression of Amot130 (S175A) promotes increased Amot80 protein steady state 
levels beyond that seen with stable expression of wild-type Amot130 (Figure 6-3C). Based upon 
the role of Amot80 in increasing growth in mammary epithelial cells, this may in part explain 
why the mutant Amot130 (S175A) is able to activate growth and CTGF transcription beyond that 
seen in control cells. It is unknown how the unphosphorylated Ser-175 Amot130 could increase 
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Amot80 levels; however, by doing so it would impact YAP nuclear activity. Overall, based upon 
this work, it is hypothesized that a majority of the inhibition of Amot130 is through its ability to 
be phosphorylated by LATS. Thus, a final proposed mechanism for the nuclear import of YAP in 
response to the serum factors in the microenvironment of the cell occurs via specific binding of 
YAP to the unphosphorylated Amot130 dimerized with Amot80, resulting in a nuclear import 
mechanism for YAP. Upon upstream phosphorylation of Amot130 at Ser-175 by LATS, this 
complex breaks down and Amot130 promotes the degradation or cytosolic sequestration of YAP. 
In support of these theories, Amot130 has recently been shown to activate YAP by bringing it 
into the nucleus in cells grown to low confluence (Yi et al., 2013); however, how it is triggered 
and the mechanism of action remains to be investigated. Importantly, the results of this study 
could be an important link between the cellular microenvironment and the nuclear import of 
YAP. Future studies will likely uncover how Amot130 and Amot80 get into the nucleus and what 
their precise roles are there. Further, it is likely that the nuclear control of Angiomotin is through 
a switch that is regulated by Hippo signaling and the microenvironment of the cell. 
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Figure 6-3 The Role of Nuclear Amot130 in YAP-Dependent Transcription. 
(A) Indicated breast cancer cells were transfected with TEAD luciferase reporter constructs. 
Luminescence was measured using a dual-luminometer measuring TEAD luciferase activity in 
these cells harvested at low confluence. Relative fold changes of TEAD luciferase in YFP-tagged 
Amot130 expressing cells over TEAD levels in control cells are presented. (B) MDA-MB-468 
cells were subjected to nuclear fractionation. Immunoblot of lysates from both fractions for two 
independent experiments are shown for proteins indicated. GAPDH and snRNP70 were used to 
determine quality of nuclear fractionation. Blots were cut from a larger experiment. (C) 
Immunoblot analysis of lysates from HEK 293T cells expressing YFP-tagged wild-type Amot130 
or Amot130 (S175A) examining Angiomotin and GAPDH protein levels. 
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6.3. The Dual Role of AIP4 in Mammary Epithelial Cell Growth 
 
Generally, the Nedd4 family ligases have diverse roles in cell signaling including the 
ubiquitination and regulation of proteins that control cell growth (Chen and Matesic, 2007; Rotin 
and Kumar, 2009). For example, AIP4 has dual roles in cell growth. Little is known regarding the 
means by which AIP4 is switched between the opposing roles of growth arrest and pro-growth 
signaling. AIP4, which localizes to the trans-Golgi network and recycling endosomes (Angers et 
al., 2004; Marchese and Benovic, 2001), promotes cell growth by inhibiting apoptosis through 
polyubiquitination and signaling the degradation of the transcription factor p73 (Rossi et al., 
2005) and the pro-apoptotic factor tBid (Azakir et al., 2010). AIP4 also promotes cell 
proliferation more directly by similarly inducing the degradation of LATS1 (Salah et al., 2011). 
This degradation of LATS1 results in YAP and TAZ being less restricted from activating cellular 
growth. Conversely, AIP4 induces both poly- and mono-ubiquitination of Notch1 (Qiu et al., 
2000) and inhibits hematopoietic stem cell proliferation by promoting its degradation (Rathinam 
et al., 2011). Further, this study highlights how binding of AIP4 to the adapter protein Amot130 
can medicate the changeover of AIP4 from a pro-growth to an anti-growth role. Specifically, the 
binding of Amot130 to AIP4 prevents AIP4 association with LATS1 and increases AIP4 
recruitment into a complex with YAP. The consequence is a functional reversal of AIP4, which 
no longer is able to degrade LATS1 and now works with Amot130 to induce inhibition of YAP 
nuclear activity. 
The Nedd4 ligases are a family of proteins that bind diverse adapter proteins and thus 
likely have a diversity of functions within cells. Future studies examining the other Nedd4 ligases 
and their roles in growth regulation in mammary epithelial cells will likely uncover dual roles for 
all Nedd4 ligases and move them away from their previously assumed roles as proto-oncogenes. 
It is likely that there are many new substrates that the Nedd4 ligases interact with that are 
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involved in growth signaling, and the Angiomotins will likely play important roles in determining 
these new substrates. 
 
6.4. The Multiple Mechanisms of YAP Ubiquitination 
 
The canonical inhibition of YAP involves phosphorylation at Ser-127 by LATS1/2, 
which induces cytosolic sequestration via 14-3-3 and marks it for recognition and targeting for 
ubiquitination by the ubiquitin ligase SCF-(β)-TRCP (Zhao et al., 2010). An array of studies 
yields that YAP inhibition by Amot130 could be dependent or independent on the 
phosphorylation of YAP at Ser-127 by LATS1/2 (Chan et al., 2011; Zhao et al., 2011a). Here, 
this study describes a possible Ser-127 phosphorylation-independent mechanism involving the 
Amot130-AIP4 complex. Similar multiple ubiquitin ligases for proteins exist throughout the 
literature, including another transcriptional co-activator BCL10 that is targeted for ubiquitination 
and degradation by both AIP4 (Scharschmidt et al., 2004) and SCF-(β)-TRCP (Lobry et al., 
2007), similarly to YAP. Thus, it is likely that YAP can be ubiquitinated and degraded by 
multiple approaches. Overall, this promotes an environment whereby the cells can inhibit its 
cellular growth via inhibition of YAP by multiple upstream signals. Specifically, the upstream 
signal of serum deprivation induces the ubiquitination of YAP, primarily upon expression of 
AIP4 and requiring Amot130 phosphorylation at Ser-175. Thus, this would argue that the 
ubiquitination, in response to serum changes, is largely through the Amot130-AIP4 complex and 
not via promoting degradation of YAP via SCF-(β)-TRCP. However, future studies will be 
needed to provide in depth analysis of the upstream signaling which differentiates which ligase, 
AIP4 or SCF-(β)-TRCP ubiquitinates YAP and the significance of this specificity. 
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6.5. Conclusion 
 
The entirety of this work lays the foundation for understanding the roles of post-
translational modifications on Amot130 in growth signaling in mammary epithelial cells. 
Mammary epithelial cells grow, divide, and die through physiological processes of the woman’s 
life cycle. Understanding how cells initiate and promote cellular division versus growth inhibition 
during these processes is important for the overall understanding of a functioning healthy breast. 
Further, examination of these pathways may lead to insights in how this same regulation goes 
awry in breast cancers. Importantly, Amot130 appears to play a dominant role in the inhibition of 
YAP in response to depriving cells of serum. Further, this dominant role is under control of the 
tumor suppressor protein kinases, LATS1/2. While Amot130 appears to be regulated via 
LATS1/2, the effects on the other Angiomotins are less pronounced. Amot130 appears to be 
supersensitive to the effects of LATS1/2 more so than the other Angiomotin family members. 
Interesting the only other family member impacted by serum deprivation was Amot80, although 
this finding is difficult to pinpoint how this fits in with overall growth control. Regardless, 
Amot130, via its induced ability to bind AIP4, plays a primary role in the inhibition of YAP-
dependent transcription. Future studies will likely uncover new post-translational modifications, 
which regulate the ability of Angiomotin to impact cellular growth control in mammary epithelial 
cells. Further, Angiomotin is a key determinate in the activity of YAP and is likely a transmitter 
of multiple microenvironmental signals. The presented alternative mechanism of YAP inhibition 
likely underlies a critical control pathway present in most cell types across mammals. Because of 
the important nature of Hippo signaling, future work will likely reveal that this alternative 
mechanism for YAP inhibition is an important way that cells respond to growth inhibition signals 
within the microenvironment. 
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APPENDIX – NUCLEOTIDE SEQUENCES AND CLONING STRATEGIES 
 
qRT-PCR Primers 
 
CTGF Forward: AGGAGTGGGTGTGTGACGA (Dupont et al., 2011) 
CTGF Reverse: CCAGGCAGTTGGCTCTAATC (Dupont et al., 2011) 
 
Cyr61 Forward: AAGGAGCTGGGATTCGATG (Wolf et al., 2010) 
Cyr61 Reverse: TCTGGCCTTGTAAAGGGTTG (Wolf et al., 2010) 
 
AMOT Forward: CTCAGACTCAGGCACCAACT (RealTimePrimers.com validated) 
AMOT Reverse: CTTGTCCCAGGATCTGAATG (RealTimePrimers.com validated) 
 
GAPDH Forward: CTCCTGCACCACCAACTGCT (Dupont et al., 2011) 
GAPDH Reverse: GGGCCATCCACAGTCTTCTG (Dupont et al., 2011) 
 
shRNA Sequences 
 
AIP4 shRNA: 
CCGGCCAGAAGGTCAAGGTCAATTAACTCGAGTTAATTGACCTTGACTTCTCTGGTTT
TT in pLKO.1 (Sigma, TRCN0000002087) 
 
Angiomotin shRNA: 
CCGGGAGGAGAATGTGATGAGACATCTCGAGATGTCTCATCACATTCTCCTCTTTTTT
G in pLKO.1 (Sigma, TRCN0000162009) 
 
LATS1 shRNA: 
CCGGCACGGCAAGATAGCATGGATTCTCGAGAATCCATGCTATCTTGCCGTGTTTTT 
in pLKO.1 (Sigma, TRCN0000001777) 
 
Scramble shRNA: shControl pLKO.1 plasmid #1864 (Addgene) 
 
Cloning Primers 
 
Amot130 Forward: ACGTGGCGCGCCATGAGAAATTCTGAAGAACAG 
Amot130 Reverse: ACGTTTAATTAATTAGATGAGATATTCCACC 
 
Amot130 (P-Y1F) Forward: GAGGAGCTGCCCACCTTCGAGGAGGCCAAAGCCC 
Amot130 (P-Y1F) Reverse: GGGCTTTGGCCTCCTCGAAGGTGGGCAGCTCCTC 
 
Amot130 (P-Y2F) Forward: GGCCCCCCCAGAATTTCCCTTCAAGGGC 
Amot130 (P-Y2F) Reverse: GCCCTTGAAGGGAAATTCTGGTGGGGGGCC 
 
Amot130 (P-Y3F) Forward: CAGCATCCCCCTGAGTTTGGAGCCAGG 
Amot130 (P-Y3F) Reverse: CCTGGCTGCTCCAAACTCAGGGGGATGCTG 
 
Amot80 Forward: TTCCCCAGGGGCGCGCCATGCCTCGGGCTCAGCCATC 
Amot80 Reverse: CTAGGAACTTACCTGGTTAATTAATTAGATGAGATATTCCACCATC 
 
AmotL1 Forward: TTCCCCAGGGGCGCGCCATGTGGAGGGCAAAGTTG 
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AmotL1 Reverse: CTAGGACTTACCTGGTTAATTAATTAGATGAGGACTTCCATCATC 
 
AmotL2 Forward: TTCCCCAGGGGCGCGCATGAGGACACTGGAAGAC 
AmotL2 Reverse: CTAGGAACTTACCTGGTTAATTAATTAGATCAGTATCTCCACCATG 
 
AIP4 Forward: ATCGGGCGCGCCATGTCTGACAGTGGATCACAGCTTGGT 
AIP4 Reverse: ATCGTTAATTAACTCTTGTCCAAATCCTTCTGTTTCTTCTAT 
 
Nedd4-1 Forward: ATCGGGCGCGCCATGGCAACTTGCGCGGTGGAGGTGTTCGGG 
Nedd4-1 Reverse: ATCGTTAATTAAATCAACTCCATCAAAGCCCTGGGTGTTTTC 
 
WWP1 Forward: ATCGGGCGCGCCATGGCCACTGCTTCACCAAGGTCTGATACT 
WWP1 Reverse: ATCGTTAATTAATTCTTGTCCAAATCCCTCTGTCTCTTCTAT 
 
WWP2 Forward: ATCGGGCGGCCATGGCATCTGCCAGCTCTAGCCGGGCAGGA 
WWP2 Reverse: ATCGTTAATTAACTCCTGTCCAAAGCCCTCGGTCTCCTCAAT 
 
Smurf2 Forward: 
ATCGGGCGCGCCATGTCTAACCCCGGAGGCCGGAGGAACGGGCCGTCAAGCTGCGC 
Smurf2 Reverse: ATCGTTAATTAATTCCACAGCAAATCCACATGTTTCTTCAAT 
 
NEDL2 Forward: ATCGGGCGCGCCATGGCTAGTTCAGCCCGGGAGCACCTGCTT 
NEDL2 Reverse: ATCGTTAATTAACTCAAGTCCAAAAGTACTGGTTTCTTCAAC 
 
NEDL1 Forward: ATCGGGCGCGCCATGGCGTCTCCTTCTAGAAACTCCCAGAGC 
NEDL1 Reverse: ATCGTTAATTAACTCAAGTCCAAAGGTGCTGGTTTCCTCTAC 
 
YAP2 Forward: ACGTGGCGCGCCATGGATCCCGGGCAGCAGCCGCC 
YAP2 Reverse: ACGTTTAATTAACTATAACCATGTAAGAAAGC 
 
AIP4 WW1 Forward: ACGTGGCGCGCCGTAACTCAAGCTCCCTTGCC 
AIP4 WW1 Reverse: ACGTTTAATTAATCAGCCCCGTTCCCAGCCAGGAGGTAG 
 
AIP4 WW2 Forward: ACGTGGCGCGCCGATAGACCAGAACCTCTACC 
AIP4 WW2 Reverse: ACGTTTAATTAATTATTCATAGTTCCGGACGGATTC 
 
AIP4 WW3 Forward: ACGTGGCGCGCCGATCCTCTTGGTCCATTGCC 
AIP4 WW3 Reverse: ACGTTTAATTAATCACTTTTCATTTAATTGACCTTG 
 
AIP4 WW4 Forward: ACGTGGCGCGCCCAATTAAATGAAAAGCCC  
AIP4 WW4 Reverse: ACGTTTAATTAATCAGTCTAGGGCAGATTTTCCTGTG 
 
YAP2 WW1 Forward: ACGTTTAATTAACTACGAGTTCATCATATTCTGCTG 
YAP2 WW1 Reverse: ACGTGGCGCGCCTCTTTTGAGATACCTGATGATG 
 
YAP2 WW2 Forward: ACGTTTAATAATCAGTTCATGGCAAAACGAGGGTC 
YAP2 WW2 Reverse: ACGTGGCGCGCCCTGTCCCAGATGAACGTCAC 
 
YAP2 WW1 & WW2 Forward: ACGTGGCGCGCCTCTTTTGAGATACCTGATGATG 
YAP2 WW1 & WW2 Reverse: ACGTTTAATTAATCAGTTCATGGCAAACGAGGGTC 
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Cloning Strategies 
 
Amot130 was cloned with primers described above and inserted into the following vectors via 
restriction enzyme PCR: pLP 3X Flag SD, pLP 2X Myc SD, pLP EYFP C1, and pLP monomeric 
Citrine YFP. 
 
Amot130 (P-Y1F), (P-Y2F), and (P-Y3F) were all mutated via site directed mutagenesis utilizing 
primers from above then inserted into the following vectors via restriction enzyme PCR: pLP 3X 
Flag SD, pLP 2X Myc SD, pLP EYFP C1, and pLP monomeric Citrine YFP. 
 
Amot130 (K481R) was designed by Eurofins then subcloned into Bluescript. Then this piece was 
inserted into the following vectors via restriction enzyme PCR: pLP EYFP C1 and pLP 
monomeric Citrine YFP. 
 
Amot80 was cloned with primers described above and inserted into the following vector via 
restriction enzyme PCR: pLP EYFP C1. 
 
AmotL1 was cloned with primers described above and inserted into the following vector via 
restriction enzyme PCR: pLP 3X Flag SD. 
 
AmotL2 was cloned with primers described above and inserted into the following vector via 
restriction enzyme PCR: pLP 3X Flag SD. 
 
AIP4, Nedd4-1, WWP1, WWP2, Smurf2, NEDL2, and NEDL1 were cloned with primers 
described above and inserted into the following vector via restriction enzyme PCR: pRETRO 3X 
Flag SD and AIP4 into pLP monomeric Cherry. 
 
YAP2 was cloned with primers described above and inserted into the following vector via 
restriction enzyme PCR: pLP monomeric Cerulean CFP. 
 
AIP4 WW1, WW2, WW3, and WW4 were cloned with primers described above and inserted into 
the following vector via restriction enzyme PCR: pGEX 6p-1 AscI/PacI. 
 
YAP2 WW1 and WW2 were cloned with primers described above and inserted into the following 
vector via restriction enzyme PCR: pGEX 6p-1 AscI/PacI. 
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